CTEP # P9771 
Clinical Center # l 6-C-0087 
Statistician: 
CTEP Drug Monitor: 
Study Sponsor: 
NCI Supplied Agents: 
IND Number: 
NCTNumber: 
Version Date: DCTD , NCI 
CTEP 
M6620 (VX-970) (NSC 780162) 
Veliparib (ABT-888) (NSC 737664) 
[STUDY_ID_REMOVED] 
Januaiy 11, 2021 
Roles: A obtains information by intervening or interacting with living individuals for research purposes; 
Bobtains identifiable private information about living individuals; cobtains the voluntary infonned 
consent of individuals to be subjects; Dmakes decisions about subject eligibility; Estudies, interprets, or 
analyzes identifiable private information or data/specimens for research purposes 
3 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   4 
 PRÉCIS  
Background : 
• Ataxia -telangiectasia -related (ATR) protein  kinase is central to the DNA damage response and 
homologous recombination, activating a series of phosphoryla tion cascades , culminating in cell 
cycle arrest to a llow time for DNA repair .  ATR additionally facilitates homologous 
recombination repair through modulation of the p53-replication protein A (p53- RPA) complex 
bound to ssDNA during the D NA repair process.   
• Poly (ADP- ribose) polymerase -1 (PARP -1) plays a pi votal role in base- excision repair  of single 
strand breaks formed either due to direct genot oxic stress or during the  processing of double 
strand breaks .  PARP also plays a role in al ternative end joining, which may contribute to 
combination activity .  PAR P-1 binding to sites of DNA damage results in activation of its 
catalytic activity and generat ion of chains of poly ( ADP -ribosyl)ated polymers, which serve as 
docking sites for recrui tment of DNA repair proteins.  
• Veliparib (ABT -888) is a potent PARP 1/2 inhibitor with clinical evidence of potentiation of 
antitumor activity in combination with cisplatin in BRCA mutation c arriers an d patients with 
sporadi c triple -negative breast cancer.  
• M6620 (VX-970) is a p otent ATR inhibitor, with IC 50 of 20 nM and antitumo r activity across a 
broad range of cell lines in combination with DNA damaging agents.  Preclinical studies show 
M6620 (VX-970) synergizes with cisplatin to induce DNA damage and anti tumor activity .  The 
addition of PARP inhibitor veliparib with ATR inhibi tor M6620 (VX-970) allows for 
impairment of DNA repair, the induction of a “BRCA null” phenoty pe, and potentiation of the 
antitumor activity of cispla tin. 
 Primary Objective:  
• To estab lish the safety, tole rability, and the maximum tolerated dose (MTD)  of th e combination 
of M6620 (VX-970) and veliparib  in combination with cisplatin in patients with advanced 
refractory solid tumors  
 
Secondary Objectives:  
• To assess the effect of the combinat ion of M6620 (VX-970), velipa rib, and cisplatin on markers 
of DNA damage and apoptosis 
• To assess antitumor activity of the combination 
 Exploratory Objective: 
• To investigate tumor genomic alterations potentially associate d with acquired resistance 
to the combination of M6620 (VX-970), veliparib , and cisplatin  
 Eligibility : 
• Patients must have histologically confirmed solid tumors for which standard therapy known to 
prolong survival has failed in the metastatic setting , or for which standard therapies do not exist  
• Patients must have had n o major surgery, radiation, or chemothera py within 3 weeks prior to 
entering the study  
• Patients must have adequate organ function  
Study Design : 
• Initially, M6 620 (VX-970) will be administered  intravenously on Days 2 and 9 of e ach 21-day 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   5 
 cycle.  Veliparib will be administered orally twice a day (q12 hours ± 1 hour) for Days  1-3 and 
8-10 of each  21-day cycle.  Cisplatin will be administered  at 40  mg/m2 intravenously on Day 1 
(and Day 8 from DL3 onwards) of each  21-day cycle. 
• As of Amendment I  (12/7 /2017), patients who have been on study for at least  6 cycles may 
have cisplatin administration held or discontinued at the discretion of the PI, Dr.  in 
recognition of the cumulative neurotoxicity seen with cisplatin treatment.  If cisplatin is not 
administere d during a cycle, M6620 (VX-970) wil l be administered on Days 1 and 8 of that 
cycle.  
• The escalation portion of the trial will follow a s tandard 3+3 design, whereby patients will be  
dose escalated in cohorts of 3 until dose- limiting toxicity is ob served  
• Once the MTD  is established, up to 15 additional patients will be enrolled to an expansion phase 
at the MTD .  Mandatory tumor biopsies will be obtained in the expansion phase to assess PD 
endpoints    

CTEP #  P9771 
Clinical Center #  16-C-0087  
   6 
  
SCHEMA  
 
 
 
 
 
 
 
D1-3                       D8-10                                                D1-3                     D8-10 
 
  
  
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 Cisplatinb 
M6620 ( VX-970)c 
Tumor  
biopsies † Velipariba Cycle 1 (duration 21 days)  Cycle 2 (duration 21 days)  
D2 
D1                               D9 Week 1  
a Veliparib po q12 hours ± 1 hour on days 1 -3, 8-10 of ea ch cycle .  Veliparib should be adm inistered before 
cisplatin and M6620 (VX -970).  
b Cisplatin IV day 1 only each cycle for dose levels up to DL 3; days 1 and 8 for dose level 3  and higher ; as 
of Amendment I  (12/7/2017),  patients who have been on study for a t least 6 cycles may have cisplati n 
administra tion held or discontinued at the discretion of the PI, Dr.  
c M6620 (VX -970)  IV days 2 and 9 of each cycle (or days 1 and 8 if cisplatin administration has been held or 
discontinued)  
† Tumor biopsies to evaluate pharmacodynamic markers of DNA damage (optional during the escalation 
phase and mandatory during the expansion phase) after administration of cisplatin on C1D1 and on C 1D9, 2-
5 hours after the day 9 dose of M6620 (VX -970).  One optional  biopsy may a lso be performed, either at  
“restaging follow -up” on day 1 ( ± 2 days) of the cycle following any restaging at which a 10-19% increase in 
tumor volume is observed (according to RECIST criteria) for patients on study  4 or more cycles, or at  the 
time of disease progression.  (For example, a r estaging fol low-up biopsy would be performed on cycle 6 day 
1 for a 10- 19% tumor volume increase detected at the restaging following cycle 4).  
‡ Circulating tumor cells (optional) will be collected at baseline (prior to a dministration of study agents), 
prior to administration of M6620 (VX -970)  on cycle 1 day 2, 8 hours (± 30 minutes)  after the start of M6620 
(VX-970)  administration on cycle 1 day 2,  on cycle 1 day 8 prior to veliparib/cisplatin administration, on 
cycle 1 day 9 prior to M6620 (VX -970)  admi nistration, on cycle 2 day 1 prior to velipari b/cisplatin 
administration, on cycle 2 day 2 prior to M6620 (VX -970)  administration and again 10 hours (± 2 hours)  after 
the start of M6620 (VX -970)  administration (or, at NCI only, at 7:00pm ± 30  minutes; the  time elapsed 
between M6620 (VX -970)  administra tion and blood collection on cycle 2 day 2 will be recorded), and on the 
first day of every subsequent cycle prior to veliparib/cisplatin adminis tration. D1 Week 2  Week 3  
CTCs‡ 
Baseline   D2  D8 D9 C2 D1 D2 C3D1  Week 1  Week 2  Week 3  
D1                         (D8) 
D9 D2 D9 (D8)  

CTEP #  P9771 
Clinical Center #  16-C-0087  
   7 
 Dosing Schema : 
 
Dose  
Level  Veliparib  
(PO q12 hou rs ± 1 hour ) M6620 (VX -970) 
 (IV Days 1/ 2 and 8/9) Cisplatin  
(IV Day 1 or Days 1 
and 8 ) 
-2 20 mg days 1-3, 8-10 40 mg/m2 40 mg/m2 day 1 
-1 40 mg days 1-3, 8-10 60 mg/m2 40 mg/m2 day 1 
1 100 mg days 1-3, 8-10 90 mg/m2 40 mg/m2 day 1 
2 100 mg days 1-3, 8-10 140 mg/m2 40 mg/m2 day 1 
3 100 mg days 1-3, 8-10 120 mg/m2 40 mg/m2 days 1, 8 
4 100 mg days 1-3, 8-10 210 mg/m2 40 mg/m2 days 1, 8 
5 150 mg days 1-3, 8-10 210 mg/m2 40 mg/m2 days 1, 8 
6 200 mg days 1-3, 8-10 210 mg/m2 40 mg/m2 days 1, 8 
7 300 mg days 1 -3, 8-10 210 mg/m2 40 mg/m2 days 1, 8 
8 400 mg days 1 -3, 8-10 210 mg/m2 40 mg/m2 days 1, 8 
 
As of A mendment L (dated 4/22/2019), the MTD for this combination has been  established a s 
DL6.  
 
 
 
  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   8 
 TABLE OF CONTENTS  
PRÉCIS  ............................................................................................................................................4  
SCHEMA  .........................................................................................................................................6  
1 OBJECTIVES  ....................................................................................................................10  
2 BACKGROUND  ...............................................................................................................10  
2.1 Rationale for combining cisplatin with ATR and PARP inhibitors .......................10  
2.2 M6620 (VX-970) ...................................................................................................13  
2.3 Velip arib (ABT -888) .............................................................................................17  
2.4 Cisplatin  .................................................................................................................19  
2.5 Correlative Studies Background ............................................................................22  
3 PATIENT SELECTION  ....................................................................................................24  
3.1 Eligibility Criteria  ..................................................................................................24  
3.2 Exclusion Criteria  ..................................................................................................25  
3.3 Inclusion of Women and Minori ties ......................................................................26  
3.4 Screening Evaluation .............................................................................................26  
4 REGISTRATION PROCEDURES  ...................................................................................26  
4.1 NCI Cli nical Center Patient Registration Process  .................................................26  
4.2 Participating Site Patient Registration  ...................................................................27  
4.3 Investiga tor and Research Asso ciate Regi stration with CTEP  ..............................27  
5 TREATMENT PLAN  ........................................................................................................28  
5.1 Agent Administration .............................................................................................29  
5.2 Intra -patient Dose Escalation  .................................................................................31  
5.3 Definition of Dose -Limiting Toxicity  ....................................................................31  
5.4 General Concomitant Medicati on and Supportive C are Guidel ines ......................33  
5.5 Duration of Therapy  ...............................................................................................35  
5.6 Duration of Follow Up ...........................................................................................36  
5.7 Criteria  for Removal from Study  ...........................................................................36  
6 DOSING DELAYS/DOSE MODIFICATIONS ................................................................36  
6.1 Dose Modifications  ................................................................................................36  
6.2 Agent- specific Dose Mod ifications: Veliparib  ......................................................37  
7 ADVERSE  EVENTS:  LIST AND REPO RTING REQUIREMENTS  ............................40  
7.1 Comprehensi ve Adverse Events and Potential Risks List  (CAEPR) for 
ABT -888 (Veliparib, NSC 737664) .......................................................................40  
7.2 Compr ehensive Adverse Events and Potential Risks list (CAEPR) for 
M6620 ( VX-970) (NSC 780162) ...........................................................................43  
7.3 Adverse Event Characteristics  ...............................................................................46  
7.4 Expedited Adverse Event Reporting ......................................................................46  
7.5 NIH- IRB and Clinical Director Reporting R equirements  .....................................51  
7.6 Secondary Malig nancy  ...........................................................................................52  
7.7 Second Malignancy ................................................................................................52  
8 PHARMACEUTICAL INFORMATION ..........................................................................53  
8.1 M6620 (VX-970) (NSC 780162) ...........................................................................53  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   9 
 8.2 Veliparib (NSC 737664) ........................................................................................55  
8.3 Cisplatin  .................................................................................................................56  
8.4 Useful Links and Contac ts: ....................................................................................57  
8.5 Agent Ordering ......................................................................................................58  
8.6 Agent Accountability .............................................................................................58  
9 CORRELATIVE/SPECIAL STUDIES .............................................................................59  
9.1 Pharmacodynamic Assays  .....................................................................................59  
9.2 Genomic Analyses  .................................................................................................64  
9.3 Huma n Data Sharing Plan ......................................................................................65  
10 STUDY CALENDAR  .......................................................................................................66  
11 MEASUREMENT OF EFFECT ........................................................................................68  
11.1  Antitumor Effect – Solid Tumors  ..........................................................................68  
11.2  Response Criteria  ...................................................................................................72  
11.3  Duration of Response  .............................................................................................74  
12 DATA REPORTING/ REGULATORY REQUIREMENTS  .............................................74  
12.1  Study Oversigh t .....................................................................................................74  
12.2  Data Reporting .......................................................................................................75  
12.3  CTEP Multicenter Guidelines  ................................................................................76  
12.4  Collaborative Agreements Language  .....................................................................76  
12.5  Genomic Data Sharing P lan ...................................................................................78  
13 STATISTICAL CONSI DERATIONS ...............................................................................78  
13.1  Study Design/Endpoints .........................................................................................78  
13.2  Sample Size/Accrual Rate ......................................................................................78  
13.3  Seco ndary Endpoints .............................................................................................78  
14 HUMAN SUBJECTS PROTECTIONS  ............................................................................78  
14.1  Justification for Subject Selection  .........................................................................78  
14.2  Evaluation of Ben efits and Risks/Discomforts  ......................................................79  
14.3  Consent and Assent Pr ocess and Documentation ..................................................79  
14.4  Proce dure for Protecting Against or Minimizing Any Potential Risks ..................81  
14.5  Patien t Advocate ....................................................................................................81  
REFERENCES ..............................................................................................................................82  
APPENDIX  A: PERFORMANCE STATUS CRITERIA .............................................................84  
APPEN DIX B:  PATIENT DRUG INTERACTIONS HANDOUT AND WALLET 
CAR D ................................................................................................................................85  
APPENDIX C: PATIENT STUDY CALENDAR AND DI ARY ................................ .................87  
APPENDIX D: PD SAMPLE COLLECTION WORKSHEETS AT THE  NCI  ...........................91  
APPENDIX E: INFORMED CONSENT FORM TEMPLATE  ....................................................95  
APPENDIX F: CTEP MULTICENTER GUIDELINES  .............................................................108  
APPENDIX G:  PROCEDURE FOR SAMPLES FOR PHARMACODYNAMIC 
STUDIES  .........................................................................................................................110  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   10 
 1 OBJECTIVES  
Primary O bjective:  
• To establish the safety, tolerability, and the maximum tolerated dose (MTD)  of the 
combination of M6620 (VX-970), an ATR inhibitor and velip arib, an  oral PARP  1/2 
inhibitor, i n combination with cisplatin in patients with advanced refractory  solid  tumors.  
 
Secondary Objectives:  
• To assess the effect of the combination of M6620 (VX-970), vel iparib , and cisplatin on 
mark ers of DNA damage and apopt osis 
• To assess the antitu mor activi ty of the combinati on 
 Exploratory Objective: 
• To investigate tumo r geno mic alterations potentially associated with acquired resistance  to 
the combination  of M6620 (VX-970), veliparib, and cisplatin  
  
2 BACKGROUND  
2.1 Rationale for  combining cisplatin with ATR and PARP inhibitors  
Platinum co mpounds act through the formation of covalent bonds with DNA purine bases, 
forming intrastrand and interstrand cross -links with DNA, sta lling replication forks  and halting 
transcription  [1].  Poly (ADP -ribose) polymerase- 1 (PARP -1) plays a pivotal role in base -excision 
repair (BER) and the DNA dam age response [2].  Once DNA damage is detected,  surveillance 
protein complexes s uch as Mre11 -Rad50-Nbs1 and Rad9/ Rad1/Hus1 recruit rep air proteins and 
halt cell cycle progression, allowing time for DNA repair.  Ataxia -telangiectasia mutated (ATM) 
protein kinase and ataxia-telangi ectasia- related (ATR) p rotein kinase, two members of the 
phosphatidyl inositol 3- kinase-l ike kinase (PIKK) fam ily, are c entral to the DNA damage repair 
process.  Depending on the type of genotoxic stress, either ATM or ATR is preferentially 
activated [3].  ATM is primarily  activated  in response to double- stranded DNA breaks (DSBs), 
while ATR is activated by a broader spectrum of genotoxic stimuli and primarily activ ated in 
response to sin gle-strand DNA breaks (SSBs) arising through the processing of DSB s or the 
stalling of DNA replic ation forks after treatment with platinum compounds.  Both kinases initiate 
a cascade of phosphorylation events, culminating in cell cyc le arrest to allow time  for repair of 
DNA.  ATR additionally facilitates homologous recom bination (HR) repair through modulation of 
the p53-replication prot ein A (p53-RPA) complex bound to ssDNA during the process of DNA 
repair [ 4].  SSBs are additional ly repaired by PARP-1 through B ER.  Binding of PARP- 1 to sites 
of DNA dam age results in activation of its catalytic activity and generation of chains of poly 
(ADP -ribosyl)ated polymers, whic h serve as docking sites for recr uitment of DNA repair proteins 
[5, 6].  The accumulatio n of lethal DSBs  during replication as a result of platinum compounds, in 
the setting of in hibition of both PA RP and ATR, allows for chemopotentiation and a means to 
overcome treatment resistance.  
 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   12 
  
Figur e 2.  Synergy of PARP inhibition + M6620 (VX-970) + cisplatin in H23 lung carcinoma 
(left panel)  vs. HFL1 human fetal lung non- cancerous (r ight panel) cell lines .  Data from MTS 
cell viability assays of the combination of PARP inhibition with rucaparib + M6620 (VX-970) + 
80 nM of cisplati n subjected to statistical Bliss an alysis in order to quantitate  synergy or 
antagonism demonstrates synergy in cancer cell lines, with minimal effect in non -cancerous cell 
lines  [Confidential communication with Vertex, unpublished data]. 
 Data from n onclin ical studies conducted by Vertex  showed that the combination of cisplatin, 
Veliparib, and M6620 (VX-970) a t clinically relevant doses and schedule was well tolerated in 
MF1 nude mice (Figure 3); body weight changes did not exceed ± 5% and were similar to v ehicle .   
 
 
Figure 3. Tolerability  of cisplatin, Veliparib , and  M6620 (VX-970) combination in MF1 n ude 
mice administered on days 1 and 8 and a ssessed for 2 cycles.  Doses/routes of administration: 

CTEP #  P9771 
Clinical Center #  16-C-0087  
   13 
 cisplatin 3 mg/kg IP; Vel iparib 50 mg/kg PO; M6620 (VX-970) 30, 60, and 90 mg/kg PO.  Drugs 
were administered on  days 1 and 8 [Confidential communication with  Verte x, unpublished data]. 
 
2.2 M6620 (VX-970)  
ATR plays a central role in the DNA damage response; therefore, inhibition of A TR is expected to 
enhance the eff ects of DNA damage, either as a result of exposure to genotoxic chemotherapy 
agents or secondary to inhere nt errors in replication .  In vitro studies show that M6620 (VX-970) 
sensitized a panel of human cancer cell lines an d primary human tumor cells to th e cytotoxic 
effects of various DN A-damaging agents whe reas norma l cells (lung and skin fibroblasts and 
mam mary epithelial cells) treated with the same DNA -damaging agents tolerated ATR inhibition 
with a reversible increase in growth [ 8]. 
 
Mechanism of Action  
 
M6620 (VX-970) is a potent, ATP- competitive, inhibitor of ATR (Ki < 300 pM ; measured Ki 
values over the range of 0.1 to 0.3 nM).  It showed > 100-f old selectivi ty against closely -related 
DNA da mage repair proteins,  ATM, and DNA-dependent protein kinase .  Minim al inh ibitory 
activity was observed against a large panel of un related protein kinases, with > 500-fold 
selectivity for ATR . 
 
Preclinical  Studies  
In vitro  studies of M6620 (VX-970) in HCT11 6 colorectal carcinoma cells, show synergism of 
M6620 (VX-970) with  vario us DNA-damaging agents, with the most dramatic response in 
combination with cisplatin , where a 20- fold reduction in t he IC 50 for cisplatin was observed.  Cell 
viability assays were asse ssed by MTS assay  at 96 hours (Figure 3 left panel) [Investigator's 
Brochure].  The effects of M6620 (VX-970) in combination with a range of DNA -damaging 
agents were also tested against a panel of lung, pancreatic, and 9 primary lung tumors in 
combinatio n with cisplatin, using CellTit er-GloTM assays, demonstrating enhanced sy nergy, with 
concurrent dose- dependent decreases in pCHK1 confirming downstream target effect, and dose-
dependent increases in pH2AX demonstrating downstream DNA -damage effect (data no t shown). 
 
M6620 (VX-970) and c isplatin were also assessed in a pan el of primary human non- small cell 
lung cancer ( NSCLC) xenografts in SCID mice with enhancement of antitumor activity in 7 of 9 
xenografts (Figure 4 right p anel).  
 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   14 
 
 
 
Figure 4.  In vitro (l eft panel ) and in viv o (right p anel) syn ergy of cisplatin and M6620 (VX -
970).  Left panel  shows MTS cell viability assays of cisplatin + M6620 (VX-970), with dose-
depe ndent increased potency with the addition of ATR inhibition with M6620 (VX-970).  Right 
panel  shows M6620 (VX-970) impro ves tumor responses to cisplatin in a PDX NSCLC model  in 
SCID mice , as reflected in reduction in tumor volumes.  M6620 (VX-970) was dosed at 60 mg/kg 
PO daily x 4, cisplatin was dosed at 1 mg/ kg IP q weekly  [14].   
 
Nonclinical Pharmacokinetics  
M6620 (VX-970) partitions between blood and plas ma, and varies with dose and species.  
Therefore, whole blood is recommended for the determination o f drug exposure.  The v olume of 
distribution in rats, mice, dogs, and monkeys (21, 20, 10, and 6 L/kg, respect ively) for M6620 
(VX-970) was high and exceede d the volume of total body water.  T issue exposure, including 
tumor, was high with maximum concentra tions reached after 3 h ours for all tissues except for 
kidney and thymus, which peaked at 6 hours.  In rats, n o accumulation or retention was observed 
in tissues and the elimination half -lives were similar across all tissues and whole blood .  Whole 
blood half -lives in rats and dogs were 11.6 and 9.8 hours, respectively .  M6620 (VX-970) had 
high plasma protein bind ing and the free fraction in human was 2.1%.  A low potential for drug-
drug interactions was predicted, based on minimal inhibition or induction of (CYP) 450 isozymes 
by M6620 (VX-970), however strong i nducers or inhibitors or CYP3A 4 may alter M6620 (VX-
970) kinetic s and blood levels.  M6620 (VX-970) was pr imarily eliminated by oxidative 
metabolism, in the urine and bile .  All metabolites observed in human hepatocyte incubations 
were also observed in eit her rat or dog hepatocyte incubat ions and in the blood, bile, or urine from 
rats or dogs .  The systemic cl earance values of M6620 (VX-970) following IV administration 
were determined to be 26 and 13 m L/min/kg in the rat and  dog, respectively.  The impact o f drug -
efflux pumps on the cellul ar activity of M6620 (VX -970) a ctivity was tested in MDR -1 and MRP-
1 expr essing cancer cells and matched drug sensitive cells, with no decrease in M6620 (VX -970) 
activity in cancer cells exp ressing drug efflux pumps [Invest igator Brochure].  
 Preclinical Sa fety Pharmacology Stu dies and T oxicology Studies  
In vitro and in vivo safety pharmacology studies designed to evaluate effects of M6620 (VX-970) against multiple prote in targets and the card iovascular system did not demonstrate any 
toxicologically signific ant effects at exposures or concentrations that significantly exceed the 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   15 
 targeted maximum circulating concentration of M6620 (VX-970) in humans.  M6620 (VX-970) 
was ad ministered by both oral and IV routes to r ats and dogs for up to 28 days.  The rat severely  
toxic dose in 10% of rats (S TD 10) was considered to be an IV dose of 30 mg/kg/day, and the dog 
highest non-severely toxic dose was considered to be an IV dose of 20 mg/kg/day.  Target org ans 
of toxicity in the rat included the testes and peripheral bloo d cell populations (r ed cell ma ss, 
eosinophils, and platelets), and M6620 (VX-970) produced mild irritation at the infusion site.  
Target organs in the dog included the liver, testes, and peripheral blood cell populations ( red cell 
mass and eosinophils) .  M6620 (VX-970) had no cardiovascular toxicities, was not genotoxic in a 
non-GLP 2 -strain mutagenicity assay, had no hemolytic potential in human blood or compatibility 
issues in human plasma, and was well -tolerated in an ac ute rabbit parenteral injection stu dy.  
M6620 (VX-970) does absorb in the ultraviolet- visible spectr um and has tissue distributio n in rats  
[Investigator’s  Brochure]. 
 Clinical Pharmacokinetic Studies  
Preliminary clinical PK  data available from the Phase I first- in-human study of M6620 (VX-970) 
[Study 001] show mean  M6620 (VX-970) plasma concentration ver sus ti me profiles were similar 
in shape to those of the corresponding whole blood profiles.  Variabi lity in the plasma matrix was 
generally reduced, however , and similar PK trends were detect ed between both mat rices.  PK  
exposures tended to increase proportionally with increasing dose based upon C
max (ranged from 
72.0 ng/mL in the 18 mg/m2 dose group to 817 ng/mL in the 140 mg/m2 dose group) and area 
under the concentration versus time curve e xtrapolated to infi nity (AUC 0-∞) (ranged from 351 
h*ng/mL in the 18 mg/m2 dose group to 6148 h*ng/mL in the 210 mg/m2 dose group).  The mean 
volume of distribution a t steady -state (Vss) ra nged from 1148 L to 1602 L and mean clearance 
ranged from 60.6 L/h to 98.2 L/h in the 140 mg/m2 and 18 mg/m2 dose groups, respectively, 
showing no apparent trends.  Similar to the whole blood matrix, the terminal elimination half- life 
was approximately 16 hours across all dose groups.  The administration of gemcitabine 2 4 hours 
prior to M6620 (VX-970) administration did not appear to affect t he pharmacokinetics of M6620 
(VX-970) [Investigator’s Brochure].   
 Clinical Experience  
As of February 2015 (data rep orting cut -off date) , preliminary safety and efficacy data are 
available for 38 subjects from Study 001 parts A and B (A: 7-14- day lead in with M6620 (VX-
970) then M6620 (VX-970) in combination with gemcitabine ; B: 21-day lead in with M6620 
(VX-970) and then M6620 (VX-970) in combination with cisplatin ) and for 11 subjec ts from 
Study 002A ( single agen t M6620 (VX-970)) [ 9].  Preliminary PK data are also available from 
study 002B (M6620 (VX-970) in combination with carboplatin) [Investigator’s Brochure] .   
 In Study 001A (M6620 (VX-970) from 18 to 140 mg/m
2 IV, gemcitabine from 50 0 to 875 mg/m2 
IV), 5 of 6 subjects with NSCLC, 7 of 13 subjects w ith other types of cancers, and  4 of 9 subjects 
with colorectal cancer ha d stable disease as best overall response, and one subject with EBV+ 
nasopharyngeal cancer exh ibited a partial response.  Several subjects had an overall response of 
stable disease for at least 4 cycles.  In Study 001B, 4 of 7 subjects had stable disease a s best 
overall response; o ne subject with endometrial cancer had stable disease for 6 cycles (ongoing at 
time of report).  In Study 002A, 3 of 10 subjects with other types of cancers had stable disease as best over all response; one subject with colorectal cancer exhibited a partial response (80% 
reduction of tumor lesion diameter) and continues on treatment after 11 cycles.  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   16 
  
During the lead-in phase of Study 001A ( single dose M6620 (VX-970) ranging from 18 to 210 
mg/m2 IV), 2 subjects had SAEs of palpitations, pyrexia, and dyspnea ; during the combination 
phase, 9 of 31 subjects had SAEs classified as related to study dru g, 3 had SAEs of Grade 1 
pyrexia classified as possibly related or  related to study drug, and 2 had SAEs of Grade 4 
thrombocytopenia classified as related to study drugs.  The most common AEs, regardless of causality, were nausea ( 20 subjects), vomiting (17 subjects), and fatigue (15 subjects) .  
 
During Study 001B, one subject had an SAE of metastases to the central nervous system that led to study drug discontinuation; during the combination phase (M6620 (VX-970) at  90 or 140 
mg/m
2 IV in combination with cisplatin 40 mg/m2 IV), 1 of 6 subjects had an SAE  of metastases 
to central nervous system and one had dyspnea, which were not related to study drugs.  The most 
common AEs, regardless of causality, were nausea (4 subjects) and fatigue (4 subjects).  
 
In Stu dy 002, 11 subjects received M6620 (VX-970) at doses ranging from 60 to 480 mg/m2 IV.  
Two subjec ts had SAEs of Grade 3 ascites, which were classified as not related to study drug, and 
Grade 3 fatigue, which was classified as possibl y related to study drug.  Serious acute 
hypersensitivity has been identified as an advers e drug reaction for M6620 (VX-970).  As of 17 
April 2015, a serious acute hypersensitivity reaction occurred in 2  of 66 subjects and a thir d 
reaction occurred after th e SAE data cut -off date of 17 April 2015, raising the estimated incidence 
of this ADR to between 4% and 5%.  
 
Preliminary clinical pharmacokinetic data are available from Studies 001 and 002.  PK exposures tended to increase proportionally with increasing dose based upon Cmax (r anged from 72.0 
ng/mL in the 18 mg/m
2 dose group to 817 ng/mL in the 140 mg/m2 dose group) and AUC0-∞ 
(ranged from 351 h*ng/mL in the 18 mg/m2 dose group to 6148 h*ng/mL in the 210 mg/m2 dose 
group).  The mean volume of distribution at steady -state (Vss) ranged from 1148 L to 1602 L and 
mean clearance (CL)  ranged from 60.6 L/h to 98.2 L/h in the 140 mg/m2 and 18 mg/m2 dose 
groups, respectivel y, showing no apparent trends.  The terminal elimination half- life was 
approximately 16 hours across all dose groups.   Overall, the Cmax were 1.36-fold greater and the 
AUC0 -∞ was 1.43-fold greater in whole blood th an plasma matrix , suggesting that plasma is an 
appropriate matrix to characterize the pharmacokinetics of M6620 (VX-970).  M6620 (VX-970) PK exposure parameters were similar when dosed alone versus after gemcitabine or carboplatin administration and indicated no apparent interactions between M6620 (VX-970) and these agents.    Dose escalation for M6620 (VX-970) on this current study P9771 was informed by results f rom 
ongoing Study 002B, which has reached  480 mg/m
2; no DLTs have been observed ( Vertex  
communication).  
At the time of Amendment L, dated 4/22/2019, 36  patients have been enrolled onto this study 
and the MTD established as DL6 (200 mg veliparib q12 hours on days 1-3 and 8-10, 210 mg/m2 
M6620 on days 2 and 9, and 40 mg/m2 cisplatin on days 1 and 8 of 21 -day cycles).   The DLTs on 
DL7 were a grade 4 thrombocytopenia and an infusion reaction to M6620 (VX970) that kept the patient from completing the cycle.  
 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   17 
 Potential Drug Interactions  
Because the drug interaction profile o f M6620 (VX-970) has not been f ully characterized, caution 
should be used when co- administering medications with M6620 (VX-970).  As M6620 (VX-970) 
is primarily metabolized by CYP3A4, concomitant administration with potent inhibitors or 
inducers of CYP3A4 should be avoided [Investigator’s Brochure]. 
2.3 Veliparib (ABT -888) 
Poly (ADP -ribose) polymerase s (PARPs) are a family of nuclear protein enzymes involved in the 
post- translational modification o f proteins and synthesis of poly (ADP -ribose) required for 
recog nition of DNA damage and repair.  PARP -1 and PARP- 2 are the best characterized members 
of the PARP family, and play a key role in the DNA damage response and repair of SSBs  through 
BER.  PARP inhibition has been shown to result in catalytic inhibition, tra pping of PARP-1 on 
DNA repair i ntermediates at SSBs , and stalling of replication forks that require BRCA -dependent 
HR for resolution [ 10]. 
 
Mechanism of Action  
Veliparib is an orally available, potent s mall molecule inhibitor of PARP 1/2 that has shown 
activity throu gh sensitization of a broad range of tumor cells and xenografts to various DNA -
damaging agents [11].  Expression of P ARP is higher in tumor cells compared to normal cells and 
increased PARP activity is one of the mechanisms by which tumor cells avoid apoptosis caused 
by DNA damaging agents [ 12].  PARP inhibition imp airs the cell’s ability to repair DNA damage 
through exposure to chemotoxic agents, such as cisplatin, and further defects in compensatory DNA repair mechanisms further impairs the ability to withstand genotoxic stress and allows for potentiation of antitumor activity.  
 Nonclinical Toxi cology S tudies  
In a variety of nonclinical models, veliparib increased the sensitivity of tumor cells to DNA -
damaging agents, including temozolomide, irinotecan, cyclophosphamide, cisplatin, carboplatin, and radiation at ther apeutic doses that do not incre ase the toxicity of chemotherapeutic agents.  
 
Pharmacokinetic Studies  
A Phase 0 study of veliparib administered as a single dose, ranging from 10 to 50 mg, to 13 subjects, showed that velipar ib was rapidly absorbed, with peak plasma levels occurring 
betwe en 0.5 and 1.5 hours post-dosing [ 13].  At a dose of 25 mg, the mean plasma concentration 
of velipa rib (0.15 µg/mL) was higher than the plasma concentration associ ated with maximal 
efficacy in nonclinical models ( 0.070 µ g/mL) for an average of 4.1 hours.  These results were 
consistent with the projected human pharmacokinetic profile based on nonclinical data.  

CTEP #  P9771 
Clinical Center #  16-C-0087  
   18 
  
In Phase 1 studies, the exposure of veliparib was approxim ately dose-proportional over the 10 
through 500 mg twice daily (BID) dosing range, with peak plasma concentrations at 
approximately 1 to 2 hours after dosing across dose levels.  The termina l half- life (t 1/2) of veliparib 
was about 6 hours, with minimal accumulation following multiple  BID dosing .  Food did not have 
a significant effect on veliparib bioavailability .  The administration of a high- fat meal had no 
significant effect on AUC and only caused a slight decrease in veliparib C max (17%) and a delay of 
approximately 1 hour in T max.  In clinical studies, the mean urinary recovery of unchanged 
veliparib was 72% and the total urinary recovery of veliparib (as parent compound and M8 metabolite) was 86%  [Investigator’s Brochure]. 
 Drug Interactions  
Velipar ib is not a reversible or time -dependent inhibitor of the human cytochrome P450 (CYP) 
enzymes CYP1A2, 2C8, 2C9, 2D6, or 3A4/5 (half maximal inhibitory concentration, IC
50 > 30 
µM).  It is not a reversible CYP3B6 inhibitor (IC 50 > 30 µ M), and causes minimal time-dependent 
inhibition of CYP2B6 at 50 µ M.  Veliparib does not significantly induce activities of major CYPs 
CYP1A2, 2B6, 2C9, and 3A4.  Veliparib is not a potent inhibitor  of the major human CYPs and 
does not significantly induce activities of major human CYP isoforms, suggesting a negligible potential for CYP -mediated drug- drug interactions at anticipated therapeutic concentrations.  
 
Veliparib is a substrate of P -gp and kidney transporters OCT2, MATE1, and MATE2K.  
Consequently, co- administration of veliparib with potent inhibitors of OCT2, MATE1, and 
MATE2K and/or P- gp may decrease veliparib renal clearance and increase its plasma exposure.  
Veliparib does not inhibit P-gp or BCRP at concentrations up to 1000 µ M.  At therapeutic doses 
in combination, veliparib has a low potential for clinical pharmacokinetic drug- drug interactions 
with transporters: P -gp, BCRP, OATP1B1, OATP1B3, OCT1, OCT2, OAT1, OAT3, MATE1, 
and MATE2K).  Veliparib may inhibit OCT1 in the liver and MATE1 and MATE2K in the kidney at higher doses (e.g., 400 mg BID)  [Investigator’s Brochure]. 
 Summary of Clinical Studies  
 
As of March 24, 2014, approximately 1255 patients have been treated with veliparib in AbbVie -
sponsored clinical trials , with veliparib administered as either monotherapy or in combination 
therapy in patients with various solid tumors .  As of March 31, 2014, approximately 1687 adult 
patients and 44 pediatric patients have been treated with veli parib in CTEP -sponsored studies.  
Veliparib has been generally administered in doses up to 500 mg BID as monotherapy, and up to 
400 mg BID in combination with cytotoxic chemotherapies or radiation therapy [Investigator’s Brochure].  Recent published result s of Phase I studies of veliparib in combination with cisplatin 
and vinorelbine in patients with advanced triple- negative breast cancer and/or BRCA mutation -
associated breast cancer show tolerability of veliparib at a dose of 300 mg BID when combined with cisplatin at 75  mg/m
2 on day 1 and vinorelbine at 25 mg/m2 on days 1 and 8 of a 21-day 
cycle.  Responses were seen in 73% of patients who carried a BRCA mutation (6/11 partial responses, 2/11 complete responses) compared with 53% of patients without a know n BRCA 
mutation (11/21 partial responses) and 33% of patients with unknown BRCA status (2/6 partial responses) .  The majority  of toxicities were hematologic [ 14]. 
 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   19 
 Veliparib, when used in combination with cytotoxic chemotherapy, is expected to have unique 
toxicities reflected in amplification of the toxicities of the backbone regimen, and have included hematologic, gastrointe stinal, and CNS toxicities, and possibly thromboembolic events in 
combination with temozolomide .  Secondary malignancies are a potential risk of veliparib based 
on its mechanism of action [Investigator’s Brochure].  
 
2.4 Cisplatin  
Cisplatin injection is current ly FDA-approved in combination with other chemotherapeutic agents 
in patients with transitional cell bladder cancer no longer amenable to local treatments, metastatic ovarian tumors after surgery and/or radiotherapeutic procedures or as second -line in the refractory 
setting, and for metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures .   
 Mechanism of Action : 
Cisplatin is a divalent inorganic, water-soluble, platinum-containing complex.  Following administration, cisplatin undergoes mono- and di- hydroxyl substitution of its cis -oriented 
chloride, allowing for interaction with negatively charged DNA bases, and the formation of interstrand and intrastrand crosslinks .  DNA adducts formed by cisplatin int erfere with DNA 
replication and transcription, leading to DNA breaks.  Pharmacokinetics : 
Cisplatin plasma concentrations decay mono-exponentially with a half- life of ~20 -30 minutes 
following bolus administrations of 50 or 100 mg/m
2, and after 2 hour or 7 hour infusions of 
cisplatin 100 mg/m2.  The total body clearance and volume of distribution at steady- state after 7 
hour infusion of cisplatin at 100 mg/m2 are ~ 15 -16 L/h/m2 and 11-12 L/m2, respectively. 
 Cisplatin does not undergo the instantaneous and re versible binding to plasma proteins that is 
characteristic of normal drug -protein binding.  However, the platinum from cisplatin, but not 
cisplatin itself, becomes bound to several plasma proteins, including albumin, transferrin, and gamma globulin .  The u nbound fraction, composed predominantly of parent drug, is cleared 
within minutes .  The ratios of cisplatin to total free (ultrafiltrable) platinum in the plasma vary 
considerably between patients and range from 0.5-1.1 after a dose of 100 mg/m
2.  Three hours 
after a bolus injection and two hours after the end of a 3 -hour infusion, 90% of the plasma 
platinum is protein bound.  The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of 5 days or more.  
 
Following cisplatin dose of 20-120 mg/m
2, the concentrations of platinum are highest in liver, 
prostate, and kidney; somewhat lower in bladder, muscle, testicle, pancreas, and spleen; and lowest in bowel, adrenal, heart, lung, cerebrum, and cerebellum.  Platinum is present in tissues for as long as 180 days after the last administration .  Maximum red blood cell concentrations of 
platinum are reached within 90-150 minutes after a 100 mg/m
2 dose of cisplatin and decl ine in a 
biphasic manner with a terminal half -life of 36 -47 days.   
 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   20 
 Only a small portion of the drug is excreted by the kidneys during the first 6 hours after 
administration .  Over a dose range of 40-140 mg/m2 given as a bolus injection or as infusions 
varying in length from 1 hour to 24 hours, 10- 40% of the administered platinum is excreted in the 
urine within 24 hours.  Over 5 days following administration of  40-100 mg/m
2 doses given as rapid, 2 -3 hours, or 6-8 hour infusions, a mean of 35-51% of the 
dosed platinum is excreted in the urine , mostly covalently bound to protein and peptides.  M ean 
urinary recoveries of platinum of about 14 -30% of the dose are found following 5- day 
administrations of 20, 30 or 40 mg/m2/day.  Only a small percentage of the ad ministered platinum 
is excreted beyond 24 hours post-infusion and most of the platinum excreted in the urine in 24 hours is excreted within the first few hours .  The parent compound is also excreted in the urine 
and accounts for 13-17% of the dose excreted within one hour after administration of 50 mg/m
2.  
The mean renal clearance of cisplatin exceeds creatinine clearance and is 62 and 50 mL/min/m2 
following administration of 100  mg/m2 as 2 hour or 6-7 hour infusions, respectively.  The renal 
clearance of f ree (ultrafiltrable) platinum also exceeds the glomerular filtration rate indicating that 
cisplatin or other platinum- containing molecules are actively secreted by the kidneys.  The renal 
clearance of free platinum is nonlinear and variable and is dependent on dose, urine flow rate, and individual variability in the extent of active secretion and possible tubular reabsorption .  There is a 
potential for accumulation of ultrafiltrable platinum plasma concentrations whenever cisplatin is administered on a daily basis but not when dosed on an intermittent basis.  No significant relationships exist between the renal clearance of either free platinum or cisplatin and creatinine clearance.  Although small amounts of platinum are present in the bile and large intestine after 
administration of cisplatin, the fecal excretion of platinum appears to be insignificant.  
 Drug Interactions: Concomitant use of cisplatin and aminoglycosides (amikacin, gentamicin, streptomycin, 
tobramycin) has the potential to increase the risk  of nephrotoxicity.  Concomitant use of 
anticonvulsant agents (carbamazepine, fosphenytoin, phenytoin, valproic acid) may result in 
subtherapeutic plasma concentrations of these agents, resulting  in seizure activity .  In a 
randomized trial in advanced ovar ian cancer, response duration was adversely affected when 
pyridoxine was used in combination with altretamine (hexamethylmelamine) and cisplatin . 
 
Adverse Reactions  
Nephrotoxicity 
Dose -related and cumulative renal insufficiency, including acute renal failu re, is the major dose-
limiting toxicity of cisplatin .  Renal toxicity has been noted in 28- 36% of patients treated with a 
single dose of 50 mg/m
2.  It is first noted during the second week after a dose and is manifested by 
elevations in BUN and creatinine,  serum uric acid and/or a decrease in creatinine clearance.  The 
severity of toxicity correlates directly with the amount of cisplatin administered in individual and cumulative doses .  Renal toxicity may be mitigated by the administration of hydration during and 
after cisplatin administration  and avoiding administration of concurrent nephrotoxic drugs. 
 Impairment of renal function has been associated with renal tubular damage, and may present with electrolyte disturbances such as hypomagnesemia, hypocalcem ia, hyponatremia, hypokalemia, 
and hypophosphatemia .  Tetany has been reported in those patients with hypocalcemia and 
hypomagnesemia.  Hypomagnesemia may be a possible permanent adverse effect of cisplatin .  
Decreased serum sodium concentrations have been  observed within 24-72 hours following 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   21 
 cisplatin infusion.  Chronic salt wasting and hyponatremia may persist after discontinuation of 
cisplatin.  
 Ototoxicity  
Ototoxicity has been observed in up to 31% of patients treated with a single dose of cisplatin 50 mg/m
2, and is manifested by tinnitus and/or hearing loss in the high frequency range (4000-8000 
Hz).  Hearing loss may be unilateral or bilateral and tends to become more frequent and severe 
with repeated cisplatin doses.  Vestibular toxicity has also bee n reported.  Ototoxic effects may be 
related to peak plasma concentration of cisplatin .   
 Ocular Toxicity  
Optic neuritis, papilledema, and cerebral blindness have been reported in patients receiving standard recommended doses of cisplatin.  Improvement an d/or total recovery usually occur with 
discontinuation of therapy.  Blurred vision and altered color perception have been reported after the use of regimens with higher doses of cisplatin or greater dose frequencies than recommended .  
The altered color per ception manifests as a loss of color discrimination, particularly in the blue -
yellow axis .  Findings on fundoscopic exam include irregular pigmentation of the macular area.  
 Neurotoxicity Peripheral neuropathy is a dose- limiting toxicity .  The severity of neuropathy varies with dose 
intensity and the total cumulative dose administered .  Symptoms usually develop during 
treatment, and persist after discontinuation of treatment, and include numbness, tingling, impairment of reflexes, vibratory sense, proprioception, and sensory ataxia.  Hematologic Toxicity  
Myelosuppression occurs in 25- 30% of patients .  The nadir platelet count and leukocyte count 
occurs between days 18 to 23 (range 7.5 to 45) with most patients recovering by day 39 (range 13 to 62).  Leukopenia and thrombocytopenia are more pronounced at higher doses (> 50 mg/m
2).  
Anemia (defined as decrease of 2 g/dL) occurs at approximately the same frequency and timing as leukopenia and thrombocytopenia.  Fever and infection have been reported in patients with neutropenia.  Gastrointestinal Toxicity  
Cisplatin is highly emetogenic ; nausea and vomiting may begin within 1 to 4 hours after treatment 
and may last up to 24 hours.  Delayed nausea and vomiting (begins or persists 24 hours or more after chemotherapy ) has occurred in patients despite adequate emetic control on the day of 
therapy.  In some cases, vomiting, nausea, and/or anorexia may persist for up to 1 week after treatment.  
 Hepatotoxicity  
Transient elevations of liver enzymes and bilirubin have been reported to be associated with cisplatin administration at the recommended doses.  
 Anaphylactic-Like Reactions Anaphylactic-like reactions have been reported in patients previously exposed to platinums.  The reactions consist of facial edema, wheezing, tachycardia, and hypotension within a few minutes 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   22 
 after drug administration .  Reactions may be controlled by intravenous epinephrine with 
corticosteroids and/or antihistamines as indicated .   
 
2.5 Correlative Studies Background  
2.5.1 Pharmacodynamic Assessment of Drug Response 
Evaluation of drug effect on DNA damage response in tumor and CTCs will be 
performed by immunofluorescence assays for measurement of DNA damage- repair 
markers, such as γ H2AX, RAD51, pNbs1, and pATR. 
 ATR phosphorylation in response to DNA damage will be used as a marker of direct target effect.   A quantitative immunofluorescence assay for pT1989- ATR will be used 
as a marker of ATR inhibitor activity.    
 Downstream from the primary biomarker are three additional biomarkers of interest:  
• Histone H2AX is one of the H2A histones present in nucleosomes from normal tissues as well as cancer tissues.  H2AX is phosphorylated at its C -
terminus (serine 139) following DNA double- strand breaks.  Phosphorylated 
H2AX, referred to as γ H2AX, can be selectively detected using antibodies by 
Western blots or immunofluorescence.  The levels of γ H2AX are directly 
correlated to the amounts of double- strand breaks per cell, and can be used as 
a dosimeter and biomarker for DNA double- strand bre aks. 
 
• Nbs1 is an adapter protein, linking Mre11 and Rad50 to form the MRN complex involved in recognition of DNA damage and initiation of the signaling cascade in response to DNA double- strand breaks.  
 
• Rad51 plays a central role in recognition of double- strand breaks and 
homologous recombination. 
 
A multiplexed immunofluorescence assay for γ H2AX, phosphorylated Nbs1, and 
Rad51 has recently been validated and published by the Pharmacodynamic Assay Development and Implementation Section (PADIS) at the Frederick National Laboratory for Cancer Research (FNLCR)  [15].  PADIS and the National Clinical 
Target Validation Laboratory (NCTVL) will carry out the testing of all 4 PD biomarkers on tumor tissue and CTCs collected from this study.  
2.5.2 Genomic Analysis  
Genomic sequencing of patient biopsies  will be performed in the laboratory of Dr. 
Mickey Williams, Director of the Molecular Characterization ( MoCha ) Laboratory , 
located at FNLCR .  MoCha is registered under Clinical Laboratory Improvement 
Amendments (CLIA) for the performance of high- complexity molecular testing for 
clinical purposes.  MoC ha will perform two types of analysis: (1) exploratory (non-
CLIA) whole exome sequencing (WES ) analysis of tumor tissues, and (2) the CLIA -
CTEP #  P9771 
Clinical Center #  16-C-0087  
   23 
 certified  Oncomine Comprehensive Assay v3 (OCAv3), a  next generation sequencing 
(NGS) assay designed to find gene mutations within tumors (somatic mutations).  
 
2.5.2.1 WES  
To address the reality that even those patien ts who respond to this drug combination 
are likely to eventually progress , genomic (whole exome) information from 
consenting patients undergoing optional tumor biopsies at restaging follow -up or at 
the time of progression will be compared with C1D1  genomic information from those 
patients to investigate the development of acquired drug resistance.  
2.5.2.2 OCAv3  
OCAv3 is  not designed to be used to find hereditary or germline mutations.  The assay 
was originally validated for the NCI- MATCH clinical trial ([STUDY_ID_REMOVED]) and is 
considered an investigational device limited by Federal law to investigational use.  Its 
performance characteristics have been determined through extensive testing by the NCI-MATCH network laboratories.  It has not been cleared by the US Food and Drug 
Administration and such approval is not required for clinical implementation.  
 OCAv3 can reliably identify the presence or absence of greater than 3,000 known mutations of interest (MOIs) in 161 unique genes, with results compared to the Human Referen ce Genome hg19.   The assay identifies greater than 3,000 annotated 
mutations of interest (MOIs) characterized into 5 mutation types: single nucleotide variants (SNV), small insertions/deletions ( indels), large (> 3 bases) 
insertions/deletions (l arge indels), copy number variants (CNV), and gene fusions.  In 
the majority of cases , we do not know the medical significance of the genetic variants 
[16, 17]. 
 This report generated from the assay is intended to provide background information to the oncology team and the patient about mutations detected within the patient’s tumor.  It does not determine assignment of a  patient to a clinical trial ; however, as MoCha i s 
a MATCH study -designated lab (see 
https://ecog-acrin.org/nci- match -eay131-
designated- labs), a CLIA OCAv3 report from MoCha indicating that a patient carries 
an eligible aMOI is sufficient for enrollment on the NCI MATCH ([STUDY_ID_REMOVED]) 
and MPACT ([STUDY_ID_REMOVED]) trials.  
 Mutations detected by the assay may be present only in the tumor, or in every cell of the body; this test also cannot tell  whether a potential germline mutation causes or will 
cause a hereditary cancer syndrome.  If the patient’s personal and/or family history are suggestive of a hereditary cancer predisposition, it is recommended that the PI arrange for the patient to meet w ith a genetic counselor and, if warranted, undergo the 
appropriate genetic test.   
 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   24 
 A Certificate of Confidentiality has been obtained from the NIH to help protect the 
privacy of all study participants.  Information on tumor gene variants will be stored in the patient’s medical records.  
 
3 PATIENT SELECTION 
3.1 Eligibility Criteria  
3.1.1 Patients must have histologically confirmed solid tumors for which standard therapy known to prolong survival ha s failed  in the metastatic setting  or for which standard 
therapies do not exist.  
3.1.2 Tumor amenable to biopsy and willingness to undergo tumor biops ies before and after 
M6620 (VX-970) treatment  during the expansion phase of the trial (biopsies optional 
during the escalation phase).  
3.1.3 Patients must have completed any chemotherapy, r adiation therapy, surgery, or 
biologic therapy ≥ 3 weeks (or  ≥ 5 half -lives , whichever is shorter ) prior to entering 
the study.  Patients must be ≥ 2 weeks since any prior administration of a study drug in an exploratory IND/Phase 0 study and ≥  1 week since any palliative radiation 
therapy.  Patients m ust have recovered to eligibility levels from prior toxicity or 
adverse events.  
3.1.4 Age ≥ 18 years of age.   
3.1.5 ECOG performance status ≤  2 (see Appendix A ). 
3.1.6 Life expectancy > 3 months. 
3.1.7 Patients must have normal organ and marrow function  as defined below: 
− absolute neutrophil count   ≥1,500/mcL  
− hemoglobin      ≥ 10 g/dL 
− platelets       ≥100,000/mcL  
− total bilirubin      ≤1.5 X institutional upper limit of normal 
− AST(SGOT)/ALT(SGPT)   ≤1.5 X institutional upper limit of normal  
        ( OR ≤  3X ULN in the setting of liver metastases)  
− creatinine       ≤1.5X institutional upper limit of normal  
 OR  
− creatinine clearance     ≥ 60 mL/min/1.73 m2 for patients with creatinine 
levels above institutional normal 
3.1.8 The effects of M6620 (VX-970) and veliparib on the developing human fetus are 
unknown.  For this reason and because cisplatin is known to be teratogenic, women of child -bearing potential and men must agree to use adequate contraception (hormonal 
or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 months  after completing study treatment.  Should a 
woman become pregnant or suspect she is pregnant while she or her partner is  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   25 
 participating in this study, she should inform her treating physician immediately .  Men 
treated or enrolled on this protocol must also agree to use adequate contraception prior 
to the study, for the duration of study participation, and for 6 months after completion 
of administration  of study agents . 
3.1.9 HIV-positive subj ects on combination antiretroviral therapy are ineligible because of 
the potential for pharmacokinetic interactions with M6620 (VX-970).  In addition, these subjects are at increased risk of lethal infections when treated with marrow -
suppressive therapy.  
3.1.10 Patients must be able to swallow whole tablets or capsules.  Nasogastric or G -tube 
administration is not allowed .  Any gastrointestinal disease which would impair 
ability to swallow, retain, or absorb drug is not allowed. 
3.1.11 Ability to understand and the willingness to sign a written informed consent form. 
3.1.12 During the expansion phase of the protocol, patients must have disease amenable to biopsy and be willing  to undergo pre - and post- treatment biopsies. 
3.1.13 Patients must have  ≥10.0 g/dL Hb and no blood transfusion in the past 28 days to 
receive Veliparib.  
3.2 Exclusion Criteria  
3.2.1 Patients who are receiving any other investigational agents.  
3.2.2 Patients with known active brain metastases or carcinomatous meningitis are excluded 
from this clinical trial.  Patients whose brain metastatic disease status has remained stable for ≥ 4 weeks following treatment of brain metastases are eligible to participate  
at the discretion of the principal investigator. 
3.2.3 Uncontrolled intercurrent illness including, but not limited to, ongoing or active untreated infection, or psychiatric illness/social situations that would limit compliance with study requirements.   
3.2.4 Patients required to be on any of the concomitant medications listed in Appendix B  
are excluded .  
3.2.5 Pregnant women and women who are breastfeeding are excluded from this study because the effects of the study drugs on the developing fetus are unknown.   
3.2.6 Patients who have had prior platinum- based therapy who have > Grade 1 
neurotoxicity or ototoxicity  at the time of enrollment will not be permitted on study.  
3.2.7 Patients with a seizure history will not be permitted on protocol due to association of veliparib with seizure activity in animal toxicology studies a t higher doses .  Patients 
on anticonvulsant medications will not be permitted on study due to the potential to lower plasma levels of anticonvulsants and risk for seizure activity.  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   26 
 3.2.8 Patients with treatment- related AML (t- AML)/MDS, or with features suggestiv e of 
AML/MDS, or who have had prior allogeneic bone marrow transplant or double 
umbilical cord blood transplantation, should not receive Veliparib due to reports of MDS and leukemia secondary to oncology therapy on CTEP-sponsored studies utilizing Veliparib.  
3.3 Inclusion of Women and Minorities  
Both men and women of all races and ethnic groups are eligible for this trial.  
 
3.4 Screening Evaluation  
3.4.1 Histologic confirmation  of primary tumor tissue or of known recurrence will be 
required from each participant to confirm diagnosis.  Pathology reports from outside institutions will be accepted.  
3.4.2 History and physical examination: Complete history and physical examination (including height, weight, vital signs, ECG,  and performance score) will be conducted 
within  8 days pri or to enrollment.   
3.4.3 Imaging Studies (Baseline): Every participant should have an evaluation of known sites of disease as part of the baseline evaluation .  All patients will be  required to 
undergo a CT scan of the chest/abdomen/pelvis to evaluate sites of  disease within 28  
days prior to enrollment.  MRI evaluation of site of disease may be performed in lieu 
of CT evaluation at the discretion of the principal investigator if it is the opinion of the investigator that this modality would provide a more accurat e assessment of disease 
than a CT would, for a given site.  
3.4.4 Laboratory Evaluation: Baseline laboratory data are to be obtained within 8 days prio r 
to enrollment:  
• Hematological Profile: CBC with differential.  
• Biochemical Profile: albumin, total bilirubin, BU N, calcium, creatinine, SGOT 
[AST],  SGPT [ ALT], magnesium, potassium, and sodium. 
• Coagulation Profile: PT, PTT, INR  required within 1 week prior to all biopsies , and 
may also be performed  as clinically indicated .   
• Serum or urine pregnancy test for female participants of childbearing  potential.  
 
4 REGISTRATION PROCEDURES  
4.1 NCI Clinical Center Patient Registration Process  
Authorized staff must register an eligible candidate with NCI Central Registration Office (CRO) 
and through the Theradex Interactive Web Respo nse System (IWRS)  within 24 hours after signing 
consent.  Access IWRS through https://iwrs.theradex.com under the “Patient” tab utilizing your CTEP- IAM Username and Password.   A registration Eligibility Checklist from the Web site  
(http://home.ccr.cancer.gov/intra/eligibility/welcome .htm) must be completed and sent via 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   29 
 o Day 15 (may be performed by patients’ home oncologist) 
• Cycle 2 and beyond 
o Day 1 prior to treatment 
o Week 2 prior to first IV treatment  
o Day 15 (optional and may be performed by patients’ home oncologist) 
 
CT scans will be performed at baseline (within 28 days prior to start of protocol therapy), and 
repeat -imaging  scans will be performed every  2 cycles (every 3 cycles for patients on study for 
more than one year, 4 cycles for p atients on study more than 3 years ).  MRI evaluation of site of 
disease may be performed in lieu of CT evaluation at the discretion of the principal investigator if it is the opinion of the investigator that this modality would provide a more accurate asse ssment 
of disease than a CT would for a given site.  
 
ECG will be performed at baseline  (within 8 days prior to start of protocol therapy), within 
approximately 1 hour after  the end of M6620 (VX-970) infusion during cycle 1 only, and as 
clinically indicated . 
 
The starting dose will start at dose level 1 per dosing schema below.  Intra -patient dose escalation 
will be allowed.    Once the MTD is established, additional patients will be enrolled to the expansion phase as described in Section 13.1. 
 
5.1 Agent Administration  
5.1.1 M6620 (VX-970)  Administration  
M6620 (VX-970) will be administered intravenously , over one hour ( ± 10 minutes)  
on days 2 and 9 of each 2 1-day cycle (or on days 1 and 8 of any cycle in which 
cisplatin is not admi nistered).  M6620 (VX-970) should not come in contact with 
0.9% Sodium Chloride due to incompatibility.  5% dextrose in water solution must be used for IV line priming and flushing.  Infuse using an infusion set containing low-sorption or non- PVC, DEHP -free tubing and an in- line 0.2 micron filter.  
5.1.2 Veliparib  administration  
Veliparib will be administered orally on days 1 through  3 and days 8 through 10  of 
each 21 -day cycle.   Veliparib should be administered before cisplatin and M6620 
(VX-970). 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   30 
 5.1.3 Cisplatin administration  
Cisplatin will be administered at 40 mg/m2 intravenously over one hour (± 10 
minutes), via central or peripheral access on day 1 (and day 8 on DL3 and higher) of 
each 21 -day cycle .  As of Amendment I  (12/7/2017), patients who have been on trial 
for at least 6 cycles may  have cisplatin administration held or discontinued while 
continuing on trial at the discretion of the PI, Dr.  to address the potential for 
cumulative neurotoxicity observed with extended  cisplatin treatment . 
• Prior to cisplat in administration, at least 500 mL of 0.9% sodium chloride with 
KCl 10 mEq/L  and magnesium sulfate 4 mEq/L injection should be 
administered over at least 60 minutes.  Following administration of cisplatin, 
at least an additional 500 mL of 0.9% sodium chlor ide with KCl 10 mEq/L  
and magnesium sulfate 4 mEq/L  injection should be administered over at least 
60 minutes.   
• Patients will additionally receive pre- medication with anti- emetics . The 
following regimen is recommended for initial antiemetic prophylaxis; administration of steroids will be at the discretion of the investigator : 
− Dexamethasone 12 mg orally at least 60 minutes prior to cisplatin on day 1 (and day 8 on DL 3 and above) of each 21-day cycle.  
− Aprepitant 125 mg orally given at least 60 minutes prior to cisplatin on day 1 (and day 8 on DL 3 and above) of each 21- day cycle, followed by 80 mg 
orally daily for days 2 and 3 (and days 9 and 10 on DL 3 and higher )* 
− Ondansetron 8 mg orally given at least 60 minutes prior to cisplatin on day 1 (and day 8 on DL 3 and above) of each 21- day cycle, and 
continued every 8 hours for days 1-5 (and days 8-12 on DL 3 and higher ) 
For patient convenience, pre-medications can alternatively be given intravenously 30 minutes prior to therapy.   
*A single 150 mg dose of fosap repitant IV may be given pr ior to cisplatin in 
lieu of the oral aprepitant , or another anti- emetic may be used if aprepitant is 
not tolerated . 
 
 Dosing Schema:  
Dose  
Level  Veliparib  
(PO q12 hours ± 1 hour ) M6620 (VX -970) 
 (IV Day s 1/2 and 8/9) Cisplatin  
(IV Day 1 or Days 1 
and 8 ) 
-2 20 mg  days 1-3, 8-10 40 mg/m2 40 mg/m2 day 1 
-1 40 mg  days 1-3, 8-10 60 mg/m2 40 mg/m2 day 1 
1 100 mg  days 1-3, 8-10  90 mg/m2 40 mg/m2 day 1 
2 100 mg days 1-3, 8-10 140 mg/m2 40 mg/m2 day 1 

CTEP #  P9771 
Clinical Center #  16-C-0087  
   31 
 3 100 mg days 1-3, 8-10 120 mg/m2 40 mg/m2 days 1, 8 
4 100 mg  days 1-3, 8-10 210 mg/m2 40 mg/m2 days 1, 8 
5 150 mg  days 1-3, 8-10 210 mg/m2 40 mg/m2 days 1, 8 
6 200 mg days 1-3, 8-10 210 mg/m2 40 mg/m2 days 1, 8 
7 300 mg days 1-3, 8-10 210 mg/m2 40 mg/m2 days 1, 8 
8 400 mg days 1-3, 8-10 210 mg/m2 40 mg/m2 days 1, 8 
 
Doses will be calculated  based on body surface area per institutional SOP. 
As of Amendment L (dated 4/22/2019), the MTD for this combination has been  established 
as DL6 . 
5.2 Intra -patient Dose Escalation   
Intra -patient dose escalation is permitted ONLY if: a)  there is no toxicity > grade 1 that is 
possibly, probably, or definitely related to the study drugs after one cycle at the patient’s  initially  
assigned dose level (subsequent cycles may be delayed up to 14 days past the end of the previous 
21-day cycle to allow for toxicities to resolve), b)  higher doses have been evaluated and 
completed without DLT, and c)  disease has not progressed.  Doses may be escalated by one dose 
level for every subsequent cycle, provided conditions a–c are met, up to the last evaluated dose level NOT associated with DLT.  
 Intra -patient dose reductions: If a patient experiences DLT during a cycle, the dose will be 
reduced by one level (if there is a lower dose level) for the next cycle, provided toxicity has recovered to ≤ Grade  1 within 14 days after completing a 21-day cycle, and the patient’s di sease 
is stable or responding.  If a patient is dose reduced twice and still experiences a DLT, then the 
patient would be removed from the study unless the patient is experiencing clinical benefit and, at the PI’s discretion, should be allowed to continue on study.  If no lower dose level exists, then the patient will be removed from the study.    Reported adverse events and potential risks are described in  Section 7.  Appropriate dose 
modifications are described in Section 6 .  No investigational or commercial agents or therapies 
other than those described below may be administered with the intent to treat the patient ’s 
malignancy. 
5.3 Definition of Dose -Limiting Toxicity  
Determination of dose- limiting toxicity (DLT) will be based on toxicities observed in the first 
cycle of therapy .  Dose escalation will proceed within each cohort according to the following 
scheme.  DLT  is defined below:  
 
Number of Patients with 
DLT at a Given Dose Level  Escalation Decision Rule  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   32 
 0 out of 3  Enter 3 patients at the next dose level.  
≥ 2 Dose escalation is stopped, and this dose is declared the maximally 
administered dose.  Three (3) additional patients will be entered at the 
next lowest dose level if only 3 patients were treated previously at that dose.  
1 out of 3  Enter at least 3 mo re patients at this dose level.  
• If 0 of these 3 patients experience DLT, proceed to the next dose level.  
• If 1 or more of this group suffer DLT, then dose escalation is stopped, and this dose is declared the maximally administered dose.  Three (3) 
additiona l patients will be entered at the next lowest dose level if only 3 
patients were treated previously at that dose.  
≤ 1 out of 6 at highest dose 
level below the maximally 
administered dose This is generally the recommended phase 2 dose.  At least 6 patients must 
be entered at the recommended phase 2 dose. 
 
Dose limiting toxicity (DLT) is defined as an adverse event tha t is related (possibly, 
probably, or definitely) to administration of study drugs and fulfills one of the following 
criteria.  
5.3.1 Grade ≥  3 Non- Hematological Toxicity  
Grade ≥  3 non- hematological toxicity thought  to be related to study medications will 
be considered dose- limiting with the following clarifications:  
Diarrhea Grade 3 will only be considered dose- limiting if it is refractory to treatment 
as outlined in Section 5.3.2, Supportive Care Guideline, and unable to be corre cted to 
Grade 2 or less within 24 hours.  Bloody or Grade 4 diarrhea will be dose- limiting.  
 Vomiting Grade 3 will only be considered dose- limiting if it is refractory to anti -
emetic therapy and unable to be corrected to Grade 2 or less  as outlined in Section 
5.3.1.    Nausea Grade 3 will only be considered dose limiting if symptoms and severity persist beyond 48 hours despite continuation of anti- emetics.  
Rise in creatinine to Grade 3, not corrected to Grade 1 or less within 48 hours with IV fluids will be considered dose- limiting .  All Grade 4 rises in creatinine will be dose 
limiting.  
 Grade ≥  3 metabolic toxicities unable to be corrected to Grade 1 or baselin e within 48 
hours (hypocalcemia, hypercalcemia, hypomagnesemia, and hyponatremia) will be considered dose limiting.  For hypokalemia or hyperkalemia, grade ≥  2 toxicities 
unable to be corrected to grade 1 or less within 48 hours will be considered dose limiting .   
 Grade 4 metabolic toxicities that are symptomatic will be considered dose limiting regardless of duration or ability to correct.  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   33 
 5.3.2 Grade 4 thrombocytopenia or Grade 3 thrombocytopenia associated with bleeding.  
5.3.3 Grade 4 neutropenia ≥  5 days or febrile neutropenia will be considered dose limiting . 
5.3.4 Any degree of leukopenia in the absence of grade 4 neutropenia ≥  5 days, or 
lymphopenia will not be considered dose limiting. 
5.3.5 Any degree of alopecia will not be considered dose limiting. 
5.3.6 Grade 3 fatigue of greater than 1 week duration. 
5.3.7 Failure to tolerate 100% of the dosing in the first cycle.  
5.4 General Concomitant Medication and Supportive Care Guidelines  
The predominant toxicity observed in clinical and non- clinical  toxicology studies was 
hematologic .  Weekly blood counts and chemistry panels will be obtained prior to treatment each 
week .  If any weekl y evaluation demonstrates grade 2 neutropenia or thrombocytopenia, treatment 
will proceed but a repeat hematology assessment wil l be obtained wi thin 48 hours for interval 
evaluation.  Platelet count must improve to Grade 1 or better and neutrophil count must improve 
to Grade 2 or better on repeat hematology assessment prior to the next cycle . 
 
All patients will be provided with the best available supportive care.  All c oncomitant medications  
should be documented prior to initiation of treatment, and be periodically reviewed with the patient.   Because there is a potential for interaction of M6620 (VX -970) and Veliparib with other 
concomitantly administered drugs, the case report form must capture the concurrent use of all other drugs, over -the-counter medications, or alternative therapies.  The PI should be alerted if the 
patient is taking any agent known to affect or with the potential for drug inte ractions.  M6620 
(VX-970) is metabolized by cytochrome P450 (CYP) 3A4 isoenzyme (CYP3A4); exposure to M6620 (VX-970) may be affected by concomitantly administered drugs that are strong inhibitors or inducers of CYP3A4.  Veliparib is metabolized by CYP1A1, 2D6, 2C19, and 3A4; i t is not 
known whether its metabolism is affected by drugs that are strong inhibitors or inducers of these 
enzymes.  To date, no clinically significant pharmacokinetic drug-drug interaction has been 
reported for Veliparib.   The study team should check a frequently- updated medical reference for a 
list of drugs to avoid or minimize use of.  
M6620 (VX-970) is a moderate inhibitor of P-gp and BCRP.  Use caution when administered with substrates of P -gp and BCRP. 
M6620 (VX-970) absorbs in the UV- visible radiation spectrum and is widely distributed including 
skin, so patients receiving M6620 (VX-970) should take protective measures to minimize sun exposure. 
To minimize the possibility of phlebitis, M6620 (VX -970) should be administered through a 
large -bore catheter into a large -caliber peripheral vein or through central venous access.  The 
intravenous infusion site should be monitored closely for the development of erythema, 
induration, purulence, tenderness, or warmth.  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   34 
 5.4.1 Nausea/Vomiting  
As cispl atin is known to be highly emetogenic, patients will receive pre- medication with the 
following anti- emetics prior to administration of cisplatin  (steroids at the discretion of the 
investigator): 
- Dexamethasone 12 mg orally at least 60 minutes prior to cispl atin on day 1 (and day 8 
on DL 3 and higher ) of a 21 -day cycle, every 21 days 
- Aprepitant 125 mg orally given at least 60 minutes prior to cisplatin on day 1 (and day 8 on DL 3 and above) of each  21-day cycle, followed by 80 mg orally daily for days 2 
and 3 (and days 9 and 10 on DL 3 and higher ) 
- Ondansetron 8 mg orally given at least 60 minutes prior to cisplatin on day 1 (and day 8 on DL 3 and above) of each 21-day cycle, and continued every 8 hours for days 1-5 
(and days 8-12 on DL 3 and higher ) 
For patient convenience, pre-medications can alternatively be given intravenously 30 minutes prior to therapy.  A single 150 mg dose of fosaprepitant IV may be given prior to cisplatin, in lieu of the 3 days of oral aprepitant, or another anti- emetic may be used if aprepitant is not 
tolerated .
   
 
If the patient  is well and beyond the first cycle, steroid dose reduction may be considered at 
the discretion of the investigator.  
 
The addition of dopamine receptor antagonists or benzodiazepines will be at the discretion of the investigator.  Vomiting will be considered refractory if it does not resolve to  ≤ Grade 1 
within 24 hours.  Nausea ≤ Grade 2  will be considered refractory if symptoms and severity 
persist past 48 hours after cisplatin dosing despite continuation of anti- emetics.  
 
5.4.2 Diarrhea  
If diarrhea develops and does not have an identifiable cause ot her than study agents, 
anti-motility agents  (e.g., loperamide, diphenoxylate/atropine) with be given after the 
first unformed stool, with continuation until the first formed stool.  Diarrhea will be considered  refractory if it does not resolve within 24 ho urs to ≤ Grade 1 with the 
above measures.  If the patient develops blood or mucous in the stool, dehydration, or hemodynamic instability, or fever along with the diarrhea, patient will receive IV fluids and antibiotics as medically indicated.  
5.4.3 Seizures  
Seizures we re seen in some animal toxicology studies for veliparib, although at doses 
higher than those anticipated in this study.  In the phase I single agent trial, seizures 
were seen at 400 -500 mg BID.  Seizures were successfully treated with lorazepam, 
which will be considered the drug of first choice for controlling seizures, should they occur on this study.  Any seizure occurring in a patient on this study will be considered a DLT.  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   35 
 5.4.4 Neutropenia  
To reduce the risk of severe myelosuppression events, a complete blo od count ( CBC) 
should be performed on weeks 1 and 2 of each cycle prior to cisplatin or M6620 (VX-
970) treatment and again on days 2, 9, and 15 of the first cycle.  Pegfilgrastim should be avoided as it requires 14 days between dosing and the next administ ration of 
chemotherapy.  Febrile neutropenia is a life -threatening complication requiring 
hospitalization and urgent broad- spectrum antibiotics, as well as an aggressive search 
for the source and microbial cause of the episode .  Growth factors to prevent 
neutropenia will not be administered prophylactically .  If necessary, they may be 
administered according to accepted American Society of Clinical Oncology (ASCO) guidelines to allow re- treatment.   
5.4.5 Anemia  
Symptomatic anemia should be treated with red blood c ell transfusion  as clinically 
indicated, and is recommended if the hemoglobin falls below 8 g/dL.  The initiation of erythropoietic therapy for the management of chemotherapy -induced anemia follows 
the American Society of Hematology/ASCO clinical practice guidelines 
(http://www .asco.org).  
5.4.6 Thrombocytopenia 
Thrombocytopenia will be closely monitored on study.  In the absence of bleeding, or 
a necessary invasive procedure, platelet transfusions should be considered for a 
platelet count ≤ 25,000/mm
3.  If invasive procedure(s) is (are) planned, or the patient 
develops bleeding, platelet transfusions will be administered as clinically indicated .  
5.4.7 Acute hypersensitivity reaction/severe infusion reaction  
Patients should be monitored during M6620 (VX-970) infusion f or these reactions, 
which may include loss of consciousness and/or hemodynamic instability, including 
hypotension.  In the event of one of these reactions, the infusion should be stopped 
immediately and standard supportive measures should be applied according to the presentation.  This may include administration of fluids and epinephrine. 
5.5 Duration of Therapy  
In the absence of treatment delays due to adverse events, treatment may continue until one of the following criteria applies:  
• Disease progression  
• Intercurrent illness that prevents further administration of treatment  
• Pregnancy 
• Patient decides to withdraw from the study, or  
• General or specific changes in the patient ’s condition render the patient 
unacceptable for further treatment in the judgment of the investigator. 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   36 
 5.6 Duration of Follow Up 
Patients will be followed for 30 days after the last dose is administered or until one of the 
following occurs: patient enrolls on another protocol, patient receives standard of care, or death, whichever comes first .  The follow -up will consist of a phone call between Days 27- 30 after the 
last dose to evaluate adverse events that were ongoing and any new events that might be deemed related to the therapy .  Toxicities considered  to be possibly, probably, or definitely relat ed to the 
study drugs that have not resolved or stabilized by Day 30 post- treatment will be followed until 
stabilization or resolution via phone calls as clinically indicated.  
5.7 Criteria for Removal from Study  
Patients will be removed from study for one of the following reasons: completed 30-day follow up period or toxicities are unresolved but stabilized, patient enrolls on another protocol, or patient receives standard of care.  The reason for study removal and the date the patient was removed must be documented in the medical record and communicated by fax to the NCI Central 
Registration Office per Section 4. 
 
6 DOSING DELAYS/DOSE MODIFICATIONS  
Toxicities should have resolved to ≤  Grade 2  (Grade 1 for some hematologic toxicities)  prior to 
starting the  next cycle.  Treatment may be delayed for a maximum of 3 weeks beyond the actual 
cycle length of  21 days for toxicities that develop and do not resolve as defined above .  Beyond 3 
weeks, the patient may remain in the study at the discretio n of the PI unless noted otherwise.  
Treatment may be delayed for a maximum of ± 1 day during a cycle due to unavoidable scheduling conflicts.  If treatment is held during a cycle, that week’s treatment will be omitted for 
the cycle and treatment will proc eed with the following week’s treatment as scheduled (e.g. , if 
Day 2 M6620 (VX-970) treatment is held, the next treatment will be Day 9 ).  Missed doses of 
veliparib will not be made up and will be documented in the patient’s diary (see Appendix C ).  
This applies starting with cycle 2 and beyond.  If this occurs during cycle 1, the patient will be considered not evaluable and will need to be replaced on study. 
  
6.1 Dose Modifications 
Dose modifications are defined below:  
6.1.1 Grade 2 drug -related toxicity: The dose of cisplatin will be reduced to 30 mg/m
2 
without a concomitant dose reduction in M6620 (VX -970) or veliparib for any Grade 
2 ototoxicity, neurotoxicity, or persisting Grade 2 rise in creatinine.  A second recurrence of Grade 2 ne phrotoxicity, ototoxicity, or neurotoxicity despite dose 
reduction will result in discontinuation of treatment.  Treatment will not be held for Grade 2 hematologic toxicities . 
Grade 3 -4 drug -related non -hematologic toxicities  attributed to all 3  drugs : Tre atment 
will be held until toxicities recover to  ≤ Grade 2 or baseline prior to re -initiating 
treatment at the next lower dose level .  If electrolyte abnormalities do not resolve to  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   37 
 grade 2 or less within 48 hours, dose reduction will be required.  Dose modifications  
for nausea , vomiting, and diarrhea will be made only if they are refractory to 
treatment and symptoms and severity persist beyond 48 hours for nausea and 
vomiting, or beyond 24 hours for diarrhea  (See Section 5.2 ).  
6.1.2 Grade 3 drug -related hematologic toxicities:  
Treatment  will be held for a maximum of 3 weeks until hematologic toxicities , except   
leucopenia in the absence of Grade 3 or higher neutropenia, have resolved to ≤  Grade 
1 prior to re -initiating treatment at a lower  dose level.   See also Section 6.2. 
6.1.3 Grade 4 Drug- related Hematologic Toxicities: Treatment  will be held for a maximum 
of 3 weeks until hematologic toxicities , except  leucopenia in the absence of Grade 4 
neutropenia, have resolved to ≤  Grade 1 prior to re -initiating treatment at a lower dose 
level . See also Section 6.2. 
6.1.4 Anaphylactic  reaction attributed to cisplatin : Symptoms have included fac ial edema, 
wheezing, tachycardia, and hypotension during or within a few minutes after drug administration .  Treatment will be held and supportive measures implemented 
including administration of epinephrine 1:1000 (1 mg/mL) 0.3 mg SQ/IM, and intravenous f luid support for hypotension.  Treatment may not be restart ed.  
6.1.5 Infusional reaction attributed to M6620 (VX-970) : Symptoms may include  pruritis, 
flushing, shortness of breath, chest tightness, dizziness, headache, increased  or 
decreased  blood pressure, los s of consciousness,  and increased heart rate.  
Severity of Symptoms   
Mild transient reaction  Give diphenhydramine H Cl 25 mg to 50  mg IV, continue 
treatment,  close monitoring of vitals q 5  min.  for 15  min. after 
onset of symptoms .   
Mild to moderate persi stent reaction  Stop treatment ; give dexamethasone 10  mg IV and  
diphenhydramine HC l 25 mg to 50 mg IV; may resume treatment 
after recovery of symptoms; premedication indicated for 
subsequent drug administration: pre-medication indicated prior to 
re-initiation: dexamethasone 12 mg PO and diphenhydramine HCl 25 mg to 50 mg PO approximately 4 to 6 hours prior to re -
challenge  
Severe symptoms (e.g. , hypotension 
requiring pressor therapy or IV 
fluids, angioedema, respiratory 
distress requiring bronchodila tor 
therapy, or generalized urti caria)  Stop treatment ; give dexamethasone 10  mg IV and  
diphenhydramine HCl 25 mg to 50 mg IV;  add broncho dilators as 
needed;  patients may not receive further treatment; the patient will 
be taken off study.    
 
6.2 Agent -specific Dose Mo difications: Veliparib  
To date, four cases of grade 4 myelodysplastic syndrome (MDS) and two cases of 
leukemia secondary to oncology therapy (one grade 4 and one grade 5) were observed on CTEP- sponsored studies utilizing veliparib.  It is possible velipari b contributed to these 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   38 
 adverse events; it is also possible that prior therapy with platinum or alkylating agents 
contributed to the development of MDS or leukemia.  If a patient is taking veliparib  in combination with other therapies, but develops bone 
marrow findings consistent with acute myeloid leukemia (AML)/MDS or severe persistent anemia requiring transfusion to maintain ≥10 g/dL hemoglobin, the patient may be allowed to continue the other therapies if they are experiencing clinical benefit and the to xicity is 
not related to the other therapies, based on the opinion of the treating investigator, and after discussion with the Principal Investigator.   Patients who d evelop MDS/AML on 
treatment should discontinue ABT -888 treatment and be managed appropriatel y. 
 In addition, patients should be monitored for persistent myelosuppression, including anemia, thrombocytopenia, and neutropenia that does not recover to normal or grade 1 between courses of treatment, as per Good Clinical Practice.  If peripheral bloo d counts do 
not recover to normal or are persistently abnormal, the patient should be evaluated for the possible development of AML/MDS using a bone marrow aspirate with cytogenetics.  veliparib  therapy should be held and discontinued if AML/MDS is documented.  A 
complete history of prior therapy should be documented, particularly prior platinum- based 
or alkylating agent therapies.  Documentation of germline BRCA mutation (gBRCAm) status, if known, should be recorded.  Management of neutropenia and thrombocytopenia   
 
CTCAE Grade  Definition  Veliparib Dose  
1-2 ANC >1.0 G/L or Platelet 
count >50 G/L Investigator judgement to continue treatment 
or allow dose interruption; dose interruptions should be for a maximum of 3 weeks; appropriate supportive treatment and causality 
investigation.  
3-4 ANC <1.0 G/L or Platelet 
count <50 G/L Dose interruption until recovered to CTCAE 
Grade ≤1 for a maximum of 3 weeks.  Upon recovery, veliparib dose should be reduced by one dose level.  If repeat CTCAE Grade 3 -4 
occurrence, further dose reduce one veliparib 
dose level.  
ANC = absolute neutrophi l count; CTCAE = Common Terminology Criteria for Adverse Events  
 
Use of hematopoietic agents   
Use erythropoietin -stimulating agents per standard of care National Comprehensive 
Cancer Network (NCCN) and/or institutional guidelines, iron supplements, and/or transfusions as clinically  indicated for management of anemi a.   P rescribing information 
for the erythropoiesis stimulating agents (including Aranesp, Epogen and Procrit) highlight that there is a potential risk of shortening the time to  tumor progression or 
disease-free survival.   Primary  prophy laxis with granulocyte colony- stimulating factor 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   39 
 (G-CSF) is not recommended .  Aranesp, Epogen and Procrit may not alleviate fatigue or 
increase energ y, and should not be used in patients with uncontrolled hy perten sion.  The 
package inserts for these agents should be consulted.  
 
If a patient develops febrile neutropenia, veliparib  should be stopped and appropriate 
management including G-CSF should be given according to local hospital guidelines.   
Please note that G -CSF should not be used within at least 24 hours of the last dose of 
veliparib  unless absolutely  necessar y. 
 
Platelet transfusions, if indicated, should be done according to local hospital guidelines. 
 
Dose modifications for  hematologic toxicity   
Patients who have veliparib  held for hematologic toxicities should have blood counts 
and differentials checked at least week ly until recovery; these data should be recorded in 
eCRF as extra laboratory  examinations.   If counts do not improve to CTCAE Grade 1 
or better despite drug cessation for 3 weeks, patients should be referred to a hematological oncologist for further assessment.    A bone marrow analysis should be 
considered. 
 
For AEs that are unrelated to the study drug, study drug may be withheld f or up to 3 
weeks at the discretion of the treating  Investigator. 
 
 Management of anemia  
 
CTCAE Grade  Definition  ABT -888 Dose  
2 Hb <10 but ≥8 g/dL  Give appropriate supportive treatment and 
investigate causality.  Investigator judgement to continue veliparib or interrupt dose for a maximum of 3 weeks.  If repeat Hb <10 but ≥8 g/dL, dose interrupt until Hb ≥10 g/dL for maximum of 3 w eeks and upon recovery dose 
reduce per the schema.   
3 Hb <8 g/dL  Give appropriate supportive treatment and 
investigate causality.  Interrupt veliparib until improved to Hb ≥10 g/dL.  Upon recovery, 
dose reduce veliparib.  
BID = twice daily; Hb = hemoglob in 
 
Common treatable causes of anemia (e.g., iron, vitamin B12 or folate deficiencies and hypothyroidism) should be investigated and appropriately managed.  In some cases, 
management of anemia may  require blood transfusi ons.  Any subsequently required 
dose interruptions related to developme nt of anemia, or coexistent with newly  
developed neutropenia, and/or thromboc ytopenia, will require veliparib dose reductions 
per the dosing schema.   
CTEP #  P9771 
Clinical Center #  16-C-0087  
   40 
  
If Hb drops to <8 g/dL despite the dose reduction or more than one blood transfusion is 
required to recover Hb levels with no alternative explanation for the anemia, veliparib should be permanently discontinued. 
 
Management of prolonged hematological toxicities while on study treatment   
If a patient develops prolonged hematological toxicity such as:  
• ≥2 week interruption/delay in veliparib  due to CT CAE Grade ≥3 anemia (Hb <8 
g/dL) and/or development of blood transfusion dependence 
• ≥2 week interruption/delay in veliparib  due to  CTCAE  Grade ≥3 neutropenia (ANC <1 x 
10
9/L) 
• ≥2 week interruption/delay in ve liparib  due to CTCAE Grade ≥3 thromboc ytopenia 
and/or development of platelet transfusion dependence (Platelets <50 x 109/L) 
 
Check  week ly differential blood counts including reticulocytes and peripheral blood 
smear.    If any blood parameters remain clini cally abnormal after 3 weeks of dose 
interruption, the patient should be referred to a hematological oncologist for further 
investigations.   Bone marrow for evaluation and cytogenetics should be considered at this stage according to standard hematological oncology prac tice.   Veliparib  should be 
discontinued if blood counts do not recover to CTCAE Grade ≤1  within 3 weeks of dose 
interruption. 
   
7 ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS  
Adverse event (AE) monitoring and reporting is a routine part of every clinical trial.  The 
following list of A Es (Section  7.1) and the characteristics of an observed AE ( Section 7.2) will 
determine whether the event requires expedited reporting (via CTEP- AERS ) in addition  to 
routine  reporting.  
7.1 Comprehensive Adverse Events and Potential Risks List (CAEPR) for ABT-888 (Veliparib, NSC 737664)  
The Comprehensive Adverse Events and Potential Risks list (CAEPR) provides a single list of reported and/or potential adverse events (AE) associated with an agent using a uniform presentation of events by body system. In addition to the comprehensive list, a subset, the Specific Protocol Exceptions to Expedited Reporting (SPEER), appears in a separate column and is identified with bold and italicized text. This subset of AEs (SPEER) is a list of events that a re 
protocol specific exceptions to expedited reporting to NCI (except as noted below).  Refer to the 'CTEP, NCI Guidelines: Adverse Event Reporting Requirements' http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf
 for 
further clarification. Frequency is provided based on 2310 patients. Below is the CAEPR for ABT -888 (Ve liparib).  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   42 
 1This table will be updated as the toxicity profile of the agent is revised.  Updates will be 
distributed to all Principal Investigators at the time of revision.  The current version can be 
obtained by contacting PIO@CTEP.NCI.NIH.GOV.   Your name, the name of the investigator, the 
protocol and the agent should be included in the e- mail.  
 
2Thromboembolic events, including deep vein thrombosis and pulmonary embolism, have been 
observed at a higher frequency compared to control arm when administered in combination with temozolomide.  
 
Adverse events reported on ABT -888 (Veliparib) trials, but for which there is insufficient 
evidence to suggest that there was a reasonable possibility that ABT- 888 (Veliparib) caused 
the adverse event:  
 BLOOD AND LYMPHATIC SYSTEM DISORDERS  - Bone marrow hypocellular; Blood and 
lymphatic system disorders - Other (pancytopenia)  
CARDIAC DISORDERS  - Cardiac disorders - Other (Takotsubo cardiomyopathy); Heart 
failure; Left ventricular systolic dysfunction; Palpitations; Sinus bradycardia; Sinus tachycardia  
Ear and labyrinth disorders  - Vertigo  
EYE DISORDERS  - Blurred vision  
GASTROINTESTINAL DISORDERS  - Abdominal distension; Ascites; Colitis; Colonic 
obstruction; Dental caries; Dry mouth; Duodenal ulcer; Dyspepsia; Dysphagia; Enterocolitis; Esophagitis; Flatulence; Gastritis; Gastroesophageal reflux disease; Lower gastrointestinal hemorrhage; Mucositis oral; Obstruction gastric; Rectal hemorrhage; Rectal pain; Small intestinal obstruction 
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS  - Chills; Edema 
limbs; Fever; Flu like symptoms; Malaise; Non -cardiac chest pain; Pain  
HEPATOBILIARY DISORDERS  - Hepatic failure; Hepatobiliary disorders - Other (cirrhosis)  
INFECTIONS AND INFESTATIONS  - Appendicitis; Catheter related infection; Infections and 
infestations - Other (peritonsillar abscess); Lung infection; Lymph gland infection; Mucosal 
infection; Sepsis; Shingles; Skin infection; Upper res piratory infection; Urinary tract infection  
INJURY, POISONING AND PROCEDURAL COMPLICATIONS  - Bruising; Dermatitis 
radiation; Radiation recall reaction (dermatologic)  
INVESTIGATIONS  - Alanine aminotransferase increased; Alkaline phosphatase increased; 
Aspar tate aminotransferase increased; Blood bilirubin increased; Cardiac troponin I increased; 
Creatinine increased; Electrocardiogram QT corrected interval prolonged; Lipase increased  
METABOLISM AND NUTRITION DISORDERS  - Hyperglycemia; Hypernatremia; 
Hypoalbum inemia; Hypocalcemia; Hypokalemia; Hypomagnesemia; Hyponatremia  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS  - Arthralgia; Arthritis; 
Back pain; Bone pain; Generalized muscle weakness; Muscle cramp; Myalgia; Neck pain; Pain in 
extremity  
Neoplasms benign , malignant and unspecified (incl cysts and polyps)  -Tumor pain 
NERVOUS SYSTEM DISORDERS  - Ataxia; Cognitive disturbance; Depressed level of 
consciousness; Dysarthria; Extrapyramidal disorder; Intracranial hemorrhage; Lethargy; Memory impairment; Movements  involuntary; Paresthesia; Peripheral motor neuropathy; Peripheral 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   45 
 Adverse events reported on M6620 (VX-970, NSC 780162) trials, but for which there is insuf ficient 
evidence to suggest that there was a reasonable possibility that M6620 (VX- 970, NSC 780162) caused 
the adverse event: 
 CARDIAC DISORDERS  - Palpitations  
GASTROINTESTINAL DISORDERS  - Abdominal pain; Ascites; Colonic obstruction; Mucositis oral  
GENERA L DISORDERS AND ADMINISTRATION SITE CONDITIONS  - Edema limbs; Fever  
IMMUNE SYSTEM DISORDERS  - Allergic reaction  
INFECTIONS AND INFESTATIONS  - Infections and infestations - Other (lower respiratory tract 
infection); Otitis externa; Sepsis; Soft tissue infec tion 
INVESTIGATIONS  - GGT increased; Hemoglobin increased; Weight loss 
METABOLISM AND NUTRITION DISORDERS  - Anorexia; Dehydration; Hypophosphatemia  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS  - Generalized muscle weakness  
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)  - 
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other (malignant neoplasm 
progression)  
NERVOUS SYSTEM DISORDERS  - Lethargy; Spinal cord compression; Syncope  
PSYCHIATRIC DISORDERS  - Confusion  
RES PIRATORY, THORACIC AND MEDIASTINAL DISORDERS  - Atelectasis; Dyspnea 
VASCULAR DISORDERS  - Hypertension; Hypotension; Thromboembolic event  
  Note: M6620 (VX -970) in combination with other agents could cause an exacerbation of any adverse event 
currently known to be caused by the other agent, or the combination may result in events never previously 
associated with either agent.  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   46 
  
 
 
7.3 Adverse Event Characteristics  
• CTCAE term (AE description) and grade: The descriptions and grading scales found in  
the revised NCI Common Terminology Criteria for Adverse Events  (CTCAE) version 4.0 
will be utilized until March 31, 2018 for AE reporting.  CTCAE version 5.0 will be utilized 
for AE reporting beginning April 1, 2018.  All appropriate treatment areas should have 
access to a copy of the CTCAE version 5.0.  A copy of the CTCAE version 5.0 can be 
downloaded from  the CTEP W eb site 
http://ctep .cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.  
 
Attribution of the AE:  
− Definite – The AE is clearly related to the study treatment.  
− Probable – The AE is likely related to the study treatment.  
− Possible – The AE may be related to the study treatment.  
− Unlikely – The AE is doubtfully related to the study treatment.  
− Unrelated – The AE is clearly NOT related to the study treatment.  
7.4 Expedited Adverse Event Reporting  
7.4.1 Expedited AE reporting for this study must use CTEP- AERS  (CTEP Adverse Event 
Expedited Reporting System), accessed via the CTEP Web site ( http://ctep .cancer.gov).  
The reporting procedures to be followed are presented i n the “ NCI Guidelines for 
Investigators:  Adverse Event Reporting R equirements  for DCTD (CTEP and CIP) and  
DCP INDs and IDEs ” which can be downloaded from the CTEP Web site 
(http://ctep .cancer.gov).  These requirements are briefly outlined in the tables bel ow 
(Section 7.4.2 ). 
In the rare occurrence when Internet connectivity is lost, a 24-hour notification is to be made to CT EP by telephone at 301-897-7497.  Once Internet connectivity is 
restored, the  24-hour notification phoned in must be entered electronically into CTEP-
AERS  by the original submitter at the site.  
 For participating sites: The site PI must immediately report to the coordinating center PI any serious adverse event, whether or not considered drug related, including those listed in the protocol or investigator brochure and must include an assessment of whether there is a reasonable possibility that the drug caused the event within 24 hours of PI awareness of the event.  The Site PI must also report any protocol deviations to the coordinating center PI within 7 days of PI awareness. Participating centers must also submit the report to their IRB in accordance with their institutional policies.  
7.4.2 Expedited Reporting Guidelines 
Use the NCI protocol number and the protocol -specific patient ID assigned during 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   48 
 1Serious adverse events that occur more than 30 days after the last administration of investigational 
agent/intervention and have an attribution of possible, probable, or definite require reporting as follows:  
Expedited 24-hour notification followed by complete report within 5 calendar days for:  
• All Grade 3, 4, and Grade 5 A Es 
Expedited 10 calendar day reports for:  
• Grade 2 A Es resulting in hospitalization or prolongation of hospitalization  
2For studies using PET or SPECT IND agents, the AE reporting period is limited to 10 radioactive half -lives, 
rounded UP to the nearest whole day, after the agent/intervention was last administered.  Footnote “1” above 
applies after this reporting period.  
Effective Date:  May 5, 2011  
 
7.4.3 Protocol- specific exp edited AE reporting exclusions 
For this protocol only, certain AEs/grades are exceptions to the Expedited Reporting 
Guidelines and do not require expedited reporting (i.e. , CTEP- AERS ).  These are a ny 
grade lymphopenia, any grade alopecia, Grade 2 electroly te (sodium, potassium, 
phosphorous, magnesium) abnormalities, G rade 2  anemia, Grade 2 hypoalbuminemia, 
Grade 2 hyperglycemia, Grade 2 INR, Grade 2 PTT, and Grade 2 hyperuricemia will NOT be reported through CTEP- AERS  but will be reported in the routine dat a 
submissions. 
7.4.4 Pregnancy, Fetal Death, and Death Neonatal  
NOTE: When submitting CTEP- AERS  reports for “Pregnancy”, “Pregnancy loss”, or 
“Neonatal loss”, the Pregnancy Information Form should also be completed for 
patients who became pregnant on study, and faxed along with any additional medical 
information to 301-230-0159.  The potential risk of exposure of the fetus to the 
investigational agent(s) or chemotherapy agent(s) should be documented in the “Description of Event” section of the CTEP- AERS  report.  
 Pregnancy  
• Because patients who become pregnant on study risk intrauterine exposure of 
the fetus to agents which may be teratogenic, DCTD/DCP is requesting that 
pregnancy should be reported in an expedited manner via CTEP -AERS  as 
Grade 3 “ Pregnancy, puerperium and perinatal conditions - Other 
(pregnancy )” under the Pregnancy, puerperium and perinatal conditions 
SOC.  
• The pregnancy outcome for patients on study should be reported via CTEP-AERS  at the time the outcome becomes known, accompanied by the same 
Pregnancy Report Form used for the initial report.  
 
Pregnancy loss 
• Pregnancy loss is defined in CTCAE as “Death in utero.”  
• Any Pregnancy loss should be reported expeditiously, as Grade 4 “Pregnancy loss” under the Pregnancy, puerperium and perinatal condit ions SOC.  
• A Pregnancy loss should NOT be reported as a Grade 5 event under 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   49 
 the Pregnancy, puerperium and perinatal conditions SOC, as currently 
CTEPAERS  recognizes this event as a patient death.  
 Death Neonatal 
• Neonatal death, defined in CTCAE as “A disorder characterized by cessation of life occurring during the first 28 days of life” that is felt by the investigator to be at least possibly due to the investigational agent/intervention, should be reported expeditiously. 
• A neonatal death should be reported expeditiously as Grade 4, “Death 
neonatal” under the General disorders and administration SOC.  
• Neonatal death should NOT be reported as “Death neonatal” under the 
General disorders and administration SOC, a Grade 5 event .  If reported as 
such, the CTEP -AERS interprets this as a death of the patient being treated.  
7.4.5 NIH-IRB Expedited Reporting of Adverse Events, Unanticipated Problems, and Deaths  
Definitions   
Adverse event  
An adverse event is defined as any reaction, side effect, or untoward event that occur s 
during the course of the clinical trial associated with the use of a drug in humans, whether or not the event is considered related to the treatment or clinically significant.  For this study, AEs will include events reported by the patient, as well as c linically 
significant abnormal findings on physical examination or laboratory evaluation.  A new illness, symptom, sign or clinically significant laboratory abnormality or worsening of a pre-existing condition or abnormality is considered an AE .  All AEs m ust be recorded 
on the AE case report form  unless otherwise noted above in Section 7.3.3. 
 All AEs, including clinically significant abnormal findings on laboratory evaluations, regardless of severity, will be followed until satisfactory resolution .  AEs should be 
reported up to 30 days following the last dose of study drug.   
 
An abnormal laboratory value will be considered an AE if the laboratory abnormality is characterized by any of the following: 
• Results in discontinuati on from the study 
• Is associated with clinical signs or symptoms  
• Requires treatment or any other therapeutic intervention  
• Is associated with death or another serious adverse event, including 
hospitalization  
• Is judged by the Investigator to be of significant clinical impact  
• If any abnormal laboratory result is considered clinically significant, the 
investigator will provide details about the action taken with respect to the test drug and about the patient’s outcome. 
 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   50 
 Suspected adverse reaction  
Suspected adver se reaction means any adverse event for which there is a reasonable 
possibility  that the drug caused the adverse event .  For the purposes of IND safety 
reporting, ‘reasonable possibility’ means there is evidence to suggest a causal 
relationship between the  drug and the adverse event.  A suspected adverse  reaction 
implies a lesser degree of certainty about causality than adverse reaction,  which 
means any adverse event caused by a drug.  Unexpected adverse reaction  
An adverse event or suspected adverse reacti on is considered “unexpected” if it is not 
listed in the investigator brochure or is not listed at the specificity or severity  that has 
been observed; or, if an investigator brochure is not required or available,  is not 
consistent with the risk information  described in the general investigational  plan or 
elsewhere in the current application .  “Unexpected” also refers to adverse events or 
suspected adverse reactions that are mentioned in the investigator  brochure as 
occurring with a class of drugs or as anti cipated from the  pharmacological properties 
of the drug, but are not specifically mentioned as occurring with the particular drug 
under investigation.  Serious  
An Unanticipated P roblem or P rotocol Deviation is serious if it meets the defini tion of 
a Serious Adverse Event  or if it compromises the safety, welfare or rights of subjects 
or others.   Serious Adverse Event  
An adver se event or suspected adverse reaction is considered serious if in the view of 
the investigator or the sponsor, it results in any of the following:  
• Death  
• A life -threatening adverse drug experience 
• Inpatient hospitalization or prolongation of existing hospitalization 
• Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions 
• A congenit al anomaly/birth defect.  
• Important medical events that may not result in death, be life -threatening, or 
require hospitalization may be considered a serious adverse drug experience when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.  
 Disability  
A substantial disruption of a person’s ability to conduct normal life functions.  Life-threatening adverse drug experience  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   51 
 Any adverse event or suspected adverse reaction that places the patient or subject,  in 
the view of the investigator or sponsor, at immediate risk of death from the  reaction as 
it occurred, i.e., it does not include a reaction that had it occurred in a more  severe 
form, might have caused death.  
 
Protocol Deviation (NIH Definition) Any change, divergence, or departure from the IRB- approved research protocol .   
 Non-compliance (NIH Definition)  
Failure to comply with applicable NIH Human Research Protections Pr ogram (HRPP ) 
policies, IRB requirements, or regulatory requirements for the protection of human research subjects.  Unanticipated Problem  
Any incident, experience, or outcome that: 
• Is unexpected in terms of nature, severity, or frequency in relation to 
(a) the research risks that are described in the IRB -approved  
 research protocol  and informed consent document; Investigator’s  
 Brochure or other study documents, and 
(b) the characteristics of the subject population being studied; AND 
• Is related or possibl y related to participation in the research; AND  
• Suggests that the research places subjects or others at a g reater risk of harm 
(including physical, psychological, economic, or social harm) than was previously known or recognized.  
7.5 NIH -IRB and Clinical Dire ctor Reporting  Requirements  
7.5.1 NIH- IRB and NCI Clinical Director Expedited Reporting of Unanticipated Problems 
and Deaths 
The Protocol PI will report in the NIH Problem Form to the NIH- IRB and NCI 
Clinical Director : 
 
• All deaths, except death s due to progressi ve disease 
• All protocol deviations 
• All unanticipated problems  
• All non-compliance 
 
Reports for serious events must be received by the NIH IRB within 7 days of PI 
awareness via iRIS.   Reports for not serious events must be received by the NIH IRB 
within 14 days of PI awareness via iRIS.  
  
7.5.2 NIH-IRB Requirements for PI Reporting at Continuing Review 
System  CTCAE Grade  # of Events Total # Attribution Serious?  Unexpected?  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   52 
 Organ Class  Term  since last CR  of Events  to Research  
        
        
The protocol PI will report to the NIH-IRB:  
1. A summary of all protocol deviations in a tabular format to include the date the 
deviation occurred, a brief description of the deviation and any corrective action. 
2. A summary of any instances of non-compliance 
3. A tabular summary of the following adverse events:  
• All Grade 2 unexpected  events that are possibly, probably or definitely related 
to the research;  
• All Grade 3 and 4 events that are possibly, probably or definitely related to the research;  
• All Grade 5 events regardless of att ribution;  
• All Serious Events regardless of attribution .   
 
7.5.3 NIH-IRB Reporting of IND Safety Reports 
Only IND Safety Reports that require a sponsor- recommended change to the protocol 
or the consent form or in the opinion of the PI increase risks to study pa rticipants will 
need to be reported to the NIH IRB.  
 
7.6 Secondary Malignancy 
A secondary malignancy is a cancer caused by treatment for a previous malignancy ( e.g., 
treatment with investigational agent/intervention, radiation , or chemotherapy).  A secondary 
malignancy is not considered a metastasis of the initial neoplasm .   
 
CTEP requires all secondary malignancies that occur following treatment with an agent under an NCI IND/IDE be reported via CTEP- AERS .  Three options are available to describe the event:  
• Leukemia secondary to oncology chemotherapy (e.g., a cute myelocytic leukemia 
[AML])  
• Myelodysplastic syndrome (MDS)  
• Treatment -related secondary malignancy  
 
Any malignancy possibly related to cancer treatment (including AML/MDS) should also be reported via the routine reporting mechanisms outlined in each protocol.   
7.7 Second Malignancy  
A second malignancy is one unrelated to the treatment of a prior malignancy (and is NOT a metastasis from the initial malignancy).  Second malignancies require ONLY routine 
reporting unless otherwise specified .   
 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   53 
 8 PHARMACEUTICAL INFORMATION  
A list of the adverse events and potential risks associated with the investigational drugs 
administered in this study can be found in Section 7 . 
8.1 M6620 (VX-970) (NSC 780162)   
Other Names: VRT -0768079, MSC2527093A, VX-970 
 Chemical Name: 5-(4-(isopropylsulfonyl)phenyl)-3- (3-(4-
((methylamino)methyl)phenyl)isoxazol-5- yl)pyrazin -2- amine  
 Classification : ATR inhibitor    CAS Registry Number: 1232416-25-9 
 Molecular Formula : C
24H25N5O3S                 M.W.: 463.55 Da 
 Mode of Action : Ataxia telangiectasia mutated and Rad3 -related (ATR) kinase is an apical 
regulator of checkpoint pathways triggered by DNA damage.  The DNA damage response (DDR) is regulated by ATR kinase and ataxia telangiectasia mutated (ATM) kinase, which are recruited to distinct DNA damage structures.  M6620 (VX-970) disrupts ATR- mediated DNA damage 
response signaling and leads to sustained accumulation of DNA damage in cancer cells co -treated 
with DNA-dam aging agents.  
 Description: The drug substance for M6620 (VX- 970) is the free base.  
 How Supplied: M6620 (VX-970) is supplied by Merck KGaA/EMD Serono, Inc. and distributed by the Pharmaceutical Management Branch, CTEP/DCTD/NCI as single-use 200 mg vials containing a sterile solution (20 mg/mL).  M6620 (VX- 970) solution for injection is a yellow 
liquid formulated in 20% betadex sulfobutyl ether sodium (w/v) and 86 mM acetate buffer, 10 mL total volume, supplied in clear glass vials in cardboard boxes with f oam inserts.  
 Preparation:  M6620 (VX- 970) solution for injection must be diluted with 5% dextrose in water 
solution prior to administration.  Do not use 0.9% Sodium Chloride due to incompatibility with M6620 (VX-970).  To prepare the infusion solution add the dose volume of M6620 (VX-970) to a non- polyvinyl chloride (non- PVC), di(2 -ethylhexyl) phthalate (DEHP) -free EVA infusion bag 
containing 5% dextrose in water.  Gently invert the IV bag 5- 10 times to mix the solution.  
Confirm the solution is clear and free of precipitates and/or particulates.  The final concentration must be between 0.075 mg/mL to 1 mg/mL .  Place the IV bag into an opaque cover to protect 
from light.    Storage: Store intact vials protected from light inside cardboard boxes at room temperature, 25°C (77°F), with excursions allowed between 15 and 30°C (59 and 86°F).    If a storage temperature excursion is identified, promptly return M6620 (VX-970) to between 15 and 30°C and quarantine the supplies.  Provide a detailed report of the excursi on (including 
documentation of temperature monitoring and duration of the excursion) to PMBAfterHours@mail.nih.gov
 for determination of suitability.  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   54 
  
Stability: Stability testing of the intact vials is on -going.  Prepared solutions must be protected 
from light and used within 4 hours from time of preparation if stored at room temperature or 24 hours if stored refrigerated (2 -8°C).  
 Route  of Administration: Intravenous (IV) infusion. 
 Method of Administratio n: Prior to administration the solution should be given one hour at 
ambient temperature to warm up if stored refrigerated following preparation. Infuse over 60 minutes using an infusion set containing low-sorption or non- PVC, DEHP -free tubing and an in-
line 0.2 micron filter.   5% dextrose in water solution must be used for IV line priming and 
flushing.  M6620 ( VX-970) should not come in contact with 0.9% Sodium Chloride due to 
incompatibility. The infusion time may be extended beyond 60 minutes (as tolerate d) but no 
more than 90 minutes if standard procedures to limit symptoms of an infusion reaction are insufficient or if the total volume of the infusion exceeds 600 mL.  To minimize the possibility of phlebitis, M6620 (VX-970) should be administered through a large bore catheter into a large caliber peripheral vein or central venous access.  
 Patient Care Implications: Monitor for infusion site reactions, irritation, and phlebitis. M6620 (VX 970) absorbs in the UV- visible radiation spectrum and is widely distributed including skin, 
so patients receiving M6620 (VX-970) should take protective measures to minimize sun exposure.  Women of childbearing potential and men should use appropriate contraception while on study drug and for 6 months after discontinuation of M6620 (VX-970). 
 
Potential Drug Interactions: M6620 (VX-970) is primarily metabolized by CYP3A4.  M6620 (VX-970) has a low potential to inhibit CYP1A2, 2C9, 2C19, 2D6, and 3A4, and a moderate potential to reversibly inhibit CYP2E1.  The potential for M6 620 (VX-970) to induce CYP450 
enzymes is low.  Concomitant administration with strong inhibitors or inducers of CYP3A4 should be avoided.  M6620 (VX-970) is a weak/moderate inhibitor of UGT1A1, UGT1A14, UGT1A9, UGT2B15, and UGT2B17.  UGT2B7, UGT1A3, and UGT1A6 were weakly or not inhibited.  M6620 (VX-970) is predicted to not inhibit significantly the metabolic clearance of SN- 38 (active metabolite 
of irinotecan) at therapeutic exposures.    M6620 (VX-970) is a moderate inhibitor of P-gp and BCRP.  Use caution when administered with substrates of P -gp and BCRP transporters.  
 
             1/2019 ew  
 
 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   55 
 8.2 Veliparib (NSC 737664) 
Other Names:  ABT -888, A -861695.0  
Chemical Name : 1H-Benzimidazole -7-carboxamide, 2 -[(2R)-2-methyl -2-
pyrrolidinyl]- 
 
Classification:  Poly ( ADP -ribose ) polymerase (PARP) Inhibitor  
CAS Registry No. 912444 -00-9 
Mode of Action : Veliparib is an inhibitor of poly(ADP -ribose) polymerase  
(PARP), a nuclear enzyme that recognizes DNA damage and 
facilitates DNA repair.  
Molecular 
Formula:  C13H16N4O 
Molecular  Weight : 244.29  
Description:  White to light yellow solid  
Solubility:  Freely soluble at 37 °C at  a pH < 6.9, soluble at pH 6.9 to 7.1, 
and slightly soluble at pH > 7.1 
How Supplied:  AbbVie  supplies and DCTD distributes Veliparib .  Veliparib  
capsu les are available in  10 mg, 20 mg, 40 mg, 50 mg, and 100 mg 
immediate release capsules.  The inactive ingredients are microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, gelatin, sodium lauryl sulfate, and titanium dioxide.  It may c ontain FD&C bl ue#1, FD&C yellow #6, or FD&C yellow 
#5.  The capsules are packaged in HDPE bottles, and each HDPE bottle contains 16 capsules or 64 capsules.  
Veliparib capsules may be repackaged from the supplied HDPE bottles into amber (or other low -actini c) chil d resis tant pharmacy 
dispensing bottles.  Expiration will be 30 days from the repackaging date (or the original retest date, whichever is earlier) when stored at 15°C to 25°C (59°F to 77°F).   
Storage:  Capsules should be stored in the original cont ainer a t 15° t o 
25°C (59° to 77°F). 
Route of 
Administration:  Oral 
Method of 
administration  Administer Veliparib  orally without regards to meals ; the capsules 
should not be crushed or chewed.   If a dose is vomited, it may be 
re-administered if whole/intac t capsules are observed in vomitus. 
Potential Drug 
Interaction  Nonclinical studies suggest ABT -888 is a substrate of P -gp, OCT2, 
and MATE1/MATE2K transporters.  Co -administration of ABT -
888 with strong inhibitors of P -gp, OCT2, and MATE1/MATE2K 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   56 
 may result  in a d ecrease  of ABT -888 renal clearance and an 
increase in ABT -888 plasma concentration.  Therefore, use caution 
when administering ABT -888 with strong inhibitors of P -gp, 
OCT2, and MATE1/MATE2K.  At high dose (e.g., 400 mg BID), 
ABT -888 may inhibit OCT1  in the  liver and MATE1/MATE2K in 
the kidney.  
 ABT -888 is not a potent inhibitor of the major human CYPs and 
does not significantly induce activities of major human CYP isoforms, suggesting a negligible potential for CYP -mediated drug -
drug interactions as  a perp etrator  at the anticipated therapeutic 
concentrations.  
 In human, ABT -888 clears primarily in the urine as intact parent 
drug along with metabolites suggesting that renal function plays an important role in the drug clearance and its metabolites.  D rug-
associated  kidney toxicities or kidney diseases could change ABT -
888 pharmacokinetics.  Use cautions when concomitantly 
administer oxalipaltin, carboplatin, cisplatin, and topotecan in patients with pre -existing renal impairment.    
Availability  Velipa rib is an inve stigational agent supplied to investigat ors by 
DCTD, NCI .  Veliparib  is provided to the NCI under a 
Collaborative Agreement between the Phar maceutical 
Collaborator and DCTD, NCI.  
 
8.3 Cisplatin  
Other Names:  cisplatinum  
Chemical Name:  cis-diammi nedichl oroplat inum(II)  
Classification:  DNA crosslinking agent  
CAS Registry 
No.: 15663 -27-1 
Molecular 
Formula : (SP-4-2)-diamminedichloroplatinum  
Mechanism of 
Action:  Cisplatin is a DNA crosslinking agent that forms intra - and 
interstrand crosslinks with  DNA, i nterfering with DNA replication 
and repair. 
How Supplied:  Cisplatin is commercially available in amber, multiple -dose vials 
containing 50, 100, or 200 mg cisplatin in solution.  Each milliliter of solution contains 1 mg of cisplatin and 9 mg sodium chlori de in 
water for injection .   
CTEP #  P9771 
Clinical Center #  16-C-0087  
   57 
 Storage:  Intact vials and reconstituted solution must be maintained at room 
temperature .  Store intact vials at 15° - 25°C (59° - 77°F) .  Do not 
refrigerate cisplatin  in vials or after dilution.  
Cisplatin that remains in an am ber via l after initial entry is stable for 
28 days if protected from light or for 7 days under fluorescent room 
light.  Large-volume solutions do not need to be protected from light if used within 6 hours after preparation .  For longer time 
periods, light protect ion is recommended .  Light protection is 
required for intensive lighting conditions; e.g., direct  sunlight 
exposure.  Although cisplatin slowly degrades to trichloroaminoplatinate (TCAP) on exposure to ambient lighting conditions, solution pH is the  predom inant factor affecting cisplatin 
stability .  Solutions with pH > 4.3 (especially > 6.3) were associated 
with loss of cisplatin and a more rapid formation of TCAP.  
Stability:  Vials bear the manufacturer’s expiration date .  Cisplatin dilution to 
0.05 or 0.5 mg/mL with 0.9% normal saline yields a solution that is stable for at least 24 hours at room temperature.  
Preparation:  Cisplatin will be diluted in 100 mL 0.9% sodium chloride injection, 
USP, for intravenous administration over 60 minutes on Day 1 (and Day 8 from DL3 and higher) of a 21- day cycle.  
 
Route of 
Administration:  Cisplatin is administered intravenously on Day 1 (and Day 8 f or 
DL3 and higher ) of a 21- day cycle.  
Method of 
administration:  Prior to cisplatin administration, at least 500 mL of 0.9%  sodium 
chloride with KCl 10 mEq/L and magnesium sulfate 4 mEq/L 
injection should be administered over at least 60 minutes.  
Following administration of cisplatin, at least an additional 500 mL of 0.9% sodium chloride with KCl 10 mEq/L and ma gnesium 
sulfate 4 mEq/L injection should be administered over at least 60 minutes.   
Availability:  Commercially available.  
8.4 Useful Links and Contacts:  
• CTEP Forms, Templates, Documents: http://ctep.cancer.gov/forms/  • NCI CTEP Investigator Registration: RCRHelpDesk@nih.gov  • PMB policies and guidelines:  http://ctep.cancer.gov/branches/pmb/agent_management.htm  • PMB Online Agent Order Processing (OAOP) application: 
https://c tepcore.nci.nih.gov/OAOP  
• CTEP Identity and Access Management (IAM) account: https://ctepcore.nci.nih.gov/iam/  
• CTEP IAM account help:  ctepreghelp@ctep.nci.nih.gov  • PMB email: PMBAfterHo urs@mai l.nih.gov  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   58 
 • IB Coordinator: IBCoordinator@mail.nih.gov   
• PMB phone and hours of service: (240) 276-6575 Monday through Friday  
 
8.5 Agent Ordering   
NCI-supplied agents may be requested by the responsible i nvestigator (or their authorized 
designee) at each participa ting institution .  Pharmaceutical Management Branch (PMB) policy 
requires that agent be shipped directly to the institution where the patient is to be treated.  PMB does not permit the transfer of agents between institutions (unless prior app roval f rom PMB  is 
obtained).  The CTEP-assigned protocol number mus t be used for ordering all CTEP -supplied 
investigational agents.  The responsible investigator at each participating institution must be 
registered with CTEP, DCTD through an annual submiss ion of FDA For m 1572 (Statement of 
Investigator), Biosketch, Agent Shipment Form, and Financial Disclosure Form (FDF).  If there are several participating investigators at one institution, CTEP -supplied investigational agents for 
the study should be ordered under the na me of one lead investigator at that institution.  
 Active CTEP -registered investigators and investigator-designated shipping designees and ordering 
designees can submit agent requests through the PMB Online Agent Order Processing (OA OP) 
applic ation ( https://ctepcore.nci.nih.gov/OAOP
 ).  Access to OAOP requires the establishment of 
a CTEP Identity and A ccess Management (IAM) account  (https://ctepco re.nci.nih.gov/iam/ ) and 
the maintenance of an “active” account status, a “current” password , and an active registration 
status.  For questions about drug orders, transfers, returns, or accountability, call (240) 276-6575 Monday through Friday between 8:3 0 am an d 4:30 pm (ET) or email 
PMBAfterHours@mail.nih.gov  anytime. 
8.6 Agent Accountability  
Agent Inventory Records – The investigator, or a responsible party designated by the investigator, 
must maintain a careful record of the receipt, dispensing and final d isposition of all agents 
received from the PMB using the appropriate NCI Investigational Agent (Drug) Accountability 
Record (DARF) available on the CTEP forms page. Store and maintain separate NCI Investigational Agent Accountability Records for each agent, stren gth, fo rmulation and ordering 
investigator on this protocol.  
8.6.1 Investigator Brochure Availability  
The current versions of the IBs for the agents will be accessible to site investigators and research staff through the PMB Online Agent Order Processing (OAOP)  application.  Access 
to OAOP requires the establishment of a CTEP Identity and Access Management (IAM) account and the maintenance of an “active” account status, a “current” password , and an 
active registration status . Questions about IB access may  be dir ected t o the PMB IB 
coordinator via email.  
 
 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   59 
 9 CORRELATIVE/ SPECIAL STUDIES  
We plan to evaluate the effect of the combination of M6620 (VX-970), veliparib, and cisplatin on 
markers of DNA damage , such as γ H2AX, RAD51, pNbs1, and pATR , in tumor biopsies  and 
circulati ng tumor cells (CTCs).  For patients on the expansion cohort, t wo biopsies will be 
obtained, one on C1D1 after administration of cisplatin  and again on C1D9 , 2-5 hours after the 
day 9 dose of M6620 (VX-970), with a third progression or restaging fol low-up biopsy optional.  
Biopsies are  mandatory  for patients on the expansion phase.  Based on the availability of tissue 
and various histologies, additional markers of DNA damage will be evaluated . 
9.1 Pharmacodynamic Assays 
Evaluation of drug effect on DNA d amage response in tumor and CTCs will be performed by 
immunofluorescence assays for measurement of DNA damage- repair markers, such as γ H2AX, 
RAD51, pNbs1, and pATR. 
 Histone H2AX is one of the H2A histones present in nucleosomes from normal tissues as well  as 
cancer tissues.  H2AX is phosphorylated at its C-terminus (serine 139) following DNA double-
strand breaks.  Phosphorylated H2AX, referred to as γ H2AX, can be selectively detected using 
antibodies by Western blots or immunofluorescence.  The leve ls of γ H2AX ar e directly correlated 
to the amounts of double-strand breaks per cell, and can be used as a dosimeter and biomarker for DNA double-strand breaks.  Nbs1 is an adapter protein, linking Mre11 and Rad50 to form the MRN complex involved in recogni tion of  DNA da mage and initiation of the signaling cascade in response to DNA double-
strand breaks.  
 Rad51 plays a central role in recognition of double-strand breaks and homologous recombination. 
 
ATR phosphorylation in response to DNA damage will be used as a m arker of direct target effect.   
A quantitative immunofluorescence assay for pT1989- ATR will be used as a marker of ATR 
inhibitor activity.    
9.1.1 Laboratory Contact  (NCI only)  
At least 24 hours prior to tumor biopsy or blood sample collection, the research nurs e 
will contact the NCI Phase I/II PK/PD Support Group in NIH Building 10:  E-mail (preferred): NCIPK -PDsupport@mail.nih.gov, Pager  (preferred) : 102-12798 
Phone: (240) 858-3963 Fax: 301- 480-5871.  For biopsies, tubes pre- labeled with the 
information specifi ed in Section 9.1.4, biopsy date, and site of tissue biopsy will be 
provided.  Initial processing and shipping of the samples will be completed as described below. 
9.1.2 Tumor Biopsies  
Biopsies will be optional during the escala tion ph ase but  mandatory  during the 
expansion phase.  Biopsies will be collected  at the following time points: 
• On C1D1 after  administration of cisplatin  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   60 
 • On C1D9, 2-5 hours after the dose of M6620 (VX-970) 
An optional third biopsy may also be collected, eit her at restaging follow -up (on day 
1 (± 2 days) of the cycle following any restaging at which a 10-19% increase in 
tumor volume is observed, according to RECIST criteria, for patients on study 4 or 
more cycles) or at the time of disease progression  (a 20% or more  increase in tumor 
volume by RECIST) . 
 
 
9.1.2.1 Biopsy Procedure 
Serial tumor biopsies will be obtained by the Interventional Radiology team by a 
percutaneous approach, a dermatologist for skin lesions, or an ENT for lesions that are easily biopsiabl e through ENT exam.  If a site is deemed appropriate for biopsy 
with minimal risk to the participant by agreement between the investigators and the biopsy team, an attempt for biopsy will be made.   Because approximately 20% of 
tumor biopsies collected on r esearch  trials  are not usable due to the presence of 
stroma or normal and/or necrotic tissue  and paired biopsies are necessary for 
analysis, up to 5 core biopsies 18 -gauge in  diameter and ≥ 1 cm in length, or 
equivalent, will be obtained  during each procedu re to try and ensure adequate tumor 
content and quality.  If possible, the lesion from which each biopsy is taken will be documented.  Acceptable biopsy procedures are:  
• Percutaneous bio psy with local anesthetic.  
• Excisional cutaneous biopsy with local anesthetic  • Other biopsy with local anesthetic and/or sedation that has been shown to have a risk of severe complications < 2%  
 
The use of imaging to facilitate biopsies will be decide d by members of the  biopsy 
team and may include ultrasound, CT scan, or MRI .  Should a CT scan be needed for 
biopsy, the number of scans for each procedure will  be limited to the minimum 
number needed to safely obtain a biopsy.  Tumor biopsies  and local an esthesia will 
be administered only if they are considered to be of l ow risk  to the participant, as 
determined by the investigators and the biopsy team.  The clinical, radiologic , 
dermatologic, ENT, and pharmacodynamic members of the research team will meet 
monthly to review the adequacy of the biopsy specimens for analysis.  C1D1 and C1D9 t umor biopsies are  optional during the escalation phase and 
mandatory  during the expansion phase (the progression/restaging follow-up biopsy is 
always optional).  Baseline biopsies will be performed following patient enrolling  on 
study.  I f an initial attempt at biopsy is unsuccessful, the patient will be given an 
option to proceed with a repeated attempt.  A separate consent form must be signed for each biopsy procedure, so patients may choose not to undergo subsequent biopsies.  If the ba seline biopsy is  unsuccessful or the patient refuses to undergo 
subsequent biopsies, no further  biopsies will be performed but the patient will 
remain on study, receive study medication, a nd other correlative studies will be 
performed .   
 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   61 
 9.1.2.2  Solid Tumor Biop sy Processing  
• All biopsy specimens should be collected, placed in pre-chilled cryogenic vials, and 
flash frozen in liquid nitrogen within 2 minutes of collection per DCTD SOP340507 (https://dctd.cancer.gov/ResearchResources/biomarkers/docs/par/SOP340507_Biops
y_Frozen.pdf ) 
 
• See Appendix G  for the collection and shipment procedures for all biopsy samples. 
 
• C1D1 and C1D9 b iopsies  should be t ransferred to PADIS  on dry ice, where they 
are stored at -80°C, or colder, and subsequently processed within 7-10 days for analysis or as directed by the Principal Investigator.  Biopsy samples will be analyzed for  γH2AX, Rad51, pNbs1, and pATR as described above ; any additional 
tissue will be flash -frozen and kept for future analysis in the Frederick National 
Laboratories CR Biorepository in liquid nitrogen freezers .  Additional studies, if 
performed, will be conduc ted following an amendment to the current protocol.  
 
• Restaging follow- up or progression biopsies should be processed  as follows : 
o As the first priority, two  cores, or equivalent tissue from dermatology or ENT 
biopsy, should be flash frozen as described abov e and transferred  on dry ice to 
Dr. Mickey Williams’ laboratory (MoCha) at the Frederick National Laboratory for Cancer Research (FNLCR).   
 Following processing, one tissue section will be stained with H&E for histopathological examination by a designated pathologist.    The remaining biopsy tissue will be extracted for nucleic acids.   DNA will be assessed for 
quantity and quality by spectroscopy (OD 260/280) and a PCR- based 
amplification quality assessment test.   All specimens that  meet necessary 
quantity and quality will be sequenced using a targeted sequencing assay.    
o Any remaining tissue collected (up to 5 cores or equivalent ) will be transferred to 
PADIS  on dry ice and stored for analysis of γH2AX, Rad51, pNbs1, and pATR . 
 
o 
Note: Per the discretion of the PI, restaging follow-up or progression biopsies may 
be used for other analyses, including analyses carried out as a part of other DTC 
clinical trials, providing that the tissue is collected pe r SOP for those analyses.  
 
9.1.2.3 Optional Archival Tissue Submission for Additional Studies  
Patients may choose to submit an additional, a rchival tumor tissue specimen that 
has been collected within 3 months prior to patient registration if the patient has  
not received any intervening cancer therapy since collection of the specimen and 
the tissue was collected and processed according to SOP340507 (https://dctd.cancer.gov/ResearchResources/biomarkers/docs/par/SOP340507_Biopsy_Frozen.pdf), including flash- freezing in liquid nitrogen, minimal cold 
ischemia time (< 5 minutes), and shipment on dry ice.   Archival tissue 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   62 
 submissions do not fulfill the requirement for a baseline (C1D1) biopsy  
because the baseline biopsy must be collected after the C1D1 cisplatin 
administration; however, qualifying archival tissue submissions will be analyzed for the same PD biomarkers as C1D1 and C1D9 biopsies to provide additional context for interpreting PD changes after drug administration. 
Please send an email to FNLCR PD Specimen Cent ral Receiving 
(NCI_PD_Support@mail.nih.gov) to advise that archival tissue is being prepared 
for shipment.  State “ P9771 PD Specimens Ready for Shipment” in the subject 
line.  If needed, FNLCR PD Central Receiving can be contacted directly at 301-846-1951 or 301-846-6747.  
9.1.3  Blood Collection for CTC Studies (Optional)  
Whole blood (at least 7.5 mL) will be collected aseptically by venipuncture or from a venous port into one 10 mL CellSave preservative tube.  Prior to CTC collection, each participating site sh ould e-mail a request for specimen collection and shipping 
materials from NCIPDSupportPADIS@mail.nih.gov  .  See Appendix G
 for the 
collection procedure for CTC samples for pharma codynamic studies. 
 At the NCI  only, w hole blood (at least 7.5 mL) will be collected aseptically by 
venipuncture or from a venous port into one 10 mL Streck tube (catalog number 218962).  One 10 mL RareCyte tube (catalog number 24-1070- 005) is also 
acceptable. Tubes must be inverted 8 times to ensure adequate mixing of the additive. 
Blood samples for CTCs will be collected at the following times:  
• at baseline  
• on cycle 1 day 2 prior to administration of M6620 (VX-970)  
• on cycle 1 day 2 , 8 hours  (± 30 minutes) after the start of M6620 (VX-970) 
administration  
• on cycle 1 day 8 prior to administration of veliparib/cisplatin administration  
• on cycle 1 day 9 prior to M6620 (VX-970) administration,  
• on cycle 2 day 1 prior to veliparib/cisplatin administration 
• on cycle 2 day 2 prior to M6620 (VX-970) administration  
• on cycle 2 day 2, 10 hours (± 2 hours) after the start of M6620 (VX-970) 
administration * 
• on the first day of every subsequent cycle prior to veliparib/cisplatin 
administration  
• at the time of restaging follow-up biopsy or progression biopsy, if applicable 
 
*At the NCI only:  CTC collection  on cycle 2 day 2 is fixed at 7:00pm (± 30 
minutes) in order to make the timing of the procedure more feasible an d convenient 
for study participants.  The time elapsed between M6620 (VX-970) administration and blood collection will be recorded.  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   63 
 Testing and data analysis will be performed by Dr. Bob Kinders (PADIS/FNLCR).   
 
9.1.4 Sample Collection and Processing 
Biospecimens will be collected and processed using validated SOPs that will ensure 
both specimen quality and patient confidentiality pursuant to informed consent provisions.  Information about each specimen (e.g., blood, tumor biopsy, per specific 
protocol) will be recorded on a PK/PD  collection worksheet. 
 Using a computerized inventory system and a backup hardcopy process, all specimen collection and processing steps will be documented and the specific location of each  
specimen will be tracked .  Each new specimen collected will be assigned a unique 
barcode identifier that can be linked to the original specimen collected and other relevant  information within the inventory system.  To ensure patient confidentiality, 
only containers used for the initial specimen collections will be labeled with patient identifiers .   
 Only the barcode identifier will be applied to all subsequent specimen containers.  When  specimens are processed and aliquoted, no patient information will be included 
on the new containers.  Original specimen containers will be discarded .  Only 
barcode- labeled  specimens without patient identifiers will be shipped for analysis 
and/or storage.  Specimen labels will indicate: CTEP protocol number, unique patient accession number,  3-digit sample number (see list below), collection time, and total 
volume collected, as appropriate .  Samples from sets of at least three patients will be 
grouped for scientific  analysis.  
 
Standardized 3- digit sample collection numbers: 
400 series: CTCs  
500 series: tumor biopsies 
 The inventory process contains other security provisions suffi cient to safeguard 
patient  privacy and confidentiality.  Access to the inventory system and associated 
documents will be restricted to appropriate individuals .  Requests to use specimens 
stored in the  repository must be approved.  The only patient information available in 
the inventory system will be the patient sex, diagnosis, and level of informed consent given.  SOPs  ensure that any changes in informed consent made by a patient and 
relayed to the PI will be reflected in the inventory system to ensure that specimens are destroyed as  appropriate .  All laboratory personnel will be trained to adhere to SOPs 
and will be monitored for high-quality performance.  Any new use of these samples will require prospective IRB review and approval .  
Access to these sampl es will only be granted following IRB approval of an additional 
protocol, granting the rights to use the material.  
 If at any time, a patient withdraws from the study and does not wish for their existing samples to be utilized, the individual must provide a written request .  Following 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   64 
 receipt of this request, the samples will be destroyed (or returned to the patient, if so 
requested), and reported as such to the IRB .  Any samples lost (in transit or by a 
researcher) or destroyed  due to unknown sample integrity (i.e., broken freezer allows 
for extensive sample thawing, etc.) will be reported as such to the IRB. 
 
9.2 Exploratory Genomic Analyses 
As of Amendment L  (dated 4/22/2019), t he MoCha laboratory at FNLCR will investigate the 
occurrence of tumor genomic alte rations potentially associated with acquired drug resistance for 
only those patients who agree to undergo an optional progression or restaging follow-up biopsy. 
9.2.1 Optional Restaging Follow -Up and Progression Biopsies  
With patient consent, tumor tissue collec ted at the (optional) restaging follow-up or 
progression biopsy may be analyzed by the CLIA- certified OCAv3  assay  and results 
will be returned to patients in the form of the Oncomine report.  If additional tumor 
tissue is available after the OCAv3 analysis, exploratory, non -CLIA certified genomic 
analyses such as WES may be conducted but the results will not be returned to patients or used for clinical decision making (Figure 5
).  Note: Per the discretion of the 
PI, restaging follow-up or progression biopsies may be used for other analyses, including 
analyses carried out as a part of other DTC clinical trials, providing that the tissue is collected per SOP for those analyses.
 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   66 
 X Identified data in BTRIS (automatic for activities in the Clinical Center)  
X De -identified or identified data with approved outside collaborators under appropriate 
agreements  
 How and where will the data be shared?  Data will be shared through:  X An NIH-funded or approved public repository: clinicaltrials.gov X BTRIS (automatic for activities in the Clinical Center)  
X Approved outside collabora tors under appropriate individual agreements  
X Publication and/or public presentations   When will the data be shared?  X At the time of publication or shortly thereafter 
 
10 STUDY CALENDAR  
Eligibility screening evaluations are to be conducted within 8 days prior to enrollment, with the 
exception of informed consent and diagnostic imaging, which must be done within 28 days prior to enrollment.  Baseline history, physical examination, laboratory evaluations, and EC G are to be 
conducted within 8 days prior to t he start of protocol therapy.  If protocol therapy is started 
within 8 days of the eligibility screening evaluations, values from the screening evaluations may be used as baseline measurements; if > 8 days have passed since the screening evaluations, the medical history, physical examination, laboratory evaluations, and EC G must be repeated prior to 
starting protocol therapy.  Baseline imaging scans must be done within 28 days prior to the start of protocol therapy.  Start of next cycle may be  changed by 1 day or delayed for up to 1 week to 
accommodate scheduling conflicts.  Treatments within a cycle may be delayed ± 1 day to 
accommodate scheduling conflicts.  History and physical examination and laboratory evaluations can be performed up to 3 days before the start of the next cycle.  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   67 
  
Study Procedure  Pre-Study 
Eligibility 
Screen  Study Treatment  
Cycle 1  Cycle 2 and subsequent 
cycles  Off 
Treatment  
Wk 1 Wk 2 Wk 3 Wk 1 Wk 2 Wk 3   
M6620 (VX -970)a  X X  X X   
Veliparibb  X X  X X   
Cisplatinc  X   X    
Informed consent  X        
Demographics  X        
Medical history  X Xl       
Concomitant  meds  X X------------------------- ------------------------------ ------------- -X  
Physical examd X Xl X  X X  X 
Vital signsd X Xl X  X X  X 
Heightd X        
Weigh td X Xl X  X X  X 
Performance statusd X Xl X  X X  X 
ECGe X X       
CBC w/diff, pltsf X Xl X X X X optional  X 
Serum chemistryf X Xl X X X X optional  X 
PT, INR, PTTg  X X      
β-HCGh X        
Adverse event 
evaluation  X X------------------------------------------------------------------- X  
Tumor  
measurementsi X Xl Tumor measurements are repeated per Section 11.1  
Documentation (radiologic) must be provided for 
patients removed from study for progressive disease.  X 
Tumor biopsyj  X X      
Circulating  Tumor 
Cellsk X X X  X    
a.  M6620 (VX -970) will be administered intravenously as a 1-hour infusion ± 10 minutes  on days 
2 and 9 of a 21-day cycle (or on days 1 and 8 of any cycle in which cisplatin is not 
administered ).   
b.  Veliparib will be administe red orally q12 hours ± 1 hour on days 1 through 3 and 8 through 10 
of a 21-day cycle.  Veliparib should be administered before cisplatin and M6620 (VX-970). 
c.  Cisplatin will be administered intravenously as a 1 -hour infusion ± 10 minutes on day 1 of a 21-
day cycle (days 1 and 8 for patients on dose level 3 and higher). As of Amendment I  
(12/7/2017) , patients who have been on trial for at least 6 cycles may  have cisplatin 
administration held or discontinued while continuing on trial at the discretion of th e PI, Dr. 
 
d.  Physical examination, including vitals, weight, and performance status, will be performed at the 
Clinical Center at the start of each cycle of treatment (up to 3 days before the start of a new cycle) and on day 8 or 9 (±1 day) of each c ycle.  Weight will be used to calculate doses per 
institutional SOP.  Height will be performed prior to  enrollment and will not need to be repeated 

CTEP #  P9771 
Clinical Center #  16-C-0087  
   68 
 prior to each treatment.  
e. ECG for eligibility  screening and at baseline  (within 8 days prior to enrolling or starting study 
drug, respectively), within approximately 1 hour after the end of M6620 (VX-970) infusion 
during cycle 1, and as c linically indicated.  
f.  Serum chemistry (albumin, total bilirubin, calcium, creatinine, phosphorus, magnesium, 
potassium, s odium, SGOT [AST], SGPT [ALT]); CBC w/diff, and platelets should be 
performed for eligibility  screening  and at baseline ( within 8 days prior to enrollment or starting 
treatment, respectively),  and prior to treatment on days 2, 8, 9, and 15 (±1 day for all) of cycle 1.  
For all subsequent cycles, these labs should be performed prior to treatment on day 1 (±1 day) 
and prior to the first IV treatment on week 2 of the cycle (day 8 or 9, ±1 day).  C1D1 values need to re- meet eligibility criteria.  C1D15 labs may  be obtained by the patient’s local physician 
and day 15 labs in subsequent cycles are optional. 
g.  PT, INR, PTT required within 1 week prior to all biopsies, and may also be performed as 
clinically indicated . 
h.  Serum or urine pregnancy test (women of childbearing potential) within 8 days prior to 
enrollment and as clinically indicated.  
i.  Radiologic examination (CT scan or MRI) will be performed for eligibility screening and  at 
baseline (within 28 days prior to  enrolling or starting study drug, respect ively) and then every 2 
cycles (every 3 or 4 cycles for patients on study for more than one or three years, respectively).   
j.  Tumor biopsies will be obtained after the administration of cisplatin on C1D1 and again on C1D 
9 2-5 hours after the day 9 dose of M6620 (VX-970).  Tumor biopsies are optional during the escalation phase and mandatory during the expansion phase. 
k.  Circulating tumor cells (optional) will be drawn as defined in Section 9.1.3.  
l: Eligibility screening results may be used for these baseline measurements if conducted within 8 days (for medical history, physical exam, vital signs, weight, performance status ECG, serum 
chemistry, and CBC) or 28 days (for tumor measurements) prior to the start of protocol  therapy.  
 
11 MEASUREMENT OF EFFECT  
11.1 Antitumor Effect – Solid Tumors  
Although response is not the primary endpoint of this trial, patients with measurable disease will 
be assessed by standard criteria.  For the purposes of this study, patients should be re- evaluated 
for response every 6 weeks (every 2 cycles ; every 3 cycles for patients on study for more than 
one year or every 4 cycles for more than three years ).  In addition to a baseline scan, 
confirmatory scans should also be obtained at least 4 weeks follo wing initial documentation of 
objective response. 
 
Response and progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) [ Eur J Ca  45:228-247, 2009].  Changes in the largest diameter (unidimensional  
measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   69 
 11.1.1 Definitions  
Evaluable for toxicity :  All patients will be  evaluable for toxicity from the time of their first 
treatment with the combination of M6620 (VX -970), veliparib, and cisplatin. 
 
Evaluable for objective response :  Only those patients who have measurable disease present at 
baseline, have received at least  one cycle of therapy, and have had their disease re -evaluated will 
be considered evaluable for response.  These patients will have their response classified 
according to the definitions stated below.  (Note:  Patients who exhibit objective disease progression prior to the end of cycle 1 will also be considered evaluable.)  
 
Evaluable Non- Target Disease Response:  Patients who have lesions present at baseline that are 
evaluable but do not meet the definitions of measurable disease, have received at least one cycle of therapy, and have had their disease re-evaluated will be considered evaluable for non- target 
disease.  The response assessment is based on the presence, absence, or unequivocal progression of the le sions.   
11.1.2 Disease Parameters  
Measurable disease :  Measurable lesions are defined as those that can be accurately measured in 
at least one dimension (longest diameter to be recorded) as ≥ 20 mm by chest x- ray or as ≥ 10 mm 
with CT scan, MRI, or calipers by clinical exam.  All tumor measurements must be reco rded in 
millimeters  (or decimal fractions of centimeters).   
 
Malignant lymph nodes:  To be considered pathologically enlarged and measurable, a lymph 
node must be ≥ 15 mm in short axis when assessed by CT scan (CT scan slice thickness 
recommended to be no greater than 5 mm).  At baseline and in follow-up, only the short axis will be measured and followed.   
 
Non-measurable disease :  All other lesions (or sites of disease), including small lesions (longest 
diameter <10 mm or pathological lymph nodes with ≥ 10 to <15 mm short axis), are considered 
non-measurable disease.  Bone lesions, leptomeningeal disease, ascites, pleural/pericardial 
effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses (not followed by CT or MRI), are considered as non- measurable.   
 
Note:  Cystic lesions that meet the criteria for radiographically defined simple cysts should not be considered as malignant lesions (neither measurable nor non- measurable) since they are, by 
definition, simple cysts.   
 
‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable lesions, if they meet the definition of measurability described above .  However, if non- cystic lesions are 
present in the same patient, these are preferred for selection as t arget lesions.   
 
Target lesions: All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in 
total, representative of all involved organs, should be identified as target lesions and recorded and measured at baseline .  Target lesions shou ld be selected on the basis of their size (lesions 
with the longest diameter), be representative of all involved organs, but in addition should be 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   70 
 those that lend themselves to reproducible repeated measurements .  It may be the case that, on 
occasion, the largest lesion does not lend itself to reproducible measurement in which 
circumstance the next largest lesion which can be measured reproducibly should be selected .  A 
sum of the diameters (longest for non -nodal lesions, short axis for nodal lesions) for a ll target 
lesions will be calculated and reported as the baseline sum diameters.  If lymph nodes are to be 
included in the sum, then only the short axis is added into the sum.  The baseline sum diameters will be used as reference to further characterize any objective tumor regression in the measurable dimension of the disease.   
 
Non-target lesions :  All other lesions (or sites of disease) including any measurable lesions over 
and above the 5 target lesions should be identified as non- target lesions and should also be 
recorded at baseline.  Measurements of these lesions are not required, but the presence, absence, or in rare cases unequivocal progression of each should be noted throughout follow- up.  
11.1.3 Guidelines for Evaluation of Measurable Disease  
All measure ments should be taken and recorded in metric notation using a ruler or calipers.  All 
baseline evaluations should be performed as closely as possible to the beginning of treatment and never more than 4 weeks before the beginning of the treatment.  
 
The same method of assessment and the same technique should be used to characterize each identified and reported lesion at baseline and during follow- up.  Imaging -based evaluation is 
preferred to evaluation by clinical examination unless the lesion(s) being follo wed cannot be 
imaged but are assessable by clinical exam.   
 
Clinical lesions :  Clinical lesions will only be considered measurable when they are superficial 
(e.g., skin nodules and palpable lymph nodes) and ≥ 10 mm diameter as assessed using calipers 
(e.g., skin nodules).  In the case of skin lesions, documentation by color photography, including a ruler to estimate the size of the lesion, is recommended .   
 
Chest x -ray:  Lesions on chest x -ray are acceptable as measurable lesions when they are clearly 
defin ed and surrounded by aerated lung.  However, CT is preferable.   
 
Conventional CT and MRI:  This guideline has defined measurability of lesions on CT scan 
based on the assumption that CT slice thickness is 5 mm or less.  If CT scans have slice thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness.  
MRI is also acceptable in certain situations ( e.g., for body scans).   
 
As with CT, if an MRI is performed, the technical specifications of the scanning sequenc es used 
should be optimized for the evaluation of the type and site of disease.  Furthermore, as with CT, the modality used at follow -up should be the same as was used at baseline and the lesions should 
be measured/assessed on the same pulse sequence .  It is beyond the scope of the RECIST 
guidelines to prescribe specific MRI pulse sequence parameters for all scanners, body parts, and diseases.  Ideally, the same type of scanner should be used and the image acquisition protocol should be followed as closely as possible to prior scans.  Body scans should be performed with breath -hold scanning techniques, if possible.  
 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   71 
 PET- CT:  At present, the low dose or attenuation correction CT portion of a combined PET- CT is 
not always of optimal diagnostic CT quality for use with RECIST measurements.  However, if 
the site can document that the CT performed as part of a PET -CT is of identical diagnostic 
quality to a diagnostic CT (with IV and oral contrast), then the CT portion of the PET- CT can be 
used for RECIST measurements and can be used interchangeably with conventional CT in accurately measuring cancer lesions over time.  Note, however, that the PET portion of the CT 
introduces additional data which may bias an investigator if it is not routinely or serially performed .   
 
Ultrasound:   Ultrasound is not useful in assessment of lesion size and should not be used as a 
method of measurement .  Ultrasound examinations cannot be reproduced in their entirety for 
independent review at a later date and, because they are operator  dependent, it cannot be 
guaranteed that the same technique and measurements will be taken from one assessment to the next.  If new lesions are identified by ultrasound in the course of the study, confirmation by CT or MRI is advised .  If there is concern about radiation exposure at CT, MRI may be used instead 
of CT in selected instances.   
 
Endoscopy, Laparoscopy:  The utilization of these techniques for objective tumor evaluation is 
not advised.  However, such techniques may be useful to confirm complete p athological response 
when biopsies are obtained or to determine relapse in trials where recurrence following complete response (CR) or surgical resection is an endpoint.  
 
Tumor markers :  Tumor markers alone cannot be used to assess response .  If markers are initially 
above the upper normal limit, they must normalize for a patient to be considered in complete clinical response.  Specific guidelines for both CA-125 response (in recurrent ovarian cancer) and 
PSA response (in recurrent prostate cancer) have been published [ JNCI  96:487-488, 2004; J Clin 
Oncol  17, 3461-3467, 1999; J Clin Oncol  26:1148-1159, 2008].  In addition, the Gynecologic 
Cancer Intergroup has developed CA- 125 progression criteria which are to be integrated with 
objective tumor assessment fo r use in first- line trials in ovarian cancer [ JNCI  92:1534-1535, 
2000].  
 
Cytology, Histology:  These techniques can be used to differentiate between partial responses 
(PR) and complete responses (CR) in rare cases ( e.g., residual lesions in tumor types, s uch as 
germ cell tumors, where known residual benign tumors can remain).  
 
The cytological confirmation of the neoplastic origin of any effusion that appears or worsens 
during treatment when the measurable tumor has met criteria for response or stable dise ase is 
mandatory to differentiate between response or stable disease (an effusion may be a side effect of the treatment) and progressive disease.   
 
FDG- PET:  While FDG -PET response assessments need additional study, it is sometimes 
reasonable to incorporat e the use of FDG -PET scanning to complement CT scanning in 
assessment of progression (particularly possible 'new' disease) .  New lesions on the basis of 
FDG-PET imaging can be identified according to the following algorithm:  
a. Negative FDG -PET at baseline, with a positive FDG- PET at follow -up is a sign of PD 
based on a new lesion.  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   72 
 b. No FDG-PET at baseline and a positive FDG- PET at follow -up:  If the positive FDG -
PET at follow -up corresponds to a new site of disease confirmed by CT, this is PD .  If 
the positive FDG- PET at follow -up is not confirmed as a new site of disease on CT, 
additional follow -up CT  scans are needed to determine if there is truly progression 
occurring at that site (if so, the date of PD will be the date of the initial abnormal 
FDG- PET scan) .  If the positive FDG -PET at follow -up corresponds to a pre- existing 
site of disease on CT that is not progressing on the basis of the anatomic images, this is not PD. 
c. FDG-PET may be used to upgrade a response to a CR in a manner similar to a biopsy 
in cases where a residual radiographic abnormality is thought to represent fibrosis or scarring .  The use of FDG -PET in this circumstance should be prospectively described 
in the protocol and supported by disease- specific medical literature for the indication .  
However, it must be acknowledged that both approaches may lead to false positive CR due to limitations of FDG -PET and biopsy resolution/sensitivity.  
 Note:  A ‘positive’ FDG -PET scan lesion means one which is FDG avid with an uptake 
greater than twice that of the surrounding tissue on the attenuation corrected image.  
11.2 Response Criteria  
11.2.1 Evaluation of Target Lesions 
Complete Response (CR) :  Disappearance of all target lesions.  Any pathological 
lymph nodes (whether target or non- target) must have 
reduction in short axis to <10 mm.  
 
Partial Response (PR) :  At least a 30% decrease in the sum of the diameters of 
target lesions, taking as reference the baseline sum 
diameters.  
 
Progressive Disease (PD) :  At least a 20% increase in the sum of the diameters of 
target lesions, taking as reference the smallest sum on 
study (this includes the baseline sum if that is the smallest on study) .  In addition to the relative increase 
of 20%, the sum must also demonstrate an absolute increase of at least 5 mm .  (Note:  the appea rance of 
one or more new lesions is also considered progressions). 
 
Stable Disease (SD) :  Neither sufficient shrinkage to qualify for PR nor 
sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.  
11.2.2 Evaluation of Non -Target Lesions 
Complete Response (CR) :  Disappearance of all non -target lesions and 
normalization of tumor marker level .  All lymph nodes 
must be non- pathological in size (<10 mm short axis).  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   73 
  
Note:  If tumor markers are initially above the upper 
norm al limit, they must normalize for a patient to be 
considered in complete clinical response.  
 
Non-CR/Non -PD:    Persistence of one or more non- target lesion(s) and/or 
maintenance of tumor marker level above the normal limits.  
 
Progressive Disease (PD) :  Appearance of one or more new lesions and/or 
unequivocal progression  of existing non- target lesions .  
Unequivocal progression  should not normally trump 
target lesion status .  It must be representative of overall 
disease status change, not a single lesion increase.     
 
Although a clear progression of “non- target” lesions only is exceptional, the opinion 
of the treating physician should prevail in such circumstances, and the progression status should be confirmed at a later time by the review panel (or Principa l 
Investigator).  
11.2.3 Evaluation of Best Overall Response 
The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started) .  The patient's best 
response assignment will depend on the achievement of both measurement and confirmation criteria.  
 
For Patients with Measurable Disease ( i.e., Target Disease)  
 
Target 
Lesions  Non-Target 
Lesions  New 
Lesion s Overall 
Response  Best Overall Response when 
Confirmation is Required*  
CR CR No CR ≥4 wks .  Confirmation**  
CR Non-CR/Non -PD No PR 
≥4 wks .  Confirmation** CR Not evaluated  No PR 
PR Non-CR/Non -
PD/not evaluated  No PR 
SD Non-CR/Non -
PD/not evaluated  No SD Documented at least once ≥ 4 
wks.  from baseline**  
PD Any Yes or 
No PD 
no prior S D, PR or CR Any PD***  Yes or 
No PD 
Any Any Yes PD 
* See RECIST 1.1 manuscript for further details on what is evidence of a new lesion.  
** Only for non- randomized trials with response as primary endpoint.  
*** In exceptional circumstances, unequivocal progression in non-target lesions may be 
accepted as disease progression.  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   74 
  
Note: Patients with a global deterioration of health status requiring discontinuation of 
treatment without objective evidence of disease progression at that time should be 
reported a s “symptomatic deterioration.”   Every effort should be made to document 
the objective progression even after discontinuation of treatment.  
 
For Patients with Non- Measurable Disease ( i.e., Non- Target Disease)  
 
Non-Target Lesions  New Lesions  Overall Respons e 
CR No CR 
Non-CR/non -PD No Non-CR/non -PD* 
Not all evaluated  No not evaluated  
Unequivocal PD  Yes or No  PD 
Any Yes PD 
*  ‘Non -CR/non -PD’ is preferred over ‘stable disease’ for non -target disease since SD is 
increasingly used as an endpoint for assessment of efficacy in some trials so to assign this 
category when no lesions can be measured is not advised  
11.3 Duration of Response  
Duration of overall response :  The duration of overall response is measured from the time 
measurement criteria are met for CR or PR (whichever is first recorded) until the first date that 
recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).  
 The duration of overall CR is measured from the time measurement criteria are first met for CR until the first date that progressive disease is objectively documented.   
 
Duration of stable disease :  Stable disease is measured from the start of the treatment until the 
criteria for progression are met, taking as reference the smallest measurements recorded since the treatment started, including the baseline measurements .   
 
12 DATA REPORTING /REGULATORY REQUIREMENTS  
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 7 (Adverse Events: List and Reporting Requirements).  
12.1 Study Oversight  
This protocol is monitored at several levels, as described in this section. The Protocol Principal  
Investigator is responsible for monitoring the conduct and progress of the clinical trial, including  
the ongoing review of accrual, patient-specific clinical and laboratory data, and routine and serious adverse events; reporting of expedited adverse events; and accumulation of reported adverse ev ents from other trials testing the same drug(s). The Protocol Principal Investigator and 
statistician have access to the data at all times through the CTMS web -based reporting portal.  
 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   75 
 All Study Investigators at participating sites who register/enroll pat ients on a given protocol are 
responsible for timely submission of data via Medidata Rave and timely reporting of adverse 
events for that particular study. This includes timely review of data collected on the electronic CRFs submitted via Medidata Rave.  
12.2 Data Reporting  
12.2.1 Method 
 This study will be monitored by the Clinical Trials Monitoring Service (CTMS).  Data 
will be submitted to CTMS at least once every two weeks via Medidata Rave (or other modality if approved by CTEP).  Information on CTMS reporting is a vailable at 
http://www.theradex.com/clinicalTechnologies/?National -Cancer -Institute -NCI-11.  
On-site audits will be conducted three times annually (one annual site visit and two 
data audits).  For CTMS monitored studies, after users have activated their ac counts, 
please contact the Theradex Help Desk at (609) 799-7580 or by email at ctms@theradex.com for additional support with Rave and completion of CRFs.  
 
Note : All adverse events that have occurred on the study, including those reported 
through CTEP- AERS , must be reported via the monitoring method identified above. 
12.2.2 Responsibility for Data Submission 
Data are to be submitted via Medidata Rave to CTMS on a real -time basis, but no less 
than once every 2 weeks. The timeliness of data submissions and timeliness in 
resolving data queries will be tracked by CTMS. Metrics for timeliness will be followed and assessed on a quarterly basis. For the purpose of Institutional Performance Monitoring, data will be considered delinquent if it is greater than 4 weeks past d ue.  
 
Data from Medidata Rave and CTEP -AERS is reviewed by the CTMS on an ongoing 
basis as data is received. Queries will be issued by CTMS directly within Rave. 
Monthly web-based reports are posted for review by the Drug Monitors in the IDB, CTEP. Onsite audits will be conducted by the CTMS to ensure compliance with regulatory requirements, GCP, and NCI policies and procedures with the overarching goal of ensuring the integrity of data generated from NCI- sponsored clinical trials. 
Guidelines may be found on the CTEP (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/adverse_events.h
tm) and CTSU websites.   An End of Study CRF is to be completed by the PI, and is to include a summary of study endpoints not otherwise captured in the database, such as (for phase 1 trials) the recommended phase 2 dose (RP2D) and a description of any dose- limiting toxicities 
(DLTs). CTMS will utilize a core set of eCRFs that are Cancer Data Standards Registry and Repository (caDSR) compliant (http://cbiit.nci.nih .gov/ncip/biomedical-
informatics -resources/interoperability -and- semantics/metadata -and- models ). 
Customized eCRFs will be included when appropriate to meet unique study requirements. The PI is encouraged to review the eCRFs, working closely with CTMS 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   76 
 to ens ure prospectively that all required items are appropriately captured in the eCRFs 
prior to study activation. CTMS will prepare the eCRFs with built -in edit checks to 
the extent possible to promote data integrity. 
12.3 CTEP Multicenter Guideline s 
This protocol will adhere to the policies and requirements of the CTEP Multicenter Guidelines.  
The specific responsibilities of the Principal Investigator and the Coordinating Center (Study Coordinator) and the procedures for auditing are presented in Appendix F . 
 
• The Principal Investigator/Coordinating Center is responsible for distributing all IND Action Letters or Safety Reports received from CTEP to all participating institutions for submission to their individual IRBs for action as req uired. 
 
• Except in very unusual circumstances, each participating institution will order DCTD-supplied agents directly from CTEP.  Agents may be ordered by a participating site only after the initial IRB approval for the site has been forwarded by the Coord inating Center 
to the CTEP PIO (PIO@ctep.nci.nih.gov) except for Group studies.  
 
12.4 Collaborative Agreements Language 
The agent(s) supplied by CTEP, DCTD, NCI used in this protocol is/are provided to the NCI under a Collaborative Agreement (CRADA, CTA, CSA) between the Pharmaceutical Company(ies) (hereinafter referred to as “Collaborator(s)”) and the NCI Division of Cancer Treatment and Diagnosis.  There fore, the following obligations/guidelines, in addition to the 
provisions in the “I ntellectual Property Option to Collaborator” 
(http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm) contained within the terms of award, apply to the use of the Agent(s) in this study: 
  
1. Agent(s) may not be used for any purpose outside the scope of this protocol, nor can Agent(s) be transferred or licensed to any party not participating in the clinical study .    
Collaborator(s) data for Agent(s) are confidential and prop rietary to Collaborator(s) and shall 
be maintained as such by the investigators.  The protoco l documents for studies utilizing 
Agents contain confidential information and should not be shared or distributed without the permission of the NCI.  If a copy of this protocol is requested by a patient or patient’s family 
member participating on the study, the individual should sign a confidentiality agreement.  A 
suitable model agreement can be downloaded from  http://ctep.cancer.gov. 
 
2. For a clinical protocol where there is an investigational Agent used in  combination with 
(an)other Agent(s), each the subj ect of different Collaborative  Agreements, the access to and 
use of data by each Collaborator shall be as follows (data pertaining to such combination use shall  hereinafter be referred to as “Multi -Party Data”):  
 
a.  NCI will provide all Collaborators with prior written notice regarding the existence and nature of any agreements governing their collaboration with NCI, the design of the 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   77 
 proposed combination protocol, and the existence of any obligations that would tend to 
restrict NCI's participation in the  proposed combination protocol. 
b.  Each Collaborator shall agree to permit use of the Multi- Party Data from the  clinical 
trial by any other Collaborator solely to the extent necessary to allow said  other 
Collaborator to develop, obtain regulatory approval or commercialize its  own Agent. 
 c.  Any Collaborator having the right to use the Multi- Party Data from these trials  must 
agree in writing prior to the commencement of the trials that it will use the  Multi -Party 
Data solely for development, regulatory approval, and commercialization of its own Agent. 
 
3. Clinical Trial Data and Results and Raw Data developed under a Collaborative Agreement will be made available to Collaborator(s), the NCI, and the FDA, as appropriate and unless additional disclosure is required by law or court order as described in the IP Option to Collaborator (http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm).  Additionally, all Clinical Data and Results and Raw Data will be collected, used  and 
disclosed consistent w ith all applicable federal statutes and regulations for the  protection of 
human subjects, including, if applicable, the Standards for Privacy of Individually Identifiable Health Information set forth in 45 C.F.R.  Part 164. 
 
4. When a Collaborator wishes to i nitiate a data request, the request should first be sent to the 
NCI, who will then notify the appropriate investigators (Group Chair for Cooperative Group studies, or PI for other studies) of Collaborator's wish to  contact them.  
 
5. Any data provided to Colla borator(s) for Phase 3 studies must be in accordance  with the 
guidelines and policies of the responsible Data Monitoring Committee (DMC), if there is a DMC for this clinical trial.  
 
6. Any manuscripts reporting the results of this clinical trial must be provided to  CTEP by the 
Group office for Cooperative Group studies or by the principal investigator for non -
Cooperative Group studies for immediate delivery to  Collaborator(s) for advisory review and 
comment prior to submission for publication.  Collaborator(s) will have 30 days from the date of receipt for review .  Collaborator shall have the right to request that publication be delayed 
for up to an additional 30 days in order to ensure that Collaborator’s confidential and proprietary data, in addition to Colla borator(s)’s intellectual property rights, are  protected .  
Copies of abstracts must be provided to CTEP for forwarding to  Collaborator(s) for courtesy 
review as soon as possible and preferably at least  three (3) days prior to submission, but in 
any case, p rior to presentation at the  meeting or publication in the proceedings.  Press releases 
and other media  presentations must also be forwarded to CTEP prior to release.  Copies of 
any manuscript, abstract and/or press release/ media presentation should be sen t to: E- mail: 
ncicteppubs@mail.nih.gov 
   
The Regulatory Affairs Branch will then distribute them to Collaborator(s).  No  publication, 
manuscript or other form of public disclosure shall contain any of Collaborator’s confidential/ proprietary information.  
 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   78 
 12.5 Genomic Data Sharing Plan 
The NIH Genomic Data Sharing (GDS) Policy does not apply to this protocol as the genomic 
analysis will be performed will be for  no more than 30 patient samples; therefore, this study 
does not meet GDS criteria, and a GDS plan is not warranted.  
 
13 STATISTICAL CONSIDERATIONS  
13.1 Study Design/Endpoints  
This Phase I study will use a standard  3+3 design with a slight modification as outlined in Section 
5.3.  Accrual will not proceed to a higher dose level until all patients have been treated at the current dose level, and the last patient treated has been observed for at least one cycle.  T he MTD 
dose for the combination of M6620 (VX-970), veliparib, and cisplatin is defined as the dose level 
at which no m ore tha n 1 of 6 patients experience a DLT during the first cycle of the treatment, and 
the dose level below that at which at least 2 (of ≤ 6) patients have DLT as a result of the drug s.  
Patients will receive cisplatin intravenously on day 1 
(and day 8 from DL3 onwards ; at the 
discretion of the PI, Dr.  after cycle 6) , M6620 (VX-970) intravenously on days 1/2 and 8/9, 
and veliparib orally q12 hours ± 1 hour on days 1-3 and 8-10 of each 21- day cycle.   
 Once the MTD is established, up to 15  additional patients will be enrolled to the expansion phase 
of the trial at the MTD .  Mandatory tumor biopsies will be obtained in the expansion phase to 
assess for pharmacodynamic endpoints.  With up to 15 patients and a tumor biopsy QA criteria failure rate of 50% with respect to paired (pre - and post-dose) biopsies, we have an 85% 
likelihood of having at least 6 usable PD samples, and 95% likelihood of having at least 5 usable samples.     
13.2 Sample Size/Accrual Rate  
We plan to accrue up to 55 patients in this study .  To allow for some patients who may have only 
evaluable and not measurable disease, the accrual ceiling is set at  60.  It is a nticipated that 2-3 
patients may be enrolled per month onto this study.  I t is expected that 12-18 months will be 
required to accrue the number of patients necessary to complete the trial.
   
13.3 Secondary Endpoints  
• To assess the effect of the combination of M6 620 (VX-970), veliparib, and cisplatin on markers 
of DNA damage and apoptosis.  
• To assess the antitumor activity of the combination   
 
14 HUMAN SUBJECTS PROTECTIONS  
14.1 Justification for Subject Selection  
This study will be open to all individuals regardless of gender, ethnicity, or race, provided that the aforementioned inclusion and exclusion criteria are met.  Patients for this study will be  recruited 
through internal referral, our physician referral base, and through various cancer information 

CTEP #  P9771 
Clinical Center #  16-C-0087  
   79 
 hotlines (i.e., Clinical Studies Support Center, 1-800-4Cancer).  To date, there is no information 
that suggests that differences in drug metabolism or effect on tumor would be  expected in one 
ethnic group compared to another.  Efforts will be made to extend accrual to  each  representative 
population, but a balance must be struck between participant safety  considerations and limitations 
on the number of individuals exposed to potentially ineffective treatments on the one hand and the need to explore racial/ethnic aspects of clinical research on  the other hand.  If differences in 
outcome that correlate to ethnic identity are noted, a follow -up study may be written to investigate 
those differences more fully.  Due to lack of knowledge of the effects of the combination of M6620 ( VX-970), veliparib, and 
cisplatin  on the fetus or infants, as well as the possibility of teratogenic effects, pregnant and 
nursing women will be excluded from this trial.  Patients with unstable or serious medical 
conditions are excluded due to the possibi lity that the combination of M6620 (VX-970), veliparib, 
and cisplatin  may worsen their condition and the likelihood that the underlying condition may 
obscure the attribution of adverse events to M6620 (VX-970), veliparib, and cisplatin .  HIV-
positive patients are excluded from the study per Section 3.1.9. 
14.1.1 Participation of Children  
This study includes patients 18 years of age and older.  Because insufficient dosing or adverse event data are currently available on the use of  combin ation of M6620 (VX-
970), veliparib, and cisplatin in patients <18 years of age, children are excluded from this study, but may be eligible for future pediatric trials .  Studies will be performed in 
patients <18 years of age when it is appropriate to do so. 
14.2 Evaluation of Benefits and Risks/Discomforts  
There may or may not be any clinical benefit to a patient from participation in this trial .  Their  
participation will benefit future cancer patients .  Potential risks include the possible occurrence of 
any of a range of side effects that are listed in the consent document .  The procedure for  protecting 
against or minimizing risks will be to medically evaluate patients as described in  Section 5 and 
Sectio n 6.  Although no compensation is available, any injury will be fully evaluated and treated 
in keeping with the benefits or care to which participants are entitled under applicable regulations. 
14.3 Consent and Assent Process and Documentation  
An associate or principal investigator on the trial will inform patients of the purpose, alternatives,  
drug administration plan, research objectives, and follow- up of this trial.  The patient will be  
provided an IRB -approved consent for review and signature and his/her questions will be 
answered .  After a decision is made to enroll into the study, a signature will be obtained from the  
patient .  The original signed consent goes to Medical Records; a copy will be placed in the 
research record.   Patients will not be consented by telephone. 
 All patients must have a signed informed consent form and an on- study (confirmation of  
eligibility) form filled out and signed by a participating investigator before entering on study.  
 
Adults who are unable to provide initial informed consent are excluded from participation on this study.  All patients > 18 years old will be offered the opportunity to assign a substitute decision 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   80 
 maker on the “NIH Advance Directive for Health Care and Medical Research Participation” form, 
so that another pe rson can make decisions about their medical care if they become incapacitated or 
cognitively impaired.  
 
14.3.1 Participation of subjects unable to give consent  
At the NCI only: Adults unable to give consent are excluded from enrolling in the protocol.  However, re-consent may be necessary and there is a possibility, though unlikely, that subjects could become decisionally impaired. For this reason and because there is a prospect of direct benefit from research participation, all subjects ≥ age 18 at the NCI only w ill be offered the opportunity to fill in their wishes for 
research and care, and assign a substitute decision maker on the “NIH A dvance 
Directive for Health Care and Medical Research Participation” form so that another person can make decisions about their medical care in the event that they become incapacitated or cognitively impaired during the course of the study. Note: The PI or AI will contact the NIH Ability to Consent Assessment Team for evaluation .  For 
those subjects that become incapacitated and do not have pre- determined substitute 
decision maker, the procedures described in MEC Policy 87-4 for appointing a surrogate decision maker for adult subjects who are (a) decisionally impaired, and (b) who do not have a legal guardian or durable power of attorney, will be followed. 
14.3.2 Informed consent of non-English speaking subjects 
If there is an unexpected enrollment of a research participant for whom there is no translated extant IRB approved consent document, the principal investigator and/or those authorized to obtain informed consent will use the Short Form Oral Consent Process as described in MAS Policy M77 -2, OHSRP SOP 12, 45 CFR 46.117 (b) (2).  
The summary that will be used is the English version of the extant IRB approved 
consent document.  Signed copies of both the English version of the consent and the 
translated short form will be given to the subject or their legally authorized representative, and the signed original will be filed in the medical record.  
 Unless the PI is fluent in the prospective subject’s language, an interpreter will be present to facilitate the conversation (using the Short Form process).  Preferably, someone who is independent of the subject (i.e., not a family member) will a ssist in 
presenting information and obtaining consent.  Whenever possible, interpreters will be provided copies of the relevant consent documents well before the consent conversation with the subject (24 to 48 hours if possible).  We request prospective IR B approval of the use of the short form process for non-
English speaking subjects and will notify the IRB at the time of continuing review of the frequency of use of the Short Form.  The Short Form process will be used no more than 5 times per language, af ter which the full consent document will be translated 
into that language. 
 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   81 
 14.4 Procedure for Protecting Against or Minimizing Any Potential Risks  
All care will be taken to minimize side effects, but they can be unpredictable in nature and  
severity .  This stud y may involve risks to patients, which are currently unforeseeable.  All patients 
will be monitored for side effects from taking study medication .  This research  represents a 
greater than minimal risk to participants, but presents the prospect of direct be nefit to individual 
subjects.  
 
The research component of this study required to obtain 3 CT tumor biopsies  confers radiation  
exposure at an effective dose of 2.4 rem .  This dose is below NIH RSC guidelines of less than 5.0 
rem per year in adults, and  represents a slightly greater than minimal risk to patients .   
 
14.5 Patient Advocate 
The patients’ rights representative is available to patients receiving treatment on this protocol at the NIH Clinical Center at (301) 496 -2626 in Building 10 of the Clinical Research Center, Room 
1-3521, on the Bethesda NIH campus.  Patients will be informed that they can contact the study  PI 
or RN at any time with questions about their medical care, and that the patients’ rights  
representative is also available to answer non -medica l questions about the study. 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   82 
 REFERENCES   
 
1. Chen, X., et al., Platinum-based agents for individualized cancer treatment. Curr Mol Med, 2013. 13(10): p. 1603- 12. 
2. Zhu, G., P. Chang, and S.J. Lippard, Recognition of platinum- DNA damag e by poly(ADP-
ribose) polymerase-1. Biochemistry, 2010. 49(29): p. 6177- 83. 
3. Jazayeri, A., et al., ATM - and cell cycle-dependent regulation of ATR in response to DNA 
double- strand breaks.  Nat Cell Biol, 2006. 8(1): p. 37-45. 
4. Serrano, M.A., et al., DNA -PK, ATM and ATR collaboratively regulate p53-RPA interaction 
to facilitate homologous recombination DNA repair. Oncogene, 2013. 32(19): p. 2452-62. 
5. El-Khamisy, S.F., et al., A requirement for PARP -1 for the assembly or stability of XRCC1 
nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res, 2003. 31(19): p. 5526-33. 6. Haince, J.F., et al., PARP1 -dependent kinetics of recruitment of MRE11 and NBS1 proteins to 
multiple DNA damage sites. J Biol Chem, 2008. 283(2): p. 1197-208. 
7. Huntoon, C.J., et al., ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy 
independent of BRCA status. Cancer Res, 2013. 73(12): p. 3683-91. 
8. Reaper, P.M., et al., Selective killing of ATM- or p53-deficient cancer cells through inhibition 
of ATR.  Nat Chem Biol, 2011. 7(7): p. 428-30. 
9. Yap, T.A., et al., Abstract PR14: Phase I trial of first -in-class ataxia telangiectasia -mutated 
and Rad3- related (ATR) inhibitor VX -970 as monotherapy (mono) or in combination with 
carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity. Molecular Cancer Therapeutics, 2015. 14(12 Supplement 2): p. PR14. 
10. Helleday, T., The underlying mechanism for the PARP and BRCA synthetic lethality: clearing 
up the misunderstandings. Mol Oncol, 2011. 5(4): p. 387-93. 
11. Donawho, C.K., et al., ABT -888, an orally active poly(ADP-ribose) polymerase inhibitor that 
potentiates DNA -damaging agents in preclinical tumor models. Clin Cancer Res, 2007. 13(9): p. 
2728-37. 12. Peralta-Leal, A., M.I. Rodriguez, and F.J. Oliver, Poly(ADP- ribose)polymerase- 1 (PARP-1) 
in carcinogenesis: potential role of PARP inhibitors in cancer treatment. Clin Transl Oncol, 2008. 
10(6): p. 318-23. 
13. Kummar, S., et al., Phase 0 clinical trial of the poly (ADP -ribose) polymerase inhibitor ABT -
888 in patients with advanced malignancies. J Clin Oncol, 2009. 27(16): p. 2705-11. 14. Rodler, E.T., et al., Phase I: Veliparib with cisplatin (CP) and vinorelbine (VNR) in advanced 
triple -negative breast can cer (TNBC) and/or BRCA mutation- associated breast cancer.  ASCO 
Meeting Abstracts, 2014. 32(15_suppl): p. 2569. 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   83 
 15. Wilsker, D.F., et al., Pharmacodynamic Responses to DNA Damage from Cancer 
Therapeutic Agents. Clin Cancer Res, 2019. in press. 
16. Caulfield , T., et al., Research Ethics Recommendations for Whole- Genome Research: 
Consensus Statement. PLoS Biol, 2008. 6(3): p. e73. 17. Berg, J.S., M.J. Khoury, and J.P. Evans, Deploying whole genome sequencing in clinical 
practice and public health: Meeting the challenge one bin at a time. Genet Med, 2011. 13(6): p. 499-
504.  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   84 
 APPENDIX A: PERFORMANCE STATUS CRITERIA  
 
ECOG Performance Status Scale  
Grade  Descriptions  
0 Normal activity .  Fully active, able to carry on all pre- disease 
performance without restriction. 
1 Symptoms, but ambulatory.  Restricted in physically strenuous 
activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work). 
2 In bed <50% of the time.  Ambulatory and capable of all s elf-
care, but unable to carry out any work activities.  Up and about more than 50% of waking hours. 
3 In bed >50% of the time.  Capable of only limited self- care, 
confined to bed or chair more than 50% of waking hours. 
4 100% bedridden.  Completely  disabled .  Cannot carry on any 
self-care.  Totally confined to bed or chair. 
5 Dead.  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   85 
 APPENDIX B :  PATIENT DRUG INTERACTIONS  HANDOUT AND WALLET CARD  
 
Information for Patients, Their Caregivers, and Non- Study Healthcare Team on Possible 
Interactions with Other Drugs and Herbal Supplements   
Patient 
Name:        Diagnosis:        Trial #:       
Study 
Doctor:       Study Doctor 
Phone #:         Study 
Drug(s):        
 
Please show this paper to all your healthcare providers (doctors, physici an assistants, nurse 
practitioners, pharmacists), and tell them you are taking part in a clinical trial sponsored by the National Cancer Institute. 
 
 These are the things that your healthcare providers need to know:
 
M6620 (VX- 970) interacts with specific enzymes in the liver or other tissues like the gut and 
certain transport proteins that help move drugs in and out of the cell.  
 Explanation  
CYP 
isoenzymes  The enzyme in question is CYP3A4 .  M6620 (VX -970) is metabolized by 
CYP3A4 and may be affected by other drugs that inhibit or induce this 
enzyme.  
Protein 
transporters  The proteins in questions are  P-gp and BCRP .  M6620 (VX -970) is a 
moderate inhibitor of these proteins and may affect drugs that are moved in 
and out of cells/organs by these transport pr oteins.  
  Veliparib (ABT -888)  is cleared from the body by certain specific drug transporter proteins.  
 
• The transporters  in question are  P-gp, OCT2, and MATE1/MATE2K .  Co-administration of 
veliparib (ABT -888) with other drugs that inhibit  P-gp, OCT2, or MATE1/MATE2K may result 
in decreased  veliparib (ABT -888) clearance by the kidneys and as a result, an  increase in 
veliparib (ABT -888) concentratio n in the blood.   
• Because the lists of these agents are constantly changing, it is important to regularly consu lt a 
frequently updated medical reference 
• Kidney  function plays an important role in the clearance of veliparib ( ABT -888).  Veliparib 
(ABT -888) levels may therefore be affected by d rug-associated kidney toxicities or kidney 
diseases .  Caution should be use d when concomitantly administering veliparib ( ABT -888) with 
oxalipaltin, carboplatin, cisplatin, and topotecan in patients with pre -existing kidney  impairment.  
 
 
These are the things that you need to know:
 
The study drugs  M6620 (VX-970) and veliparib (ABT-888)  may interact with other drugs which 
can cause side effects. For this reason, it is very important to tell your doctors about all your medicines, including: (a) medicines you are taking before this clinical trial, (b) medicines you 
start or stop taking  during this study, (c) medicines you buy without a prescription (over- the-
CTEP #  P9771 
Clinical Center #  16-C-0087  
   87 
 APPENDIX C: P ATIENT S TUDY  CALENDAR AND DIARY  
 
The study drugs are given over a 21- day period of time called cycles.  The 2 1-day treatment 
cycle will be repeated as long as you are tolerating the medications and your cancer is either 
stable or getting better.   The chart below shows what will happen to you during cycle 1 and future cycles after you sign the consent form and start the study.  Each cycle is numbered .  The left -hand column shows the 
day in the cycle, and the right-hand column tells you what will happen on that day.    
Day What to do and what will happen to you  
Before 
starting study drug  • Check in at _______ _________ [name of outpatient clinic ] 
• Get routine blood tests  
• Pregnancy test for women who are able to become pregnant 
• Have a history taken of how you feel and undergo a physical examination by a Health Care Provider  
• CT or MRI scan will be done 
• Research b lood samples will be drawn 
Cycle 1,  
Day 1  • Admitted to ________________ [name of clinical center ] 
• Get routine blood tests 
• Research blood samples will be drawn  
• Receive the first dose of veliparib (ABT -888) by mouth 
• Receive the first dose of cisplatin  through a ve in 
• Tumor biopsies will be taken for some patients 
Cycle 1,  
Day 2 • Get routine blood tests  
• Receive the first dose of M6620 (VX-970) through a vein 
• Tumor biopsies will be taken for some patients 2 to 5 hours after receiving M6620 
(VX-970) 
• Research b lood samples will be drawn 
• Continue to take veliparib (ABT -888) by mouth twice a day  about 12 hours apart 
for a total of 3 days 
Cycle 1,  
Days 8-10 • Have a history taken of how you feel and undergo a physical examination by a 
Health Care Provider  
• Get routi ne blood tests  
• Research blood samples  will be drawn  
• Take veliparib (ABT -888) by mouth twice a day about 12 hours apart for 3 days 
• Receive cisplatin through a vein on day 8 
• Receive M6620 (VX-970) through a vein on day 9 
• Tumor biopsies will be taken for some patients 2 to 5 hours after receiving M6620 
(VX-970) 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   88 
 Day What to do and what will happen to you  
Cycle 1,  
Day 15 • Get routine blood tests at your clinical center or by your home physician  
 
Cycle 2, 
Day 1 • Have a history taken of how you feel and undergo a physical examination by a 
Health Care Pro vider 
• Get routine blood tests 
• Research blood samples will be drawn  
• Start taking veliparib (ABT -888) by mouth twice a day  about 12 hours apart for 
days 1 through 3 
• Receive cisplatin through a vein  
Cycle 2, 
Day 2 • Research blood samples  will be drawn  
• Receive M6620 (VX-970) through a vein 
Cycle 2, 
Days 8-10 • Check in at ________________ [name of outpatient clinic ] 
• Have a history taken of how you feel and undergo a physical examination by a 
Health Care Provider  
• Get routine blood tests  
• Continue taking veliparib (ABT -888) by mouth twice a day about 12 hours apart on 
days 8 through 10 
• Receive cisplatin through a vein on day 8 
• Receive M6620 (VX-970) through a vein on day 9 
Cycle 2, 
Day 15 • Get routine blood tests at your clinical center or by your home physician ( optional)  
Cycle 3, 
and 
onward • Check in at ________________ [name of outpatient clinic ] 
• Have a history taken of how you feel and undergo a physical examination by a 
Health Care Provider  
• Get routine blood tests  
• CT scan to determine how your tumor is responding to the treatment will be done 
every 6 weeks (every 2 cycles, or every 3 cycles if you have been on study for more than one year, every 4 cycles if on study for more than 3 years) 
• Research blood samples  will be drawn before Cycle 3 treatment  
• Cisplatin  will be given through a vein on Day 1 and 8 of each cycle  
• M6620 (VX-970) will be given through a vein on Day 2 and 9 of each cycle 
• veliparib (ABT -888) will be taken orally twice a day  about 12 hours apart on 
days 1 through 3 and 8 through 10 of each cycle  
  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   89 
 Study Diary 
 
 
Patient Name:  __________________                                    _______________________  Instructions:  
 Please complete this form and return to the research nurse or doctor every cycle (21 days)  
 Dose of veliparib (ABT -888) (number of capsules):  
Time of dosing:   Take veliparib (ABT -888) capsules twice each day (morning and evening , 
about 12 hours apart) on days 1 to 3 and 8-10  
 Cycle number:      _________ Start date:  _________ 
 
 
Patient Signature:  _____________________________________   
Date Day Time taken  
AM                    PM  Comments : 
Side effects/missed dose 
 
1    
 
2    
 
3    
 
4 No veliparib (ABT-
888) taken today   
 
5 No veliparib (ABT-
888) taken today   
 
6 No veliparib (ABT-
888) taken today   
 
7 No veliparib (ABT-
888) taken today   
 
8    
CTEP #  P9771 
Clinical Center #  16-C-0087  
   90 
  
9    
 
10    
 
11 No veliparib (ABT-
888) taken today   
 
12 No veliparib (ABT-
888) taken today   
 
13 No veliparib (ABT-
888) taken today   
 
14 No veliparib (ABT-
888) taken today   
 
15 No veliparib (ABT-
888) taken today   
 
16 No veliparib (ABT-
888) taken today   
 
17 No veliparib (ABT-
888) taken today   
 
18 No veliparib (ABT-
888) taken today   
 
19 No veliparib (ABT-
888) taken today   
 
20 No veliparib (ABT-
888) taken today   
 
21 No veliparib (ABT-
888) taken today   
CTEP #  P9771 
Clinical Center #  16-C-0087  
   95 
 APPENDIX E : INFORMED CONSENT FORM TEMPLATE  
 
Study Title:  Phase I Study of Veliparib (ABT -888), an Oral PARP Inhibitor, and M6620 (VX-
970), an ATR Inhibitor, in Combination with Cisplatin in Patients with Refractory Solid Tumors  Introduction  We invite you to take part in this research study.  First, we want you to know that: 
Taking part in this research study is entirely voluntary.  You may choose not to take part, or you may withdraw from the study at any time.  In either case, you will not lose any benefits to which you are otherwise entitled.    You may receive no benefit from taking part.  The research may give us know ledge that may 
help people in the future. 
 Second, some people have personal, religious or ethical beliefs that may limit the kinds of medical or research treatments they would want to receive (such as blood transfusions).  If you have such beliefs, please discuss them with your doctors or research team before you agree to the study.  Now we will describe this research study.  Before you decide to take part, please take as much time as you need to ask any questions and discuss this study with family, friends or your personal 
physician or other health professional. 
 Why is this study being done?  
 The purpose of this study is to test the safety of a combination of 3 drugs (M6620 (VX-970), veliparib (ABT -888), and cisplatin) to find out the doses of these drugs that can be safely given 
to humans and to learn if these drugs have activity against tumors.  Although we hope this experimental therapy will decrease the size of your tumor, we cannot promise or predict the benefits of the treatment at this time.  The drugs used in this study have known side effects that will be reviewed with you by your medical team before you sign this consent form.   Cisplatin is currently approved by the US Food and Drug Administration (FDA) for the treatment of patients with bladder,  ovarian, and testicular cancers in combination with other 
chemotherapy agents.  Veliparib (ABT-888) and M6620 (VX-970) are not approved by the FDA.  Combining veliparib (ABT -888) and M6620 (VX-970) with cisplatin is thought to block proteins 
that are know n to be important for cancer cell growth.  
 We are also studying the genes in your tumor to  help us understand how your tumor responds to 
these 3 drugs.  Blood, tissue, and tumor cells contain genes that are made up of DNA and serve as 
the “instruction book” for each cell in the body.  We know that variations in some tumor genes play an important role in how cancers respond to drugs.  Determining whether different tumor gene 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   96 
 variations affect how veliparib (ABT-888), M6620 (VX-970), and cisplatin work agains t tumors 
will help scientists understand why some patients might stop  responding to these drugs. 
 
 Why are you being asked to take part in this study?  
 You are being asked to take part in this research study because you have advanced cancer that has progre ssed after receiving standard treatment, or for which no effective therapy exists.  We 
hope that this combination of study drugs will slow down the growth of your cancer.  How many people will take part in this study?  
 Up to 60 patients will take part in t his study at multiple sites around the US.  
 What will happen if I take part in this study?  
 If you are accepted and you choose to take part, you will begin receiving veliparib (ABT-888) and cisplatin on the first day, followed by M6620 (VX-970) on the seco nd day.  Cisplatin and 
M6620 (VX-970) are given as an infusion through a vein.  The drugs are given in cycles, and each cycle is 21 days (3 weeks) long. 
• Cisplatin is given the first day of each cycle and on day 8 for some patients , for at least the 
first 6  cycles     
• M6620 (VX-970) is given on day 2 and day 9 of each cycle (or day 1 and day 8 if no cisplatin is given during that cycle)   
• Veliparib (ABT -888) is given orally twice a day on days 1 through 3 and days 8 through 
10 of each cycle  
 
Each patient may receive a different dose based on when he or she entered the study.  Your dose of 
study drugs may be decreased by the study doctor if you are not tolerating it well, or increased if you are tolerating it well.   Most of the exams, tests, and procedures y ou will have are part of your regular care such as a 
complete medical history, blood tests, and scans to measure your tumors.  We would also do a pregnancy test in women who are able to become pregnant.  The team will also give you a chart describing the tests and procedures that will be done each day during the study.  Standard procedures being done because you are in this study; these may be done more often because you are in the study:  
• Clinic visit: to ask how you are feeling and to evaluate you with a physical examination during 
week 1 and 2 of each cycle before you receive treatment . 
• Vital signs and physical examinations: will be performed during the clinic visits.  
• Blood tests:  Measurement of your white blood cells, red blood cells, platelets, blood sugar, 
electrolytes, and of how your liver and kidneys work will be done during the first two days of the first week of each cycle, the second week before you receive treatment every cycle, and the 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   97 
 third week of the first cycle ( this third week visit can be done with your home physician).  
About 1 tablespoon (15 mL) of blood will be drawn per visit.  
• CT scans  or other imaging tests such as MRI (an examination using magnetic field and radio 
waves) that detect your tumor will be done before the study and every 6 weeks while you are 
receiving study drugs.  This is done so that any benefit of the treatment can be determined, and if your cancer is not responding to the treatment, the study team can tell you and discuss other treatment options (discussed further below ).   
• EKGs (a recording of the heart’s electrical activity) to check for signs of possible damage to 
your heart.  
 You will also have tests and procedures done because you are in the study to see how the study drugs are affecting your body.  If you develop any side effects, you may be asked to visit more often.  You will be asked to keep a diary to record the exact time you took veliparib (ABT-888), and to report any side effects you may have.  If you miss a dose or vomit the dose, please make a note of this  in your diary and contact your team immediately to receive further instructions.  Please 
bring the study diary with you to each clinic visit.   Tests and procedures being done to see how the drug is affecting your body:  
 
• Research blood tests: We will also  be collecting blood samples from some patients to find out 
the effects of the drug on any tumor cells in the blood.  Blood samples will be collected from patients at the beginning of the study, and prior to receiving study drugs on days 1, 2, and 9 of cycle 1, days 1 and 2 of cycle 2, and on day 1 of cycle 3 and every subsequent cycle.  The total 
blood for all these tests will be up to 2 tablespoons (about 30 mL) . 
• Tumor Biopsy:  You may be asked to undergo imaging-directed biopsy of your tumor 
(removal of a  small bit of tissue for microscopic examination) once  on day 1 and again on day 
9 in the first cycle only .  We are collecting biopsy samples to study the effects of study drugs 
on your tumor and to search for any gene variations in your tumor that may help us understand how it responds to these drugs .  Biopsies are an important part of this trial and are done for 
research purposes.  Biopsies are optional in the early part of this study (called the dose escalation phase)  but mandatory at a certain point in the study called the expansion phase.  
If you decide not to have biopsies collected, you will still receive study drugs and other tests that are part of the study and detailed above.  However, at the expansion phase, willingness to undergo tumor biopsies w ill be required for taking part in this study.  We will tell you if 
biopsies are required before you decide to take part in the study. 
 
No more than three  biopsy procedures will be performed during the study.  After the first 
biopsy, if you decide not to have further biopsies, you will still receive study drugs and have other tests that are part of the study.  You will be asked to sign a separate consent form for each biopsy procedure.  
 Tumor biopsies are only collected by trained personnel.  Biopsies are c ollected using a small 
needle under imaging guidance (CT, MRI, or ultrasound as deemed appropriate by the interventional radiologist performing the biopsy).  Imaging helps the specialized radiologist know that the needle has been placed into the tumor mass.   
CTEP #  P9771 
Clinical Center #  16-C-0087  
   98 
  
Typical risks of biopsy collection include, but are not limited to, bleeding, infection, pain, and scarring.  If you experience any complications from the biopsy, medical care will be offered to you.  You will be counseled in more detail about biopsie s, and you will be asked 
to sign a separate consent form that will describe the procedures and risks at that time.  Your safety is the most important thing at all times.  If upon attempting the first biopsy, no tissue can be obtained or it has caused you harm, further biopsies will not be done.  After you are enrolled in this study, if for any reason the biopsies cannot be done safely, you may still receive the study drugs but the biopsies will not be done.  The biopsies are for research purposes and will not benefit you.  They might help other people in the future.  Even if you sign “yes” to have biopsies, you can change your mind at any time.  Please read each  sentence below and think about your choice.  After reading the 
sentence, circle the initial answer that is right for you: 
 Have you been informed  regarding what phase of the study you will be in?   
Escalation phase_______  Expansion phase________ Initials __________ 
  
I agree to have the tumor biopsies for the escalation phase of the research study (optional).  
 Yes              No                Initials_________ 
 
I agree to have the tumor biopsies for the expansion phase of the research study (mandatory). 
 Yes              No                N/A ______  Initials _________ 
 Optional Tumor Genomic Sequencing  
Targeted Sequencing —If your cancer looks like it is getting worse, you may choose to 
have another, optional tumor biopsy before leaving the study and have a targeted genomic sequencing test done on this tumor tissue in a  clinically approved laboratory.  You and your 
doctor will receive the results of this test, and the results will be in your electronic medical record.  Your doctor will discuss these results with you and tell you about any gene variations that might make you able to take part in targeted therapy clinical trials in the future , such as the NCI MATCH ([STUDY_ID_REMOVED]) and MPACT ([STUDY_ID_REMOVED]) trials. 
Exome Sequencing —If you choose to have the optional, third tumor biopsy, w e are also 
requesting your permission to perform exome sequencing on your tu mor biopsies and link 
this information to information from your medical history.  You are not required to agree to 
exome sequencing to take part in this trial.  Your tumor tissue contain s genes, which are 
made up of DNA ( deoxyribon ucleic acid) and serve as  the "instruction book" for the cells 
that make up our bodies.  Exome sequencing will determine the exact order of the base pairs (DNA building blocks ) in your tumor.  We know that variations in the base pairs of some 
tumor genes play an important role in how cancers respond to drugs.  Information about your gene variations combined with information from your medical history may help us understand how your tumor responds to the study drugs and why it has stopped responding.     
CTEP #  P9771 
Clinical Center #  16-C-0087  
   99 
 If you agree, w e will identify gene variants in your tumor biopsy samples collected at the 
beginning and end of treatment with exome sequencing, but this information will be for 
research purposes only and we will not give you any individual results from this sequencing or add this information to your medical records.  This is because it will probably take a long time for this project to produce health -related information that we will know how to 
interpret accurately.  However, we will tell you if we find that you have a communicable disease that we are required by law to report.  
I agree to allow genomic sequencing for research purposes:  
Yes              No                Initials_________ 
 How long will I be in this study?  
 
You will stay in the study as long as you are tolerating the drugs and your tumors are either stable or getting better, but you can choose to leave the study at any time.  For some study procedures, we will need you to come to ________________ [name of center].    Stopping Therapy  
You can decide to stop at any time.  If you decide to stop for any reason, it is important to let your study doctor know as soon as possible so you can stop safely.  If you stop, you can decide whether or not to let the study doctor continue to include your medical information in the study. Your study doctor will tell you about new information or changes in the study that may affect your health or your willingness to continue in the study. 
Your study doctor may take you out of the study: 
• If your health changes and the study is no longer in your best interest  
• If new information becomes available  
• If you do not follow the study rules 
• If the study is stopped by the sponsor, IRB, or FDA 
 
Follow- up  
You will be followed for 30 days after taking the last dose of study drugs.  We will call you between  days 27- 30 to ask about any side effects that were ongoing when you stopped therapy, 
or any new side effects that might be related to the study therapy.  If you have side effects that might be related to the study drugs that have not gotten better after 30 days, we will call you every 2 weeks until the side effects have become stable or gotten better.  The follow-up period will end if you enroll in another study or start receiving standard therapy.    Alternative Approaches or Treatments  What other choic es do I have if I do not take part in this study?  
 Instead of being in this study, you have these options: 
• you may choose to have the usual approaches described above  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   100 
 • you may choose to take part in a different study, if one is available 
• you may continue your standard care as usual  (see table below) , and not take part in this 
study 
• or you may choose not to be treated, but you may want to receive comfort care to relieve 
symptoms  
Please talk to your doctor about these and other options.  Your doctor may dec ide that it is not 
safe for you to receive a particular treatment or you have the right to refuse a treatment, but before you decide to take part in this study you should discuss all available treatment options with your local doctor. 
 
Risks or Discomforts of Participation  
 
What side effects or risks can I expect from being in the study?  
 If you choose to take part in this study, there is a risk that the treatment may not be as good as the usual approach for your cancer or condition at shrinking or stabiliz ing your cancer.  
 You also may have the following discomforts: 
• Spend more time in the hospital or doctor’s office.  
• Be asked sensitive or private questions about things you normally do not discuss. 
• May not be able to take part in future studies. 
 The agents used in this study may affect how different parts of your body work such as your liver, kidneys, heart, and blood.  The study doctor will test your blood and will let you know if changes occur that may affect your health.  There is also a risk that you co uld have side effects from the study drug(s)/study approach. 
 Here are important things to know about side effects:  
• The study doctors do not know who will or will not have side effects. 
• Some side effects may go away soon, some may last a long time, and som e may never go 
away.  
• Some side effects may make it hard for you to have children. 
• Some side effects may be mild.  Other side effects may be very serious and even result in death. 
 You can ask your study doctor questions about side effects at any time.  Her e are important ways 
to make side effects less of a problem:  
• If you notice or feel anything different, tell your study doctor.  He or she can check to see if it is a side effect.  
• Your study doctor will work with you to treat your side effects. 
• Your study doctor may adjust the study drugs to try to reduce side effects. 
• Your study doctor will give you a drug interactions handout and wallet card that lists possible interactions.  
 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   101 
 The tables below show the most common and the most serious side effects doctors know about.  
Keep in mind that there might be other side effects doctors do not yet know about.  If important new side effects are found, the study doctor will discuss these with you.  
• Some patients on this study have had low platelet counts and low red and white blood cell counts in their blood, possibly due to this drug combination.  These conditions can cause bruising, bleeding, slow blood clotting after an injury, tiredness, weakness, shortness of breath, and can keep your body from fighting off infections.   
 Risks and side effects related to veliparib (ABT -888)  may include:  
 
COMMON, SOME MAY BE SERIOUS   
In 100 people receiving ABT-888 (veliparib), more than 20 and up to 100 may have:  
• Nausea  
• Tiredness  
• Bruising, bleeding  
 
OCCASIONAL, SOME MAY BE SERIO US   
In 100 people receiving ABT -888 (veliparib), from 4 to 20 may have:  
• Anemia which may require blood transfusion  
• Infection, especially when white blood cell count is low 
• Belly pain  
• Constipation, diarrhea, vomiting 
• Weight loss, loss of appetite  
• Dehydration 
• Dizziness, headache  
• Changes in taste  
• Rash  
 
RARE, AND SERIOUS  
In 100 people receiving ABT -888 (veliparib), 3 or fewer may have:  
• Cancer of bone marrow caused by chemotherapy  
• Damage to the bone marrow (irreversible) which may cause infection, bleeding, may 
require transfusions 
• A new cancer resulting from treatment of earlier cancer  
• Seizure  
• Blood clot which may cause swelling, pain, shortness of breath  
 
  Risks and side effects related to M6620 (VX-970)  may include:  
POSSIBLE, SOME MAY BE SERIOUS  
 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   102 
 • Anemi a which may require blood transfusion  
• Diarrhea, nausea, vomiting  
• Tiredness  
• Allergic reaction which may cause rash, low blood pressure, wheezing, shortness of breath,  
swelling of the face or throat  
• Infection, especially when white blood cell count is low which may cause painful and frequent urination 
• Bruising, bleeding  
• Pain in tumor  
• Dizziness, headache  
• Itching, rash  
• Flushing  
 
While taking M6620 (VX-970), you should take protective measures to minimize sun exposure. 
 Risks and side effects related to cispla tin may include: 
 
COMMON, SOME MAY BE SERIOUS  
In 100 people receiving cisplatin, more than 20 and up to 100 may have:  
• Nausea, vomiting  
• Infection, especially when white blood cell count is low 
• Anemia which may cause tiredness, or may require blood transfusions 
• Bruising, bleeding 
• Kidney damage which may cause swelling, may require dialysis  
• Hearing loss including ringing in ears 
 
 
 
OCCASIONAL, SOME MAY BE SERIOUS  
In 100 people receiving cisplatin, from 4 to 20 may have:  
• Allergic reaction which may cause ra sh, low blood pressure, wheezing, shortness of 
breath, swelling of the face or throat  
• Confusion 
• Difficulty with balance  
 
 
  
RARE, AND SERIOUS  
In 100 people receiving cisplatin, 3 or fewer may have:  
• Cancer of bone marrow caused by chemotherapy later in life 
• Seizure  
  
Risks associated with genomic sequencing:  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   103 
 Privacy Risks 
Your privacy is very important to us and we will use many safety measures to protect your 
privacy.  Your research samples will be stored with a coded identifier, not your name.  Any  
personal data about you will also be stored in a sequence computer database with that code identifier.  All information that can directly link you to the tissue or personal information 
will not be shared with investigators using your specimens for research.   This includes 
information that  contains your name, medical record number, date of birth, or address. 
There are protections in place that restrict who can see the results of your genetic tests.   
However, there remains a risk someone could get unauthorized access or break into the 
system that stores information about you.  Every precaution will be taken to minimize this 
risk.  There also may be other privacy risks that we have not foreseen. 
Genetic variant results that we return to you will become part of your medical record at the NIH.   In spite of all of the safety measures that we will use, we cannot guarantee that your 
identity will ever become known.  For instance, if you or a family member releases information about you or your involvement in this study, or an insurer, employer, or other person obtains your written consent to receive information from your NIH medical record, your identity, information about your enrollment in this study and genetic variant results may be included in a release of your  medical records.  
Protections against misuse of genetic information  
Since some genetic variations can help to predict the future health problems of you and your relatives, this information might be of interest to health providers, life insurance companies, and others.  Patterns of genetic variation also can be used by law enforcement 
agencies to identify a person or his/her blood relatives.  
There are state and federal laws that protect against genetic discrimination.   There is a 
federal law called the Genetic Information Nondiscrimination Act (GINA).  In general, this 
law makes it  illegal for health insurance companies, group health plans, and most 
employers to discriminate against you based on your genetic information.  GINA also does not apply to members of t he United States military, to veterans obtaining health care 
through the Veteran’s Administration or the Indian Health Service.  GINA does not forbid insurance medical underwriting based on your current health status, including your cancer.  GINA also does  not protect you against discrimination by companies that sell life 
insurance, disability insurance, or long- term care insurance.  However, your cancer 
diagnosis will often be considered more important that genetic information about risk for developing another condition when evaluating you during medical underwriting. 
Emotional and psychological risks  
As part of the research study, it is possible that you could learn that you have genetic risks 
for another disease or disability.  This may be upsetting and, depending on what you learn, might create a need to make challenging decisions about how to respond.  Although your 
genomic information is unique to you, you share some genomic similarities with your children, parents, brothers, sisters, and other blood relatives. Therefore, learning your 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   104 
 testing results could mean something about your family members and might cause you or 
your family distress.  Before joining the study, it may be beneficial to talk with your family members about whether and how they want you to share your results with them. 
 Birth Control 
If you are a woman who is breast feeding or pregnant, you may not take part in the study because 
we don’t know how this medicine would affect your baby or your unborn child.  If you are a woman who can become pregnant, or are the partner of a woman who can become pregnant, you and your partner will need to practice an effective form of birth control before starting study treatment, during study treatment, and for 6 months after you finish study treatment.  If you think 
that you or your partner is pregnant, you should tell your study doctor or nurse at once.   
Effective forms of birth control include  using at least two of the following :  
• abstinence  • intrauterine device (IUD)  
• tubal ligation  • vasectomy  
• barrier  methods (condoms)   
• hormonal (birth control pills, injections, or implants)  
Also, if you are a woman taking hormonal birth control, please tell your study doctor or nurse.  
Some patients on this study may be given medication to control the side effects of nausea and vomiting that can make some forms of hormonal birth control stop working or work less well.  You may need to use an alternative form of birth control during this time. 
 Potential Risks Related to Blood Samples  
Possible side effects from drawin g the blood sample include mild pain, bleeding, bruising, and 
infection at the site of the needle insertion.  Fainting or light- headedness can sometimes occur, but 
usually last only a few minutes.  
 Potential Benefits of Participation  
 Are there benefits t o taking part in this study?  
 The aim of this study is to see if this experimental treatment will cause your tumors to shrink.  We do not know if you will receive personal, medical benefit from taking part in this study.  These potential benefits could include shrinking of your tumor or lessening of your symptoms, such as pain, that are caused by the cancer.  Because there is not much information about the drugs’ effect 
on your cancer, we do not know if you will benefit from taking part in this study, although the knowledge gained from this study may help others in the future who have cancer.   
 
Research Subject’s Rights 
What are my rights if I take part in this study?  
Taking part in this study is your choice.  You may choose either to take part or not to take part in 
this study.  If you decide to take part, you may leave the study at any time.  No matter what decision you make, there will be no penalty to you, and you will not lose any of your regular benefits.  Leaving the study will not affect your medical care.  You can still get your medical 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   105 
 care from our institution if you are eligible and choose to participate in another trial.  We will tell 
you about new information or changes in the study that may affect your health or your willingness to continue in the study.  In the case of injury resulting from this study, you do not lose any of your legal rights to seek payment by signing this form.  Will my medical information be kept private?  
 We will do our best to make sure that the personal information in your medical record will be kept private.  However, we cannot guarantee total privacy.  Your personal information may be given out if required by law.  If information from this study is published or presented at scientific meetings, your name and other personal information will not be used.  
Organizations that may look at and/or copy your medical records for research, quality assurance, and data analysis include:  
• The National Cancer Institute (NCI) and other government agencies, like the Food and Drug Administr ation (FDA), involved in keeping research safe for people. 
 
• Designated investigators from oth er cancer centers participating in this study, including 
MD Anderson Cancer Center  and Dana -Farber Cancer Institute . 
 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov , as required 
by U.S. Law.  This Web site will not include information that can identify you.  At most, the 
Web site will include a summary of the results.  You can search this Web site at any time.  
 [Note to Local Investigators: The NCI has recommended that HIPAA regulations be addressed by the local institution.  The regulations may or may not be included in the informed consent form depending on local institutional policy.]  
 Certificate of Confidentiality  
To help us protect your privacy, the NIH has obtained a Certificate of Confidentiality  from the 
Depa rtment of Health and Human Services.  The Certificate is designed to prevent us from being 
forced to disclose identifying information for use in any federal, state , or local civil, criminal, 
administrative, legislative, or other court proceeding, even if faced with a court subpoena.  You 
should understand, however, that a Certificate of Confidentiality does not prevent you or a 
member of your family from voluntarily  releasing information about yourself or your 
involvement in this research.  We may not withhold information if you give your insurer or 
employer or a law enforcement agency permission to receive information about your 
participation in this project.  This means that you and your family must also actively protect your 
own privacy. 
The Certificate d oes not prevent us from taking steps, including reporting to authorities, to 
prevent serious harm to yourself or others. Such disclosures will be made as described  below. 
The research team may share your information with:  
• The Department of Health and Human Services (HHS), to complete federal 
responsibilities for audit or evaluation of this project;  
• Public health agencies, to complete public health reporting requirem ents;  
• NIH representatives, to complete NIH responsibilities for oversight of this study;  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   106 
 • Your primary care physician if a medical condition that needs urgent attention is 
discovered;  
• Appropriate authorities to the extent necessary to prevent serious harm to yourself 
or others.  
 
What are the costs of taking part in this study?  
 
You and/or your health plan/insurance company will need to pay for some or all of the costs of treating your cancer in this study.  Some health plans will not pay these costs for p eople taking 
part in studies.   Check with your health plan or insurance company to find out what they will pay 
for.  Taking part in this study may or may not cost your insurance company more than the cost of 
getting regular cancer treatment.  
The NCI will supply t he study agents veliparib (ABT -888) and M6620 (VX-970) at no charge 
while you take part in this study.  Even though it is unlikely, there is a possibility that at some point the supply of study agents may run out, necessitating taking you off-study.  The NCI will not provide cisplatin free -of-charge, so you or your health plan may need to pay for cisplatin and 
the personnel who give it to you.  
 [If applicable, inform the patient of any tests, procedures or agents for which there is no charge.  
The explanation, when applicable, should clearly state that there are charges resulting from performance of the test or drug administration that will be billed to the patient and/or health 
plan.  For example, “The NCI is supplying (drug) at no cost to you.  However, you or your health plan may need to pay for costs of the supplies and personnel who give you the (drug).”] 
 
You will not be paid for taking part in this study.  
 
For more information on clinical trials and insurance coverage, you can visit the National Cancer 
Institute’s Web site at http://cancer.gov/clinicaltrials/understanding/insurance -coverage.  You 
can print a copy of the “Clinical Trials and Insurance Coverage” information from this Web site.  
 Another way to get the information is to call 1 -800-4-CANCER (1 -800- 422-6237) and ask them 
to send you a free copy.  What happens if I am injured because I took part in this study?  
 It is important that you tell your study doctor, __________________ [investigator’s name(s)],  if 
you feel that you have been injured because of taking part in this study.  You can tell the doctor in person or call him/h er at __________________ [telephone number]. 
 You will get medical treatment if you are injured as a result of taking part in this study.   You 
and/or your health p lan will be charged for this treatment.  The study will not pay for medical 
treatment.    
 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   107 
 Who  can answer my questions about the study?  
 
You can talk to your study doctor about any questions or concerns you have about this study.  Contact your study doctor __________________ [name(s)]  at __________________ [telephone 
number].  For questions about your rights while taking part in this study, call the ________________________ [name of center] Institutional Review Board (a group of people who review the research to protect your rights) at __________________ (telephone number).  [Note to Local Investigator: Contact information for patient representatives or other individuals in a local institution who are not on the IRB or research team but take calls regarding c linical 
trial questions can be listed here.]    
 Where can I get more information?  
 You may c all the National Cancer Institute’s Cancer Information Service at: 1 -800-4- CANCER 
(1-800-422-6237).  You may also visit the NCI Web site at http://cancer.gov/. 
• For NCI’s clinical trials information, go to: http://cancer.gov/clinicaltrials/  
• For NCI’s genera l information about cancer, go to http://cancer.gov/cancerinfo/  
 You will get a copy of this form.  If you want more information about this study, ask your study doctor.   Signature  
I have been given a copy of all _____ [insert total of number of pages]  pages of this form.   I 
have read it or it has been read to me.   I understand the information and have had my questions 
answered.   I agree to take part in this study.  
 Participant  ________________________________ 
  Date _____________________________________ 
CTEP #  P9771 
Clinical Center #  16-C-0087  
   108 
  
APPENDIX F: CTEP MULTICENTER GUIDELINES  
 
If an institution wishes to collaborate with other participating institutions in performing a CTEP sponsored research pro tocol, then the following guidelines must be followed. 
 Responsibility of the Protocol Chair  
• The Protocol Chair will be the single liaison with the CTEP Protocol and Information Office (PIO).  The Protocol Chair is responsible for the coordination, develo pment, 
submission, and approval of the protocol as well as its subsequent amendments.  The protocol must not be rewritten or modified by anyone other than the Protocol Chair.  There will be only one version of the protocol, and each participating institution will use that document.  The Protocol Chair is responsible for assuring that all participa ting 
institutions are using the correct version of the protocol. 
• The Protocol Chair is responsible for the overall conduct of the study at all participating institutions and for monitoring its progress.  All reporting requirements to CTEP are the responsib ility of the Protocol Chair.  
• The Protocol Chair is responsible for the timely review of Adverse Events (AE) to assure 
safety of the patients.  
• The Protocol Chair will be responsible for the review of and timely submission of data 
for study analysis.  
 Respo nsibilities of the Coordinating Center  
• Each participating institution will have an appropriate assurance on file with the Office for Human Research Protection (OHR P), NIH.   The Coordinating Center is responsible 
for assuring that each participating institu tion has an OHRP assurance and must maintain 
copies of IRB approvals from each participating site.  
• Prior to the activation of the protocol at each participating institution, an OHRP Form 
310 (documentation of IRB approval) must be submitted to the CTEP PI O. 
• The Coordinating Center is responsible for central patient registration.  The Coordinating 
Center is responsible for assuring that IRB approval has been obtaine d at each 
participating site prior to the first patient registration from that site.  
• The Coor dinating Center is responsible for the preparation of all submitted data for 
review by the Protocol Chair.  
• The Coordinating Center will maintain documentation of AE reports.  There are two options for AE reporting: (1) participating institutions may report directly to CTEP with a copy to the Coordinating Center, or (2) participating institutions report to the Coordinating Center who in turn report to CTEP.  The Coor dinating Center will submit 
AE reports to the Protocol Chair for timely review.  
• Audits may be  accomplished in one of two ways:  (1) source documents and research 
records for selected patients are brought from participating sites to the Coordinating Center for audit, or (2) selected patient records may be audited on- site at participating 
sites.  If  the NCI chooses to have an audit at the Coordinating Center, then the 
Coordinating Center is responsible for having all source documents, research records, all IRB approval documents, NCI Drug Accountability Record forms, patient registration 
lists, response assessments scans, x -rays, etc. available for the audit.  
CTEP #  P9771 
Clinical Center #  16-C-0087  
   109 
  
Inclusion of Multicenter Guidelines in the Protocol 
• The protocol must include the following minimum information:  
• The title page must include the name and address of each participating institution and the 
name, telephone number and e- mail address of the responsible investigator at each 
participating institution.  
• The Coordinating Center must be designated on the title page. 
• Central registration of patients is required.  The procedures for registra tion must be stated 
in the protocol. 
• Data collection forms should be of a common format.  Sample forms should be submitted with the protocol.  The frequency and ti ming of data submission forms to the 
Coordinating Center should be stated. 
• Describe how AEs w ill be reported from the participating institutions, either directly to 
CTEP or through the Coordinating Center. 
• Describe how Safety Reports and Action Letters fro m CTEP will be distributed to 
participating institutions.   
 
Agent Ordering Except in very unusual circumstances, each participating institution will order DCTD -supplied 
investigational agents directly from CTEP ( see Section 8.4 ).  Investigational agents may be 
ordered by a participating site only after the initial IRB approval for the site has been forwarded by the Coordinating Center to the CTEP PIO.   
CTEP #  P9771 
Clinical Center #  16-C-0087  
   110 
 APPENDIX G: PROCEDURE FOR SAMPLES FOR PHARMACODYNAMIC STUDIES  
 
 
Collecti on of Biopsies  
 
Materials for shipping biopsy specimens will not be provided.  Core needle biopsies and biopsies from dermatologic and ENT lesions should be collected, placed in pre-chilled cryogenic vials, flash frozen in liquid nitrogen within 2 minutes of collection, and shipped on dry ice.  Refer to 
SOP 340507 
(https://dctd.cancer.gov/Research Resources/biomarkers/docs/par/SOP340507_Biopsy_Frozen.pd
f ) for detailed instructions on core needle biopsy collection and handling, including the sample 
shipping manifest, batch record,  and instructions for requesting FedEx labels.   Sample handling 
SOPs a re still in development for biopsies collected from dermatologic and ENT lesions; please 
contact FNLCR PD Central Receiving ( NCI_PD_Support@mail.nih.gov, 301-846-1951 , or 301-
846-6747) for additional instr uctions regarding these tissue types.  
Participating  site b iopsy samples will shipped via FedEx  to:  
Attention:  NCI-F/FNLCR  
1073 Beasley Street,  
Fort Detrick  
Frederick, MD 21701 Phone:  
 
At the NCI only,  biopsy samples w ill be shipped via courier to:  
Attn:  
Frederick National Laboratory for Cancer Research  
Leidos Biomedical Research, Inc.  
1050 Boyles Street 
 
Frederick, MD 21702 
Phone:  
 
Isolation of CTCs  
 Prior to CTC collection, each participat ing site should e -mail a request for specimen 
collection and shipping materials from NCI_PD_Support@mail.nih.gov.  Allow at least six business days for receipt of the blood shipment containers; a confirmation e -mail with the 
expec ted shipping date will be sent.  Blood (at least 7.5 mL) will be collected aseptically by 
venipuncture or from a venous port into one 10 mL CellSave preservative tube; the collected 
blood s amples are stable for up to 48 hours at room temperature (15˚C to 30˚C) prior to 
processing.   
Participating site CTC s amples will be shipped to:  
Attention:  
NCI-F/FNLCR  
1073 Beasley Street,  

CTEP #  P9771 
Clinical Center #  16-C-0087  
   111 
 Fort Detrick  
Frederick, MD 21701 
Phone:  
 
At the NCI only,  CTC samples will be shipped via courier to:   
Attn: PADIS CTC Laboratory  
Frederick National Laboratory for Cancer Research  
Leidos Biomedical Research, Inc.  
1050 Boyles Street 
 
Frederick, M D 21702 
Phone: 301.846.4711 
E-mail NCIPDSupportPADIS@mail.nih.gov  prior to shipping CTC samples with expected 
arrival dat e/time and a description of contents.  All shipments should include a description of 
contents on the outside label/shipping slip, and a detailed packing slip should be included with 
the samples.  Because of the 48-hour window of CTC sample stability, CTC s amples should be 
shipped to arrive when specified below: 
 
Collection Day  Day/time  samples  must  arrive at PADIS  
Monday  Wednesda y (early morning)  
Tuesday  Thursday  (early morning)  
Wednesday  Friday (early morning)  
Thursday  Friday (early morning)  
CTC sampl es may not be collected on Fridays  
Saturday  Monday  (early morning)  
Sunday  Tuesd ay (early morning)  
 
